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CHAPTER 1 
INTRODUCTION 
Chapter 1 
1.1 BONE 
1.1.1 A dynamic tissue 
Bone provides rigid mechanical support, protects vital organs and serves as a 
reservoir of ions, such as calcium and phosphate, that can be mobilized from bone. There 
are two types of bone: cortical bone, which is composed of densely packed, mineralized 
collagen laid down in layers and provides rigidity, and trabecular bone which is spongy 
in appearance, and also consists of mineralized collagen and provides strength and 
elasticity. There are also two types of bone formation: intramembranous ossification, 
which primarily takes place in the calvarium and starts within the connective tissue, and 
endochondral ossification, which takes place in long bones and starts with the formation 
of cartilage followed by bone formation and mineralization. The mineralized matrix is 
composed of collagenous and noncollagenous proteins and contains a variety of locally 
produced growth factors. 
The integrity of the skeleton is maintained by continuous remodeling of bone that 
occurs throughout life. TIle three major types of bone cells are the osteoblasts, osteocytes 
and osteoclasts. Osteoblasts are bone forming cells and lie together with the lining cells, 
which are inactive osteoblasts, on the endosteal surfaces of bone. The osteoblasts form 
new bone on previously resorbed bone, by synthesizing bone matrix (osteoid), which 
subsequently mineralizes. Osteoblasts are derived from local mesenchymal tissue. 
Osteocytes are osteoblasts, that have been trapped in the mineralized matrix and have 
changed their functional and morphologic characteristics. They have multiple processes 
that reach out through lacunae in bone tissue, and may have a mechanosensor function 
in bone. Osteoclasts, bone resorbing cells, are multinucleated cells which are responsible 
for bone resorption. Osteoclasts are derived from circulating mononucleated 
hematopoietic precursors, although their precise origin is still unknown. Proliferation and 
differentiation of skeletal cells are influenced by many factors, including systemic 
hormones, like 1,25-dihydroxyvitamin D3 and parathyroid hormone (PTH), as well as 
locally produced factors. Linkage of bone formation to bone resorption is called 
"coupling", Under normal physiological conditions, in the remodeling process bone 
formation and resorption are strictly coupled. In pathophysiological situations there is a 
disbalance, e.g. in case of osteoporosis there is more resorption in relation to formation, 
and it is conceivable that locally produced growth factors play an important role as 
mediators in the coupling process (Figure 1). 
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Schematic representation of the proposed role of local factors in coupling bone formation to bone resorption. 
Development of osteoblasts and osteoclasts from their precursors is affected by systemic hormones, like 1,25-
dihydroxyvitamin D3 (1,25-(OHhD3)' Upon activation by 1,25.(OHhD3' osteoblasts synthesize factors, which 
lllay either directly affect osteoblast and/or osteoclast function Of may be stored in the bone matrix. Local 
factors stored in the hone matrix Illay be released and activated during bone resorption by ostcoclasts and 
subsequently affect osteoblast and/or osteoclast function. Lining cells are inactive ostcoblasts. 
1.1.2 Bone matrix proteins 
The primary component of the organic bone matrix is collagen, which is 
essentially collagen type I. Furthermore, several non·collagenous bone matrix proteins 
have been identified. The most important non· collagenous bone matrix proteins are 
summarized in Table 1. In view of the present thesis two of these proteins, osteocalcin 
and osteopontin will be discussed more extensively. 
1.1.3 Osteoea/cin 
Osteocalcin represents 15-20% of the non· collagenous proteins in the bone matrix. 
The osteocalcin gene consists of four exons and three introns from which a low 
molecular weight protein of 5.8 kD is synthesized which consists of 49 amino acid 
residues after cleavage of a prepropeptide of 10 kD. Vitamin K is required for the 
11 
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TABLE 1 
Most important non-coUagenous bone matrix proteins, subdivided according to structure. 
Noncollagcllous bone matrix proteins 
Potcoglycans and hyaJuronan Chondroitin sulfate proteogican 
Biglycan 
Decorin 
Glycoproteins Alkaline phosphatase 
Osteonectin 
Bone acidic glycoprotein-75 
RGD containing proteins Fibronectin 
Vitronectin 
Osteopontin 
Bone sialoprotcin 
Thrombospondin 
Gla containing proteins Ostcocalcin 
Matrix Gla protein 
Protein S 
Growth factors 
Proteolipids 
Serum proteins 
carboxylation of osteocalcin, which is catalyzed by the vitamin K-dependent carboxylase, 
the enzyme responsible for the posttranslational conversion of three glutamyl (Glu) to 
gamma-carboxyglutamyl (Gla) residues (1,2). Osteocalcin has a high affinity for Ca2+, 
due to the carboxylated residues. 
Osteocalcin is expressed only postproliferatively in the mature osteoblast at the 
onset of extracellular matrix mineralization (3) (Figure 2). Furthermore, odontoblasts 
have been shown to produce osteocalcin (4). Recently, osteocalcin production has been 
shown in cells isolated from bovine aortic media, which show osteoblastic potential (5), 
and in bone marrow megakaryocytes and peripheral blood platelets (6). 
12 
Figure 2 
z 
o 
m 100 
a: 
a. 60 
x u, 
~ 60 
::; 
x 40 ~ 
* 20 
Introduction 
MATRIX 
PROLIFERATION MATURATION MINERALIZATION 
AP OP OC Ca" 
.·rt'lt:·-: .. 
, .... , ., .. 
, '..."11 
··········0 
7 14 21 26 35 
DAYS IN CULTURE 
Temporal expression of cell gcO\vth and osteoblast phenotype related genes during the development of ;11 
vitro formed bone-like tissue by normal diploid rat osteoblasts as reported by Stein and Lian (3). The 
proliferation period is characterized by the expression of c-Cos, histone H4 and collagen type I (ColI). 
Alkaline phosphatase (AP) is expressed postproliferatively and associated with extracellular matrix 
maturation. With the onset of extracellular matrix mineralization, osteopontin (OP) and ostcocalcin (OC) 
are expressed, and calcium (Ca2+) accumulates in the extracellular matrix. 
The exact function of osteocalcin in bone is unknown, but a role of osteocalcin 
in bone resorption has been suggested. Warfarin, which inhibits the carboxylation of 
osteocalcin and reduces the amount of osteocalcin in bone, probably as a result of the 
lack of calcium binding Gla residues, has been used in several studies in which the role 
of osteocalcin in bone was investigated. In warfarin-treated lambs, a reduction in bone 
turnover is observed (7) and from results oblained by using warfarin-treated bone 
panicles, a role for osteocalcin has been suggested in the recruitment and/or 
differentiation of bone resorbing cells (8-10). Furthermore, osteocalcin is a chemo-
atlraclant of human peripheral blood monocytes and macrophages (11-13). The mineral 
binding properties of osteocalcin as well as its patlern of expression suggest a role for 
osteocalcin in bone mineralization. Recently, the absence of osteocalcin has been shown 
to increase bone mass in osteocalcin deficient mice (14). A small fraction of osteocalcin 
is released into the circulation and is used as a marker of bone turnover ill vivo. 
The production of osteocalcin is regulated by sleroid hormones and local factors 
in bone, including 1,2S-(OHhD3 (15-17), glucocorlicoids (17-19), estrogen (20,21), 
13 
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thyroid hormone (22,23), PTH (17,24,25), TGFIl (26), basic and acidic FGF (n) and 
IGF-I (28,29). In the promoter region of the rat osteocalcin gene several regulatory 
elements, involved in basal and modulated osteocalcin gene transcription, have been 
characterized. These include a vitamin D response element (VDRE) (30-32), AP-l 
binding sites, one overlapping the VDRE, and another one overlapping the so-called 
osteocalcin box, which contains CCAAT as the central motif (33,34). Furthermore, a 
TGFJl responsive element (35), a binding site for Msx homeodomain proteins (36,37), 
glucocorticoid response elements (GREs) (38,39), and NMP-2 binding sites (40,41) have 
been identified. Stein and Lian (42) proposed a three dimensional model for the rat 
osteocalcin promoter in which chromatin stmcture and nucleosome organization play an 
important role in snpporting crosstalk between promoter elements (Figure 3). 
The human osteocalcin promoter, which has 70% sequence homology with the rat 
osteocalcin promoter, also contains a VDRE (43,44) with an overlapping AP-I binding 
site (45,46). Furthermore, a GRE overlapping the TATA box (47,48) and a binding site 
for NF kappa B have been identified (49). 
basal transcription 
proximal DNase HS 
distal DNase HS 
ViI D enhan<:emont 
Figure 3 
Model for the three dimensional organization of the osleocalcill gene promoter as proposed by Stein and 
Lian (42). This model shows the spatial organization of the osteocalcin promoter based 011 Ilucleosomc 
localization and the interaction of regulatory sites with the nuclear matrix; sites A, Band C with a complex, 
previously designated nuclear matrix protein-2 (NMP-2), containing an acutc myelogenous leukemia (AML)· 
related transactivation protein. Chromatin structure and nuclear architecture restrict mobility of the promoter 
and may reduce distances betwecn distal and proximal promoter elementsi e.g. VDR/RXR complexes 
binding the vitamin D response element (VDRE) and the corc transcriptional machinery (transcription factor 
lIB =: TFlIB): HS == Hypersensitive site, TFs '" Transcription factors. 
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1.1. 4 Osteopontin 
Osteopontin is a phosphorylated glycoprotein that is rich in sialic acid. The 
osteopontin gene consists of seven exoIlS and six introns from which a 264-301 amino 
acids containing protein is synthesized. The exact length depends on species. Among 
species, a high level of conservation of amino acid residues consists in three regions. A 
highly conserved region in the NH2-terminus is thought to be a substrate for intracellular 
kinases responsible for catalyzing the phosphorylation of osteopontin. Near the center 
of the molecule is the highly conserved ORO OS sequence, which has binding properties 
for the cell surface "Jl3 integrins on several cell types (50). The COOH-terminal portion 
of osteopontin contains a non-ROD cell attachment component (51). Posttranslational 
modifications, including phosphorylation, glycosylation and sulfation may allow the 
formation of distinct forms of osteopontin (52-54). 
Osteopontin is not only expressed in bone tissue, but also in several other tissues, 
including kidney, ovary, uterus, mammary gland, gastrointestinal tract, and dental tissue 
(55-58). In bone, osteopontin is synthesized and secreted by osteoblasts, osteocytes and 
osteoclasts. Preosteoblasts primarily synthesize the 55 kO form of osteopontin, which is 
a low-phosphorylated and -sulfated form, whereas the more mature osteoblasts secrete 
the 44 kD form of osteopontin, which is highly phosphorylated and sulfated (59). The 
synthesis of the 55 kD form correlates with the formation of the 'cement' layer, prior to 
bone deposition, whereas the 44 kD form associates with hydroxyapatite, and may be 
involved in regulation of crystal growth (59). In primary rat osteoblasts, osteopontin is 
marginally expressed during the period of active proliferation, decreases 
postproliferatively and is increased at the onset of extracellular matrix mineralization (3) 
(Figure 2). 
The 44 kD osteopontin has been postulated to be involved in the osteoclast 
binding to the mineral surface mediated by the "Jl3 integrin and the ROD sequence in 
the osteopontin protein (60-62). Osteopontin is present at the bone surface facing the 
clear zone of osteoclasts, which is the site where the osteoclast attaches to bone. Lower 
amounts of osteopontin are present at the bone surface facing the ruffled border of the 
osteoclast, where resorption takes place. Likewise, the integrin is enriched in the clear 
zone of the osteoclast, but not in the ruffled border area (63). 
Osteopontin synthesis by osteoblasts is regulated by several systemic and local 
factors, including 1,25-(OHh03 (64), PTH (65), estrogen (66), TOFIl (67), leukemia 
inhibitory factor (68), platelet-derived growth factor (69) and IOF-I (70). 
The osteopontin genes of several species have been cloned and putative CAAT 
IS 
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and TATA sequences have been found in the promoter regions (66,71,72). In the mouse 
osteopontin promoter, a YORE has been identified (73), whereas, recently, in the rat 
osteopontin promoter a proximal and a distal YORE have been identified and 
characterized (72). 
1.2 VITAMIN D 
1.2.1 Vitamin D metabolism 
One of the major calciotrophic and bone regulatory hormones is vitamin O. The 
seco-steroid vitamin D3 is either obtained from the diet or is synthesized in the skin from 
biologically inert 7-dehydrocholesterol under the influence of ultraviolet light. Next, 
vitamin D3 is converted to the inactive hormonal precursor 25-(OH)D3 by the enzyme 
25-hydroxylase in the liver. Subsequently, the enzyme l,,-hydroxylase converts 25-(OH)D3 
to the biologically active form 1",25-dihydroxyvitamin D3 (1",25-(OH}zD3) in the kidney 
(Figures 4 and 5). 
Formation of the biologically active form of vitamin 0 3 is tightly regulated 
through modulation of l,,-hydroxylase activity. PTH and reduced levels of calcium and 
phosphate are the most important stimulators of l,,-hydroxylase activity. Alternatively, 
25-(OH)D3 is converted to 24,25-dihydroxyvitamin D by the renal enzyme 24-hydroxylase 
under stimulation of 1,25-(OH)zD3. In addition, I,,-hydroxylase activity is inhibited by 
Figure 4 
7 -dehydrocholesterol diet 
,~,I- ullra-vlolSlllghl \ ~ / ~ /~ ~ /Inle'tlne 
vitamin 0 3 
2s,hYd,OXY,HSoll7 
L/llvar 
25-hydroxyvitamin 0 3 
,u.hYdrOXYI8S01 ~ ~dney 
10,25-dlhydroxyvltamin 0 3 
Formation of the biologically active form of vitamin D3• 1,25-dihydroxyvitamin D3. 
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Chemical slructure of the seco-steroid 1,25-dihydroxyvitamin D3 (1,25-(OHhD3)' 
1,25-(OHhD3' providing a negative regulatory feedback loop in the synthesis of the 
biologically active form of vitamin D3 (74-76). 
Also in other target cells, 1,25-(OHhD3 stimulates 24-hydroxylase enzyme activity, 
thereby initiating its own C-24 catabolic pathway. 24-Hydroxylase converts 1,25-(OH}zD3 
to 1,24,25 trihydroxyvitamin D3 (77). 
Vitamin 0 3 metabolites circulate in the blood primarily in equilibrium association with 
the vitamin D binding protein (OBP) (78), but also several other plasma proteins, 
including albumin, low density lipoprotein (LOL), high density lipoprotein (HOL), and 
chylomicrons (79,80), bind vitamin 0 3 metabolites. 
1.2.2 Mechanism of action of vitamin D 
1,25-(OHh03 exerts its principal biological action through binding to the vitamin 
o receptor (VOR), although non-genomic actions of 1,25-(OHh03 have also been 
reported (81-84). 
The VOR is a member of the steroid/thyroid hormone receptor superfamily that 
consists of intracellular transcription factors that, upon activation by their cognate ligand, 
17 
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Vitamin D receptor structure, subdivided into regions with specific functions. Only phosphorylation sites for 
which fUllctional importance has been reported, arc indicated. 
exert their action through binding to a DNA element (hormone response element), 
thereby modulating transcription of a cis-linked gene. The human VDR gene consists of 
9 exoilS (85) and is located on chromosome 12q13-14 (86·88). The full length hVDR 
eDNA comprises 4,605 bp. The exact start site of the open reading frame is still under 
debate. Initially, the hVDR eDNA has been defined as a 115 bp noncoding leader 
sequence, 1,281 bp open reading frame and 3,209 bp of 3' noncoding sequence. 
TIle VDR protein structure consists of 427 amino acids and can be subdivided 
into six regions (A to F) to which specific functions have been assigned including ligand 
binding, dimerization, nuclear localization, DNA binding and trans activation (Figure 6) 
(89-93). Among members of the steroid hormone receptor superfamily, the NH2-terminal 
domain (A/B), which is highly variable in sequence and length, is important for the 
transactivation function. 111is region is involved in the activation of target gene 
transcription and probably achieves its effect by interacting with the core transcriptional 
machinery and/or other transactivating factors. 
The DNA binding domain (DBD) (Figure 6, region C) exhibits the highest degree 
of homology among members of the steroid hormone receptor superfamily. This region 
represents a globular fold which contains two distinct zinc clusters, that consist of zinc 
ions that are tetrahedrally coordinated by four cysteine residues located at the base of 
each loop (Figure 7). The so-called P-Box is located in the first zinc cluster and contains 
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Part of the DNA binding domain of the vitamin D receptor, containing two distinct zinc (Zn) clusters, 
Circled amino acids belong to the P-Box, whereas boxed amino acids belong to the D-Box. Arrows indicate 
amino acids for which substitution mutations have been found in patients with hereditary vitamin D resistant 
rickets. 
the second pair of zinc contacting cysteines. Three amino acids in the PoBox have been 
shown to be essential for recognition (cEGckG) of the vitamin D response element 
(VDRE). The Glu (E) residue has been shown to contact specifically the third 
nucleotide in the Vitamin D response element (94) (Figure 7). TIle a-helical structure 
of the PoBox and downstream amino acids is important for deoxynucleotide contacts and 
fits into the major groove of the DNA helix (95). The D-Box, that consists of the five 
amino acids between the NH2-terminal pair of cysteines in the second zinc cluster, is 
important for contacts with the phosphate backbone of DNA and for dimerization. For 
dimerization also regions in the first Zn finger and in the T-region, which is localized 
COOH-terminal in the DBD close to the hinge region, have been shown to be important 
(96,95). Interaction of the aromatic side chains of conserved amino acids in the 
amphipathic helices provides the globular structure of the DBD. Importance of individual 
amino acids in the DBD for the functionality of the VDR is furthermore illustrated by 
mutations in the DBD that occur in hereditary vitamin D resistant rickets (HVDRR). 
Several mutations in the DBD have been identified in patients with I-IVDRR, including 
substitution mutations at the tip and at the base of the first Zn finger, amino acids 30 
(85), 32 (98) and 42, 44 (99), respectively, as well as the second Zn finger, amino acids 
70 (85) and 77 (100,101), respectively (Figure 7). Furthermore, a mutation has been 
identified which introduced a stop codon at codon 70 in the DBD, leading to the 
formation of a truncated VDR (102). 
19 
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Downstream of the DBD is the hinge region, which is involved in nuclear 
localization (Figure 6, region D). In some patients with HVDRR a mutation, introducing 
a stop codon at codon 149, has been identified in the hinge region, which leads to the 
formation of a truncated VDR (102,103). The ligand-binding domain is located COOH-
terminally of the hinge region (Figure 6, region E). Residues involved in ligand binding 
reside at either end of the ligand binding domain. Furthermore, the ligand binding 
domain is involved in heterodimerization and in protein-protein interactions leading to 
transcriptional activation as well as nuclear localization (104,105). A mutation in the 
ligand binding domain of the VDR has been identified at codon 271 in patients with 
HVDRR leading to absence of a biological response to 1,25-(OHhD3 (103). Like in 
DBD and hinge region, also in the ligand binding domain a mutation has been found 
that introduces a stop codon (codon 292), leading to the formation of a truncated VDR 
(102,106). For the small COOH-tenninal region (Figure 6, region F) no specific function 
has been identified yet. 
Binding of 1,25-(OHhD3 alters the conformation of the VDR and enhances the 
phophorylation of the VDR. The VDR can be phosphorylated at several sites (107) by 
several kinases, including protein kinase C (108,109), cAMP-dependent protein kinase 
A (110) and casein kinase II (111,112). Specific phosphorylation sites are located at 
serine residues 51 (108) and 208 (112). Phosphorylation of the VDR is important for its 
binding to the vitamin D responsive elements (discussed below) and for its 
trans activation function (113). The unoccupied VDR is predominantly localized in the 
cytoplasm (114). Upon binding of its ligand, the cytosolic VDR is transported to the 
nucleus through a microtubule-mediated mechanism (115,116). TIle importance of 
translocation of the VDR to the nucleus for the 1,25-(OHhD3 bioactivity is illustrated 
by a case of HVDRR, where translocation to the nucleus was impaired (117). 
To regulate transcriptional activity, the activated nuclear VDR binds to specific 
nucleotide sequences in the promoter regions of vitamin D responsive genes. These so-
called vitamin D response elements (VDREs) consist of direct repeats of hexameric half 
elements spaced by three nucleotides. For high affinity binding to the VDRE the VDR 
requires a binding partner, termed receptor auxiliary factor (RAF) or nuclear accessory 
factor (NAF) (118-121). Isoforms of the retinoic-X-receptor (RXR) have been identified 
as the possible receptor auxiliary factor. In vitro synthesized RXR forms heterodimers 
with VDR and binds to the VDRE (122-124). The porcine intestinal accessory factor has 
recently been shown to be a RXR (125). In human osteoblastic cells, the endogenous 
accessory factor has been shown not to be RXR alpha, despite of the ability of RXR 
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alpha and VDR, synthesized in vitro, to bind the hOC VDRE (126). Three RXR genes 
have been identified (127), which suggests that various VDR-RXR heterodimers may 
control transcription differently or possibly affect transcription of different genes. 
Recently, interaction of the VDR with a component of the core transcriptional 
machinery, TFIIB, has been shown. The C-tenninalligand binding domain of the VDR 
interacts with a 43-residue amino-terminal domain of TFIIB (128,129). Whether the 
nuclear protein complex binding to the VDRE contains additional proteins or factors is 
unknown. In contrast to heterodimers, several groups have suggested the binding of 
VDR/VDR homodimers to certain VDREs (130-133). 
Distinct VDREs, which have the potential to interact with different receptor 
homo- and heterodimers have been identified in the promoters of several genes, 
including the human (43,44) and rat (30-32) osteocalcin, mouse osteopontin (73), rat 
cytochrome P450 24-hydroxylase (132,134-136) as well as the mouse calbindin D28k 
(137), chicken 13 integrin (138) and chicken carbonic anhydrase-II genes (139) (Table 2). 
In the human PTH gene a VDRE has been identified that consists of a single hexameric 
element and mediates transcriptional repression in response to 1,25-(OHlzD3 (140). 
Members of the steroid/thyroid hormone receptor family bind HREs with distinct 
spacing requirements between the half sites of the HREs (141,142). Within the VDREs, 
however, also differences have been found in spacing between half sites and the identity 
of the complexes capable of binding to VDREs (130-133). VDR/VDR homodimers bind 
to hexanucleotide repeats with 6 nucleotides spacing, whereas VDR/RXR heterodimers 
bind to VDREs with three nucleotides spacing. However, conflicting results have been 
Table 2 
Sequences of vitamin D response elements (VDREs) in tbe promoters of several genes, 
rat ostcocaldn VDRE 5'·GGGTGA alg AGGACA·3' 
human osteocalcin YDRE 5'-GGGTGA acg GGGGCA-3' 
mouse osteopontin VDRE 5'·GGTICA ega GGTICA-3' 
rat cytochrome P45024 YDRE 5'-AGGTGA gIg AGGGCG-3' 
rat calbindin D-28K YORE 5'-GGGGGA tgt GAGGAG-3' 
avian integrin 83 YDRE 5'·GAGGCA gaa GGGAGA-3' 
chicken carbonic anhydrase II VDRE 5'-GGGGGA aaa AGTCCA-3' 
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Table 3 
Sequences of vitamin D response elements (VDREs) for which VDR/VDR homodimer binding has been 
reported. 
human osteocalcin VDRE 5'-OGGTGA ctcace GGGTGA-3' 
rat cytochrome P45024 VDRE 5'-GGTCGA gcccag GGITCA-3' 
mouse osteopontin YDRE 5'·GGTICA ega GGTfCA-3' 
obtained in determining the character of the dimers that bind the osteopontin VDRE, 
which is a VDRE with 3 nucleotides spacing between the half elements. Carlberg et al. 
(130) showed that RXR is required for VDR binding to the osteopontin VDRE, whereas 
Freedman et al. (131) and Nishikawa et al. (133) reported VDR/VDR homodimer 
binding to the osteopontin VDRE (Table 3). 
Ligand binding seems to be a prerequisite for binding of the VDR complex to the 
VDRE, especially for binding of heterodimers to the VDRE (143). Also ligand-
independent VDR-DNA interaction has been described (121). In the presence of the 
ligand for RXR, 9-cis retinoic acid, heterodimer binding to the VDRE is reduced 
(124,144). 
Finally, interaction of nuclear protein complexes with regulatory elements depends 
on chromatin structure. Genes located in heterochromatin are unable to bind 
transcription factors. In euchromatin regions the expression of genes also depends on 
chromatin structure. Positioning of nucleosomes determines the availability of regulatory 
elements. Furthermore, nucleosomes may play an important role in the interaction 
between regulatory elements and/or regulatory elements and the basal transcriptional 
machinery (145,146). 
Figure 8 shows a model for the genomic mechanism of action of 1,25-(OHlzD3 
in target cells. 
1.2.3 Effects of Vitamin D 
The main effect of 1,2S-(OH)2D3 is elevation of plasma calcium levels in order 
to maintain plasma calcium homeostasis. Therefore, 1,2S-(OHlzD3 exerts effects on the 
intestine, kidney and bone. In response to slight hypocalcemia PTH secretion is 
increased, followed by an increase in renal 1,2S-(OHlzD3 production, which stimulates 
transepithelial calcium transport across the gut. Both PTH and 1,2S-(OHlzD3 increase 
calcium transport from the renal tubular lumen into the bloodstream. In addition, 1,25-
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(OH}zD3 Can increase PTH-stimulated bone calcium mobilization_ Once calcium needs 
are met, PTH secretion is suppressed as well as production of 1,25-(OH}zD3 (147,148). 
1,25-(OH}zD3 affects skeletal metabolism by regulating proliferation and 
differentiation of osteoblasts (3) and several parameters of osteoblastic function, 
including VDR level (149), alkaline phosphatase activity (150), and the production of 
several proteins (lSI): osteocalcin (15-17), osteopontin (64) and procollagen type I (152), 
IGF-I and IGF-BPs (153,154), IGF receptors (ISS), and TGFfi (156,157). Furthermore, 
1,25-(OH}zD3 affects cytoskeletal proteins (158,159). Previously, 1,25-(OH}zD3 effects 
on the osteoclast were thought to be exerted indirectly via the osteoblasts (160). 
However, recently, VDR transcripts have been shown also in osteoclasts, suggesting that 
1,25-(OH}zD3 may modulate osteoclast function directly (161). Furthermore, 1,25-
(OH}zD3 modulates differentiation of osteoclast progenitors (162). 
Besides the effects of 1,25-(OH}P3 on classical target tissues, 1,25-(OH}zD3 has 
been shown to affect several non-classical target tissues, of which many have been 
reported to contain the VDR, including the hematolymphopoietic system, muscles, brain, 
mammary gland, placenta, pancreas, thyroid, lung, liver and skin (148). In addition to 
normal tissues and organs, VDRs have been identified also in several malignant cell 
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types. Inhibition of proliferation of cancer cells by 1,25-(OHlzD3 has led to the 
speculation that 1,25-(OHlzD3 may be clinically useful as an anticancer agent (163-166). 
1.3 LOCALLY PRODUCED FACTORS IN BONE 
1.3. I Introduction 
A large series of growth factors and cytokines is produced by bone cells or in the 
vicinity of bone, e.g. bone marrow cells. These locally produced factors can broadly be 
subdivided into bone matrix bound and soluble factors (Table 4). Among them are 
transforming growth factor II (TGFll) type 1 and 2, insulin-like growth factors I (IGF-I), 
Table 4 
Matrix bound and soluble factors locally produced in bone 
Matrix bOllnd factors 
Transforming growth factor 8 (TGFB) 
Bone morphogenetic proteins (BMPs) 
Insulin-like growth factors (IGP-I, IGF-II) 
Platelet derived growth factor (PDOF) 
Fibroblast growth factors (FGFs) 
Other matrix proteins, including osteocalcin, osteopontrn, 
bone sialo protein (BSP) (see also Table 2) 
Soluble factors 
Interleukins (IL-l, IL-6, IL-IO) 
Prostaglandins (PGs) 
B2 Microglobulin 
Tumor necrosis factors (TNFa, TNF8) 
gamma-Interferon (gamma-IFN) 
Macrophage colony-stimulating factor (M-CSF) 
Granulocyte macrophage colony-stimulating factor (GM-CSF) 
Leukemia inhibitory factor (LIF) 
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and bone morphogenetic protein-2 (BMP-2), which have been investigated in this study. 
1.3.2 The TGFfJ supeifamily 
TGFG and BMP-2 belong to the TGFG superfamily. 111e TGFB superfamily is 
divided in several subfamilies, which show a higher or lower amino acid sequence 
homology. Seven cysteine residues are highly conserved in members of the superfamily, 
which is subdivided into the TGFI3, Miillerian inhibitory substance (MIS), inhibin/activin, 
and the Vg-related subfamilies. Bone morphogenetic proteins 2 belongs to the Vg-related 
subfamily (Figure 9). 
Figure 9 
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comparison of the amino acid sequences of the mature regions of TGFO superfamily members as reported 
by Rosen and Thies (227). Percentage of amino acid homology is depicted. 
1.4 TRANSFORMING GROWfH FACTOR Il 
1.4.1 TGFfJ stntcture 
TGFI3 is synthesized and secreted in a latent, biologically inactive form (167,168), 
and consists of the two polypeptide chains noncovalently linked to the remainder of the 
TGFI3 proregion. This proregion prevents interaction of TGFB with TGFB cell surface 
receptors (169) (Figure 10). In addition, a TGFI3 binding protein, which varies in size 
depending on the cell type by which it is expressed, is disulphide linked to the TGFI3 
proregion of the latent complex (170). In serum, an additional latent form ofTGFI3 exists 
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consisting of TGFI3 complexed with "2 macroglobulin (171). TGFI3 can be activated by 
extreme pH conditions, e.g. by the low pH under the ruffled border of the osteoclast 
during bone resorption (172-174) or by proteolytic activity (175) (Figure 10). However, 
activation of latent TGFJ3 has also been reported to occur through binding to the IGF-II 
receptor (176). In mammalian cells three different types ofTGFl3s have been identified, 
TGFI31, TGF132 and TGFIl3. In addition, TGF134 and TGFl3s have been identified in the 
Figure 10 
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chicken and Xenopus laevis genomes, respectively. Besides homodimers, also TGFll 
heterodimers consisting of one polypeptide chain from one type of TGFJl linked to a 
polypeptide chain from anothert type of TGFll, e.g. TGFll1.2 and TGFll2.3, have been 
identified (177). 
1.4.2 Expression of TGFj3 
TGFll is expressed by a number of cell types, both normal and oncogenically 
transformed cells (178). In particular, TGFll is expressed during embryonic development, 
when expression of TGFll occurs in a spatial and temporal pattern, particularly in tissues 
of mesenchymal or mesodermal origin. High expression is observed at sites undergoing 
intense development and morphogenesis, including osteogenesis, (179,180). The largest 
amounts of stored TGFll in the body are found in bone, although platelets contain the 
highest concentrations of TGFll. 
1.4.3 Mechanism of action of TGFj3 
TGFll binds to three cell surface receptors, two glycoproteins of 53 and 70-100 
kD, called receptors I and II, respectively, and a membrane proteoglycan, designated 
betaglycan (181). Betaglycan may act as a component presenting TGFll to its signalling 
receptors I and II (182). TGFll receptors I and II are transmembrane receptors that 
contain a serine/threonine kinase domain on the cytoplasmic surface and are usually 
coexpressed in cells. The type I receptor is unable to bind ligand in the absence of type 
II receptors (183,184). Similarly, type II receptors are unable to signal in the absence of 
type I receptors (185). Type II receptors can interact with different type I receptor 
isoforms. The process of receptor activation is schematically depicted in Figure 11. The 
type II receptor is constitutively autophosphorylated and binds ligand independently of 
receptor type I. Subsequently, receptor I recognizes the TGFll/receptor type II complex 
and forms a stable complex with receptor type II. Until now, it is unknown whether 
receptor type I recognizes TGFll, which is conformationally changed after binding to 
receptor type II or that receptor type I recognizes the interface of the TGFll/receptor 
II complex. Next, receptor type I is phosphorylated on serine and threonine residues in 
the so-called GS domain of receptor I, a stretch of 30 amino acids preceding the kinase 
domain and conserved in type I receptors, by the kinase activity of receptor type II. 
Phosphorylation of the type I receptor is required for signal transmission. (186-188). 
Upon activation of the type I receptor a cascade of events may occur eventually leading 
to a biological response. Factors that have been suggested to belong to the signal 
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transduction pathway ofTGFIl include protein kinase C (189-191), phosphatidylcholine-
phospholipase C (192), myelin basic protein (MBP) kinases (193), Src family of protein 
tyrosine kinases (194) and p21ras (195,196). Recently, TGFIl responsive elements have 
been identified in the osteocalcin gene (35) and the epidermal growth factor receptor 
gene (197). TGFIl responsiveness of the osteocalcin gene involves binding of AP-1 
proteins (35). 
1.4.4 Effects of TGFp all bOlle 
TGFJl is involved in the process of bone formation and healing through 
stimulation of chondrogenesis and osteogenesis. Increased bone matrix apposition is 
observed after TGFIl treatment and autoinduction of TGFIl synthesis is observed in 
osteoblasts and chondrocytes (198-201). Stimulation of bone formation by TGFIl is at 
least in part mediated through prostaglandin synthesis (202). TGFJl has potent effects on 
bone cells in vitro. However, these effects depend on the maturation stage of the cells. 
In some cultured osteosarcoma cell lines, including ROS 17/2.8, UMR 106 and MG 63 
cells, TGFIl inhibits proliferation and stimulates differentiation (203,204), whereas in 
primary osteoblasts, MC3T3 and Saos cells TGFIl stimulates proliferation and inhibits 
differentiation (203,205-209). Furthermore, TGFIl affects the production of bone matrix 
proteins and other phenotypic markers of osteoblasts (26,67,204,210). Beside its effects 
on bone formation, TGFIl also affects bone resorption. In the neonatal mouse organ 
culture system large doses of TGFIl stimulate bone resorption (211). However, in fetal 
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rat long bone cultures bone resorption has been reported to be inhibited by TGFIl (212). 
TGFIl does not affect osteoclastic bone resorption directly (213), but primarily affects 
osteoclast precursor proliferation, fusion of precursors to form multinucleated osteoclasts 
and migration of osteoclasts (202,214-216)_ Furthermore, TGFI3 regulates matrix 
degradation by decreasing plasminogen activator activity and increasing the activity of 
plasminogen activator inhibitor (217-219). In transgenic mice, overexpression ofTGFIl1 
induced several skeletal abnormalities, including impaired bone mineralization and 
disrupted architecture of the epiphyseal growth plate (220). 
1.5 BONE MORPHOGENETIC PROTEIN-2 
/.5.1 Slmcture, expressioll alld effecls 011 bone 
Nine BMPs have been identified, but only BMP-2 to BMP-9 are members of the 
TGFI3 superfamily. In Table 5 BMP-2 to BMP-9 are listed with their synonyms. BMPs 
are synthesized as dimeric precursor proteins that are posttranslationally processed into 
active 30 kD homodimeric proteins before secretion. They belong to the Vg-related 
subfamily of the TGFIl superfamily. 
BMP-2 has been localized in several embryonic organ systems, including heart, 
Table 5 
List of bone morphogenetic proteins belonging to the TGFG superfamily and their synonyms. BMP-l is not 
a member of this family. 
Bone morphogenetic proteins (BMPs) 
Factor I Synonym 
BMP-2 BMP-ZA 
BMP-3 Ostcogenin 
BMP-4 BMP-2B 
BMP-5 
BMP-6 
BMP-7 Osteogenic protein-1 (OP-1) 
BMP-8 Osteogenic protein-2 (OP.2) 
BMP-9 
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nervous system, hair and tooth buds, as well as in areas of skeletal formation (221,222) 
and in osteosarcoma cells (223). 
BMPs bind to a specific family of type ! and II receptors related to the 
serine/threonine kinase receptors of the TOFJ3 family, that are probably activated by a 
mechanism comparable to that of the TOFIl family (224,225) (Figure 10). 
BMP-2 is an osteoinductive factor that is, in contrast to TOFJ3, capable of 
inducing ectopic bone formation (226,227). In addition, BMP-2 has been shown to be 
involved in bone defect repair by inducing new bone formation (228,229). Moreover, the 
BMP-induced bone formation follows the sequence of events observed in embryonic 
endochondral bone formation: mesenchymal cells are transformed into chondroblasts, 
cartilage is formed and subsequently replaced by bone. 
BMP·2 affects differentiation of mesenchymal stem cells into adipocytes, 
chondrocytes or osteoblasts depending on its concentration (230,231). BMP-2 has been 
shown to regulate proliferation and differentiation of embryonic skeletal precursor cells 
(232). In vilro, BMP-2 induces osteoblast differentiation of isolated cells from bone 
marrow and calvaria and of cell lines as indicated by increased expression of osteocalcin, 
collagen type I and alkaline phosphatase activity (233-239). Furthermore, BMP-2 
enhances the expression of interleukin-6, TOFIl 1 (240), IOF-! and IOF-II (241) in 
osteoblast-like cells. 
1.6 INSULIN-LIKE GROWfH FACTOR-! 
1.6.1 Sin/cillre, expression and effecls on bone 
IOF-! is a single-chain polypeptide with structural homology to pro insulin (48%). 
In serum, IOF-! is bound to an acid labile subunit and members of the family of the IOF 
binding proteins (lOFBPs). These act as transport proteins, prolong the half-life of IOFs, 
provide a means of tissue-specific localization and modulate interaction of IOFs with 
their receptors (242). Six IOFBPs have been cloned, of which IOFBP-I, IOFBP-3 and 
IOFBP-4 bind IOF-i. Except for IOFBP-I, all IOFBPs are produced in bone (243). 
The IOF-I receptor mediates most cellular effects of IOF-i. This receptor is a 
membrane receptor that consists of an extracellular a-subunit linked to a 
transmembrane/cytoplasmic Il-subunit, which together form the all half-receptor. The 
mature IOF-I receptor is formed by linkage of two half-receptors. The cytoplasmic part 
of the receptor contains tyrosine kinase activity and tyrosine residues that are 
autophosphorylated by the kinase of the other Il subunit upon ligand binding. 
Subsequently, insulin receptor suhstrate I (IRS-I) is phosphorylated, followed by a 
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cascade of events that has not yet been fully established (244). 
IGF-I is expressed by a wide variety of cells and organs, including liver, testis, 
ovary, lymphoid and hematopoietic organs, salivary gland, adrenal medulla, parathyroid 
gland, nervous system, bone marrow and chondrocytes (245). Expression of IGF-I has 
also been reported in murine osteoblasts (246,247). However, conflicting results have 
been obtained on the expression of IGF-I in human osteoblasts (248,249). Receptors for 
IGF-I have been identified in fetal rat os teo blasts (250). 
At the moment IGF-I is considered as an autocrine and paracrine stimulator of 
bone formation during bone remodelling. Systemic IGF-I may playa role in achieving 
normal longitudinal skeletal growth. IGF-I has been shown to enhance both osteoblast 
and osteoclast differentiation. IGF-I enhances procollagen type I mRNA levels and type 
I collagen synthesis in osteoblast-enriched cultures of fetal rat calvaria. At the same time, 
IGF-I decreases collagenase expression, thereby decreasing collagen degradation (251-
253). Furthermore, IGF-I increases alkaline phosphatase activity and osteocalcin 
production (28,254-256). Besides the effects on the osteoblast, IGF-I also affects the 
osteoclast. Osteoclast formation and activity has been reported to be enhanced by IGF-I, 
although this effect may be mediated indirectly through the osteoblast (257,258). 
1.7 SCOPE OF THE THESIS 
Bone remodelling is a complex process, which needs to be tightly regulated. In this 
regulation both hormones and locally produced factors play a role. During bone 
formation, systemic factors may act either directly or indirectly on the osteoblast. 
Systemic factors may affect the osteoblast indirectly by modifying the synthesis, activity 
or binding of local factors (259). Local factors are synthesized by osteoblasts and 
nonosteoblastic skeletal cells and may act in an autocrine or paracrine way. In addition, 
local factors that are synthesized by the osteoblast during bone formation may act on the 
osteoclast, thereby linking bone formation to bone resorption. During bone resorption, 
osteoclasts resorb bone matrix and may thereby release factors that in turn act on the 
osteoblast. In some tissues local factors have been described to influence the synthesis 
of steroids or production of enzymes involved in the steroidogenesis (259). 
In vitro, 1,25-(OHlzDJ has been shown to increase TGF£I synthesis in osteoblasts 
(156) and in vivo, vitamin D deficiency resulted in a reduction of TGF£I in bone (157). 
IGF-I release is inhibited by 1,25-(OHlzDJ in mouse osteoblastic cells (153,154). 
Several reports have indicated the importance of local factors in the action of 
steroids on bone. Those reports primarily focussed on the effects of steroids on the 
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synthesis of local factors, which in turn affect the bone remodelling process. In contrast, 
the studies described in this thesis deal with the effect of the presence of local factors 
on the action of the systemic hormone, 1,25-dihydroxyvitamin D3 in bone. The locally 
produced factors that were studied in this thesis are TGFll, BMP-2 and IGF-I, which 
have been identified as stimulators of bone formation. 
The following topics have been studied: In Chapter 2 we investigated the effect of TGFfi 
on YDR levels in osteoblast-like cells and studied the importance of receptor regulation 
for two biological responses to 1,25-(OHlzD3, osteocalcin and osteopontin expression. 
Next, we investigated the mechanism whereby TGFfi modulates 1,25-(OHlzD3 
enhancement of osteocalcin and osteopontin expression in osteoblast-like cells (Chapter 
3). The importance of modulation of VDR level by TGFll for another biological 
response to 1,25-(OH}zD3, induction of 24-hydroxylase activity in osteoblast-like cells, is 
studied and described in Chapter 4. 
Furthermore, we compared the effects ofTGFf.l, BMP-2 and IGF-I on the 1,25-(OH}zD3-
induced increase in osteocalcin and osteopontin expression (Chapter 5) and 1,25-
(OH}zD3-stimulated bone resorption (Chapter 6). In Chapter 6, also the presence and 
distribution of these locally produced factors in bone was studied. 
Finally, Chapter 7 deals with the identity of nuclear protein complexes that bind to the 
osteocalcin and osteopontin YDREs in the promoter regions of these genes. The results 
are discussed in Chapter 8 and summarized in Chapter 9. 
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ABSTRACT 
In the present study the interaction between a locally produced factor in bone, 
transforming growth factor Il (TGFIl) and a systemic regulator of bone metabolism, 
1,25-dihydroxyvitamin D3 (1,25-(OHhD3) was investigated. 
In rat (UMR 106, ROS 17/2.8) and human (MG 63) osteoblastic cell lines and 
in isolated fetal rat osteoblasts, TGFf3 caused a comparable increase in vitamin D 
receptor (VDR) level. A maximum was observed after 6 h at 1 ng/ml TGFi3. 
Scatchard analysis revealed that up-regulation of VDR is due to an increase in 
receptor number and not to a change in affinity. This was supported by Northern blot 
analysis, which showed a dose- and time-dependent increase in VDR mRNA by 
TGFi3. To assess the significance of the TGFf3-induced increase in VDR level for 
1,25-(OHhD3 effects, cells were preincubated with TGFi3 for 4 h (causing a 2-3 fold 
increase of the VDR level) and subsequently incubated with 1,25-(OHhD3 for 4 h 
and 24 h. TGFf3 preincubation potently inhibited subsequent 1,25-(OHhD3 
stimulation of osteocalcin production in both ROS 17/2.8 and MG 63 cells on protein 
as well as mRNA level. A similar inhibition by TGFi3 was observed on the 1,25-
(OHhD3-induced increase in osteopontin mRNA. 
The current study demonstrates dissociation between regulation of VDR level 
and modulation of two 1,25-(OH)2D3 biological responses by TGFll in osteoblast-like 
cell lines of different origin. This dissociation shows that besides interaction at VDR 
level also at other levels in the cell interaction(s) between TGFIl and 1,25-(OHhD3 
exist. Besides, these data emphasize the potential importance of the interplay of 
locally produced factors and systemic calciotrophic hormones in the regulation of 
bone metabolism. 
INTRODUCTION 
The seco-steroid 1,25-(OHhD3 is an important regulator of calcium homeosta-
sis. Besides stimulation of calcium absorption in the intestine an important effect of 
1,25-(OH)2D3 in response to a decrease in serum calcium concentration is stimulation 
of bone resorption (1). The vitamin D receptor (VDR) in bone is located in the bone 
forming cell (osteoblast) and not in the bone resorbing cell (osteoclast) (2,3). This 
indicates that 1,25-(OHhD3 stimulates bone resorption indirectly via the osteoblast 
(4). 
50 
TGFfJ-indliced dissociation between VDR level alld 1,25-(OH)~3 action 
Regulation of receptor number is thought to be an important mechanism by 
which target cell responsiveness to hormones is modulated. Several factors, including 
1,25-(OHlzD3 itself (5,6), glucocorticoids (7,8), parathyroid hormone (9,10), epidermal 
growth factor (11) and retinoic acid (12), have been demonstrated to modulate VDR 
level. Osteoblast responsiveness to 1,25-(OHlzD3 has been linked to VDR level. 
Induction of 24-hydroxylase activity by 1,25-(OHlzD3 closely paralleled VDR level 
after retinoic acid pretreatment (12). For both a stimulatory (24-hydroxylase) and 
inhibitory (collagen synthesis) bioresponse (13) the magnitude of the response to 1,25-
(OHlzD3 was directly correlated with the abundance of receptors (depending on rate 
of cell proliferation). Chen et al. (8,14) showed that receptor up-regulation increased 
the magnitude and sensitivity of responses to 1,25-(OHlzD3. However, with another 
steroid hormone, glucocorticoid, a dissociation was observed between receptor 
regulation and bioresponse (15). 
Transforming growth factor 1l (TGF1l) is produced in bone, and present as a 
latent complex (16). TGF1l has been thought to be activated during bone resorption 
by the low pH under the ruffled border of the osteoclast and to play an important 
role in the local regulation of bone remodeling (16,17). TGF1l has been shown to 
increase VDR level in UMR 106-06 cells after 3 days of incubation (18). Interaction 
between 1,25-(OH)P3 and TGFll has been described in MG 63 cells in the regulati-
on of biological responses after coincubation (19). 
In the present study we investigated the effect of TGFll on VDR level in 
several osteoblast-like cell lines and studied the sjgnificance of this modulation of 
VDR level for 1,25-(OHlzD3 stimulation of osteocalcin production, osteocalcin 
mRNA and osteopontin mRNA synthesis. In general, this study emphasizes the 
importance of interactions between systemic and locally produced factors for the 
regulation of bone metabolism. 
MATERIALS AND METHODS 
Materials 
[23,24.3H1-1,25(OH)2D3 (105.5 Ci/mmol) was obtained from Amersham International 
(Aylesbury, Buckinghamshire, United Kingdom) and non-radioactive 1,25(OH)2D3 was generously 
provided by LEO Pharmaceuticals BY (Weesp, the Netherlands). TGFB type 2 was generously provided 
by Dr. J. Feyen, Sandoz Pharma Ltd (Basel, Switzerland). Fetal calf serum (FCS), aMEM medium, 
penicillin, streptomycin and glutamine were purchased from Flow Laboratories (Irvine, United Kingdom) 
and BSA fraction 5 from leN Pharmaceuticals, Inc. (Costa Mesa, CA, USA). The rat VDR eDNA probe 
(1.7 kb) was generously provided by Dr. J.W. Pike (Houston, TX, USA). the rat osteocalcin probe (0.52 
kb) and the rat osteopontin probe (1.3 kb) by Dr. M. Noda (West Point, PA, USA). Rat osteocalcin 
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antiserum was a generous gift of Prof. R. Bouillon (Leuven, Belgium). All other reagents were of the 
best grade commercially available. 
Cell culture 
MG 63 cells were generously provided by Prof. R. Bouillon and ROS 17/2.8 cells by Dr. S.B. 
Radan (Merck, Sharp & Dohme Research Laboratories, West Point, PA, USA). UMR 106, ROS 17/2.8 
(rat), and MG 63 (human) cells were seeded at 50,000 cclls/cm2 and cultured for 24 hours with aMEM 
supplemented with 2 mM glutamine, 0.1% glucose, 100 Vlml penicillin, 100 Vlml streptomycin and 10% 
fetal calf serum (FeS), Next, medium was replaced by aMEM with 2% charcoal-treated FCS and cells 
were cultured for a 24 h· or 48 h-period during which the cells reached confluence. During this period, 
cells were incubated with the agents to be tested. Fetal rat osteoblasts were isolated from 20-day old fetal 
calvaria by sequential EDTA and collagenase treatment (20), seeded at 25,000 ceUs/cm2 and cultured for 
four days as described for the cell lines. 
Preparatioll of cell extracts and {3HJ1,25(OHJ-jJ 3 binding assay 
For single point assays, conditions were employed which were previously shown to provide valid 
estimates of total receptor content in cytosoHc extracts (6). Cells were incubated and cultured as 
described above. Next, the cell pellet was extracted on ice in a hypertonic buffer consisting of 300 mM 
KCl, 10 mM Tris-HCI (pH 7.4), 1 mM EDTA, 5 mM dithiothreitol, 10 mM sodium molybdate and 0.1 
% Triton X-IOO. High-speed supernatants were obtained and 250 It! aliquots were incubated overnight at 
4°C: 1) for single point assays with 0.25 nM fH11,2S-(OH}zD3 or 2) for scatchard analysis with several 
concentrations of r3H}1,2S-(OH}zD3 (ranging from 0.2 nM to 0.01 nM), in the absence or presence of a 
200-fold molar excess of unlabeled hormone. Receptor bound 1,25-(OH}zD3 was separated from 
unbound ligand by charcoal adsorption (21). 
Osteocalcill assay 
The incubation protocol to study the significance of TGFll-induced increase in VDR level for the 
l,25-(OH)2D3-stimulated osteocalcin production is shown in the inset in Fig. SA. Cells were preincubated 
with TGFB for 4 h followed by the addition of 1,25-(OH}zD3 or vehicle without removal of TGFB. 
Osteocalcin measurement in medium of MG 63 cells was performed by use of the INCSTAR (Stillwater, 
Minnesota, USA) 1251 RIA kit for osteocalcin. Before measurements medium was freeze dried and 
reconstituted in assay buffer, so that medium was concentrated 6-fold. Cellular osteocalcin level of MG 
63 cells was below detection limit. Osteocalcin measurements in cells and medium of ROS 17/2.8 cells 
were performed according to the method described by Verhaeghe et al. (22). Sample preparation of cell 
extracts: cells were washed in PBS-triton X-l00 (0.1%), removed in 0.5 ml6 M guanidine-HCl in 0.1 M 
Tris-buffer (pH 8.0) and next assayed for osteocaldn. 
DNA and protein meaS/lremellts 
Changes in DNA content were assessed by the fluorimetrical method of Johnson-Wint and 
Hollis (23). Protein concentration was measured according to the method of Bradford (24). 
Nortl/em and dot blot analysis 
RNA isolation was performed according to the method of Chomszinski (25). Electrophoresis of 
toW.l cytoplasmic RNA (30 Ilg) through a formaldehyde gel and Northern blotting (Gcne Screen filters) 
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Time-course of the effect of 1 ng/illi TGFI3 on VDR level in A) UMR 106, B) ROS 17/2.8 and C) MG 
63 cells. Cells were cultured as described in Materials and Methods and incubated for the time indicated 
with 1 ng/ml TGFB. Data arc expressed as mean ± SO of single point assays in duplicate of two 
separate experiments. '" p<O.05; U p<O,OO5; *** p<O.OOl versus control 
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were performed according to the method described by Davis et al. (26). Dot blots were performed 
according to the method described by Samhrook ct a1. (27). 
Hybridization of Northern blots: Northern blots were prehybridizcd for 2 hours at 42°C in a 
buffer containing 50% formamide, 0.2% SDS, 1x Denhardt's solution, 5x sse (lx sse", 150 ruM Nael 
and 15 ruM Na citrate, pH 7,0), 20 nlM NaHzP04 • 6% dextran sulphate, 1 ,ug/ml herring sperm DNA 
and then hybridized for 16·24 h at 42°C with 32P_labeled eDNA probe. Filters were washed twice with 2x 
sse and 0.5% SDS for 5 minutes at room temperature, once with 2x sse and 0.5% SDS for 30 minutes 
at 50°C and once in 1x sse and 0.5% SDS for 30 minutes at room temperature and exposed to X-ray 
films. The eDNA probes included 1.7 kb rat VDR fragment, 0.52 kb rat ostcocalcin fragment, 1.3 kb rat 
osteopontin fragment, 1,2 kb hamster fl-actin fragment, and 0,8 kb human GAPDH fragment. For 
rehybridization filters were washed for 2 h at 65°C with 5 mM Tris-HCI (pH 8.0), 0,2 ruM NazEDTA 
(pH 8,0), 0,05% sodiumpyrophosphate and O,lx Dcnllardt's solution, 
Data analysis 
To assess significance of interaction between two agents tested data were analyzcd with analysis 
of variance for 2-way design, Other statistical analyses were performed using Student's t-test. 
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Figure 2 
Responses to different doses of TGFfi of VDR level in ROS 17/2,8 (open bars), UMR 106 (solid bars) 
and MG 63 (semi-solid bars) cells, Cells were cultured as described in Materials and Methods and 
incubated for 4 h with TGFfl, Data are expressed as percentage of control of single point assays (fmol 
bound/mg protein) in duplicate of two separate experiments, Increases in VDR level arc significant 
(p<O,OOl versus control) in all incubations, except for ROS 17/2,8 cells at O,QIng/rul TGFB, 
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RESULTS 
The effect of TGFfJ on VDR level ill several osteoblast-like cells. 
In UMR 106 (Fig. 1A), ROS 17/2.8 (Fig lB) and MG 63 (Fig. Ie) cells 1 
ng/ml TGFJ3 caused a time-dependent increase in 1,25-(OH}zD3 binding with a 
maximum after 6 h. After 24 h 1,25-(OH}zD3 binding decreased towards prestimulati-
on level in all cell lines, although 1,25-(OH}zD3 binding was still significantly elevated 
in both ROS 17/2.8 and UMR 106 cells. As shown in Fig. 2, in all three cell lines 
tested TGFJ3 caused a dose-dependent up-regulation of the VDR. A maximum effect 
was observed with 1 ng/ml TGFI.l. In UMR 106 and MG 63 cells a significant 
increase was already observed. after treatment with 0.01 ng/ml TGFI3, whereas in 
ROS 17/2.8 cells a first significant increase in VDR level was observed after incubati-
on with 0.1 ng/m] TGFI.l. The EDso for the effect on VDR was 0.05-0.1 ng/ml in 
UMR 106 and MG 63 cells and about 0.5 ng/m] in ROS 17/2.8. 
In ROS 17/2.8 cells basal VDR level was higher than in MG 63 and UMR 106 
cells. During the period we cultured the ROS 17/2.8 cells (about 20 passages) basal 
VDR decreased from 133.10 ± 8.22 fmol eH]1,25-(OH}zD3 bound/mg protein to 
8.95 ± 0.49 fmol eH]1,25-(OH}zD3 bound/mg protein. However, independent of 
basal VDR level TGFI.l (1 ng/ml) caused a two-fold increase in VDR level (data not 
shown). 
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Figure 3 
Scatchard analysis of TGFfi effed on 1,25-(OHhD3 binding in UMR 106 cells. Cells were cultured as 
described in Materials and Methods and incubated for 24 h with or without 1 ngjml TGFG. 
55 
Chapter 2 
Besides these osteoblast-like cell lines also in isolated fetal rat osteoblasts 
TGFll (1 ng/ml) increased 1,25-(OHhD3 binding (from 16.51 ± 0.31 fmol [3H]I,25-
(OHhD3 bound/mg protein to 29.29 ± 1.28 fmol [3H]I,25-(OHhD3 bound/mg 
protein). Both for the cell lines tested and the primary cultures the maximal increase 
in VDR level at 1 ng/ml TGFll was 2-3 fold. 
Scatchard analysis (Fig. 3) revealed that the increase in 1,25-(OHhD3 binding 
in UMR 106 cells was not due to a change in the apparent dissociation constant of 
the VDR. An important role for new receptor synthesis in the TGFll effect on VDR 
is further demonstrated by mRNA analysis. TGFll increased VDR mRNA in ROS 
17/2.8 (Figs. 4A and B) and UMR 106 cells (data not shown) in a dose- and time-
A 
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B 
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l1-actin 
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Figure 4 
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Effect of TGP6 incubation on VDR mRNA in ROS 17/2.8 cells and the effect of coincuhation with 
actinomycin D. CeUs were cultured as described in Materials and Methods and incubated A) for 2 and 4 
h with 1 ng/ml TGF3 (T) or control (C) medium, or B) for 4 h with various doses of TGFB or C) for 4 
h with or without 1 ng/ml TGF3 (T) and 1 pg/ml actinomycin D (A). VDR mRNA data are shown in 
three dilutions of total RNA (15 p.g, 5 JIg and 1 p.g). Actin mRNA reflects a representative of one of 
these dilutions. 
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dependent manner. The TGFJl·induced increase in VDR mRNA in ROS 17/2.8 cells 
was completely blocked during coincubation with the transcription irdlibitor actinomy· 
cin D (1I'g/ml) (Fig. 4C). 
Effects of TGFfJ pretreatmellt 011 1,25·(OH)fJ3 stimulation of osteocalcin production. 
To study the relationship between receptor level and 1,25·(OHlzDJ effects on 
osteocalcin production cells (ROS 17/2.8 and MG 63) were preincubated with TGFIl 
for 4 h (causing an increase in VDR level) and subsequently incubated with 1,25· 
(OHlzDJ for 4 hand 24 h without removal of TGFIl. The incubation protocol is 
shown in diagram in the inset in Fig. 5A. The effects of 4 h preincubation with three 
concentrations of TGFIl (0.1, I, 10 ng/ml) on subsequent stimulation (24 h) of 
osteocalcin production by various 1,25·(OHhDJ concentrations (10-11.10-8 M) were 
studied. Cell proliferation was not affected by the continuous presence (28 h) of 
TGFIl in these experiments (data not shown). Basal osteocalcin production, measured 
in medium, was lower in MG 63 cells than in ROS 17/2.8 cells. In contrast to ROS 
17/2.8 cells cellular osteocalcin content in MG 63 cells was below detection level. In 
both ROS 17/2.8 and MG 63 cells incubation with TGFIl (4 h preincubation with 
TGFIl followed by 24 h without addition of 1,25·(OHhDJ) did not modulate basal 
osteocalcin production (Figs. SA and B). 1,25-(OHhDJ caused a dose·dependent 
increase in osteocalcin production, which was not significantly affected by preincubati· 
on with 0.1 ng/ml TGFIl in both ROS 17/2.8 (data not shown) and MG 63 (Fig. 5A) 
cells. However, 1 ng/ml (ROS 17/2.8 and MG 63 cells) and 10 ng/ml TGFIl (ROS 
17/2.8 cells), which doubled VDR level, irdlibited the 1,25·(OHhDJ stimulation of 
osteocalcin production (Figs. 5A and B). Studies with ROS 17/2.8 cells showed that 
10 ng/ml TGFIl was generally more potent than 1 ng/ml and that the effect of TGFIl 
is not the result of inhibition of osteocalcin secretion as it could be observed both in 
the medium and cellular extracts (data not shown). Time course studies with ROS 
17/2.8 cells revealed that an inhibitory effect of TGFB could be observed as soon as 
an effect of 1,25-(OHhDJ on osteocalcin production was detected, i.e. in the cells 
after 8 h 1,25-(OHhD3 incubation and in the medium after 16 h incubation (data not 
shown). The data on dissociation between TGFIl-induced up·regulation of VDR and 
1,25·(OHlzD3 stimulation of osteocalcin production in ROS 17/2.8 and MG 63 cells 
are illustrated in Figs. 6A and B for stimulation of osteocalcin production by 10-8 M 
1,25·(OHlzD3. Next, we studied the effect of TGFIl on the 1,25·(OHhD]'induced 
increase in osteocalcin mRNA in ROS 17/2.8 cells. Basal osteocalcin mRNA was not 
affected after incubation with TGFJJ for 8 h (4 h TGFJJ preincubation followed by 4 h 
without 1,25-(OHhD3) as well as after 28 h (4 h preincubation followed by 24 h 
without 1,25-(OHhDJ). Incubation for 24 h with 1,25-(OH)z03 induced a significant 
57 
Chapter 2 
A MG-63 
150 
• No TGFI3 TGFO t 
<l; 4 h t 1,25(OH>2Da 
z 125 0 0.1 ng/ml 24h 0 
'" 
TGFB 
~ 100 **** 
- • 1 ng/ml z 
0 TGFB •• 
--' 75 <l; T 0 
0 •• w 50 f-- ... (/) • T 0 1 1 
'" 
25 
Co 
0 
0 10-11 
-10 
10 Hi9 168 
11 ,25(OH)2D31 (M) 
B 
ADS 17/2.8 
30 
• No TGFI3 •• •• 
<l; I z 25 0 1 ng/mr ** 0 
0> TGFB I ~ 20 
- • 10 ng/ml z 
0 TGFB 
• 
--' 15 .. • 
... 
<l; T T 0 T 
0 
w 10 f--(/) 
0 
• 0> 5 • ... c 
0 
0 10.11 10
10 -9 
10 168 
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The effect of preincubation with TGFB on 1,25·(OH)2D3-induced increase in medium osteocalcin content 
of A) MG 63 and B) ROS 17/2.8 cells. Cells were cultured as described in Materials and Methods and 
incubated for 4 h with 0.1 Of 1 ng/llli TGFIl and subsequently (without medium change) for 24 h (as 
illustrated in the inset ill Fig. SA) with several doses of 1,25·(OHhD3' Data are expressed as mean ± 
SD of single point assays in duplicate of two separate experiments. + p<O.05 calculated as significance of 
interaction, U p<O.OO5 versus control, *u p<O.OO5 calculated as significance of interaction, *"'** 
p<O.OOl versus control. 
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Effect of TGFG on VDR level in relation to its effed on l,25-(OH)zD3-stimulatcd osteocalcin production 
in A) MG 63 and B) R()S 17/2.8 cells. Cells were cultured as described in Materials and Methods and 
incubated as shown in diagram in the inset of Fig. SA. Data represent medium levels of osteocalcin 
(open bars) after 24 It incubation with 10 nM 1,25-(OHhDJ with 4 h preincubation with TGFG and 1)5-
(OH)zD3 binding data (solid bars) after 4 h of preincubation with TGFfi expressed as mean ± SD of 
single point assays in duplicate of two separate experiments, '" p<O,(}()5, ** p<O.OOt versus control and 
*** p<O.OOl, **** p<O.OO5 calculated as significance of interaction. 
increase in osteocalcin mRNA, whereas incubation for 4 h with 1,25-(OHhD3 
induced a small, not-significant increase in osteocalcin mRNA (Fig. 7), Pretreatment 
for 4 h with 1 ng/ml TGF3 almost completely blocked the increase in osteocalcin 
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rnRNA by subsequent treatment with 1 nM 1,25-(OHhD3 for 24 h. The 4 h 1,25-
(OHhD3 action was not significantly inhibited. However, there is certainly no 
potentiation of the 1,25-(OH)zD3 action as a result of the TGFl3-induced up-regulati-
on of the vitamin ° receptor. Generally, data obtained on rnRNA level confirm the 
effects observed on protein level. 
Effect of TGFfJ pretreatlllellt all 1,25-(OH):/J3 induction of osteopontin mRNA. 
Similar experiments as described for osteocalcin measurements were perfor-
med to study the effect of TGFLl pretreatment on 1,25-(OHhD3 induction of 
osteopontin mRNA in ROS 17/2.8 cells. As shown in Fig. 8, 24 h 1 nM 1,25-(OHhD3 
induced an increase in osteopontin mRNA. After 28 h of incubation with TGFl3 (4 h 
preincubation with TGFl3 followed by 24 h without 1,25-(OHhD3) a small, significant 
increase in basal osteopontin rnRNA was observed. The 1,25-(OHhD3-induced 
increase (24 h) was almost completely blocked by 4 h pretreatment with 1 ng/ml 
TGFl3. In short term incubations (4 h TGFl3 followed by 4 h l,25-(OHhD3 incubati-
on) both TGFl3 and 1,25-(OHhD3 did not affect osteopontin mRNA synthesis 
significantly (Fig. 8). 
Together, as for the data on osteocalcin, the data obtained with respect to 
osteopontin after 24 h demonstrated a dissociation between TGFl3-induced up-
regulation of VDR and the regulation of 1,25-(OHhD3 biological activity (Le. 
increased VDR level is not followed by a potentiation of 1,2S-(OHhD3 effects). 
DISCUSSION 
VDR levels have been described to be regulated by several factors (5-12,28), 
including TGFf3 (18). In contrast to the data of Schneider et al. (18), who observed an 
increase after 72 h, we already observed a TGFl3 effect on VDR level after 2 h with a 
maximum after 6 h. Our observations seem to represent a direct regulation of VDR 
level, whereas the data obtained by Schneider et al. may be the indirect result of 
changes in proliferation and differentiation of the cells. This is conceivable because 
TGFl3 modulates the proliferation and differentiation of osteoblasts (29-33) and the 
VDR level has been reported to vary between developmental stages of cells (34,35). 
However, in our experiments 28 h incubation with TGFf3 did not affect proliferation. 
Our data show a comparable increase in VDR level by TGFl3 in several osteoblast 
cell lines and in isolated fetal rat osteoblasts, which indicates that this TGFl3 effect is 
not specific for transformed cells and is independent of species and state of differenti-
ation. Data obtained with ROS 17/2.8 cells indicate that the effect of TGFl3 is 
independent of basal VDR level. TIle increase in apparent VDR level can be the 
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ng/ml TGFB and subsequently (without mediuDl cbange) for 4 It and 24 h with 1O-9M 1,25-(OHhD3' 
Northern blots were quantitated by densitometric scanning, Data are expressed as the ratio of the 
amount of ostcocalcin OlRNA to that of GAPDH mRNA. * p<O,05 versus control. ... p<O.05 calculated 
as significance of interaction. 
Figure 8 
« 
z 
a: 
E 
J: 
o 
!L 
« (') 
::r: 
z 
a: 
E 
c 
';: 
c 
o 
0. 
o 
ID 
1,; 
o 
10 
9 
8 
2 
D control 
* 
TGFB 
C!!!! 1,25-(OH),D3 
I11III TGFB/1 ,25-(OH),D3 
4 h 24 h 
Tbe effect of preincubation with TGFB on 1,25-(OHhD3-induccd increase in osteopontin mRNA in ROS 
17/2.8 cells. Cells were cultured as described in Materials and Methods and incubated for 4 h with 1 
ng/ml TGFB and subsequently (without medium change) for 4 hand 24 h with 10-9 M 1,2S-(OHhD3' 
Northern blots were quantitated by densitometric scanning. Data are expressed as the ratio of the 
amount of osteopontin mRNA to that of GAPDH mRNA. '" p<O.OOl versus control. ++ p<O.OOl 
calculated as significance of interaction. 
61 
Chapter 2 
result of I) an increase in receptor affinity, 2) an increase in new receptor synthesis, 
and/or 3) increase in half-life of the receptor or its mRNA. Scatchard analysis 
revealed that TGFB increases the VDR number without a change in the apparent 
dissociation constanl. The effect of actinomycin D on TGFB-stimulated 1,25-(OHlzD3 
binding indicates an effect on new synthesis of VDR rather than on VDR half-life 
and this is confirmed by rnRNA analysis. Although we did not perform nuclear run-on 
experiments the fact that actinomycin D completely abolishes the TGFB-induced 
increase in VDR rnRNA level suggests that the TGFB effect is mainly the result of 
stimulation of VDR gene transcription and not of an increased VDR lORNA half-life. 
However, additional posttranscriptional effects can not be excluded. 
In both NIH 3T3 fibroblasts and ROS 17/2 cells TGFB activates the 012(1) 
collagen promoter via a specific sequence in the promoter that is the binding site for 
nuclear factor I (NFl) (36). In view of this the current data are suggestive for the 
presence of a TGFB-responsive element or NFl binding site in the VDR gene. 
However, as the sequence of the 5'-flanking region of the rat VDR gene is yet 
unknown it was not possible to identify such sequences in the VDR gene and also 
within the known 115 nucleotides of the promoter region of the human VDR gene 
(37) no NFl binding site could be detected. Kim el. al (38) demonstrated that TGFB 
and phorbol ester act through the same site in the promoter of the TGFB-gene. It is 
not likely that TGFB and phorbol ester/protein kinase C act through the same site in 
the VDR gene as 4 h phorbol ester treatment results in a decrease (39), whereas 
TGFIl causes an increase in VDR InRNA. 
For several 1,25-(OHlzD3 responses a relation with VDR level has been 
described (8,12-14). The present study shows that although TGFIl increases VDR 
level it potently inhibits 1,25-(OHlzD3-stimulated osteocalcin production (Figs. 6A 
and B). This dissociation is not unique for osteocalcin since the 1,25-(OHlzD3-
induced increase in osteopontin lORNA was also inhibited by TGFB (Fig. 8). Since we 
initially studied the effect of TGFIl preincubation on 24 h stimulation by 1,25-
(OHlzD3, it was conceivable that during 24 h of incubation postreceptor mechanisms 
induced by TGFIl were more important than VDR up-regulation. These postreceptor 
mechanisms might be absent or less important in rapid responses to 1,25-(OHlzD3. 
However, time course studies revealed that an inhibitory effect of TGFB could be 
observed as soon as an effect of 1,25-(OHlzD3 on osteocalcin production was 
detected. Although not yet significant, the inhibitory effect of TGFB pretreatment on 
1,25-(OHlzD3-induced increase in osteocalcin mRNA was already observed after 4 h 
incubation with 1,25-(OHlzD3. These data obtained with the TGFIl preincubation 
studies show an interaction between TGFIl and l,25-(OHlzD3 with respect to 
osteocalcin and osteopontin mRNA synthesis at another level than VDR regulation. 
62 
TGFjJ-induced dissociation between VDR level and 1,25-(OH)fJ3 action 
This is supported by the observations that 0.1 ng/ml TGFB caused a significant 
increase in VDR level, whereas it did not affect 1,25-(OHlzD3-induced osteocalcin 
production. 
Our results show interaction between TGFB and 1,25-(OHlzD3 in the regulati-
on of osteocalcin production. Osteocalcin is a chemoattractant for human peripheral 
blood monocytes and macrophages (40,41) and data have been reported that osteocal-
cin is involved in recruitment and/or differentiation of bone resorbing cells (42,43). 
Recently, it has been shown that TGFB, at doses effective in the present study, 
inhibits 1,25-(OHlzD3-induced formation of osteoclast-like cells in human and mouse 
bone marrow cultures (44,45). Combining these data from literature and the current 
data on the potent inhibitory effect of TGFB on 1,25-(OHlzD3-stimulated osteocalcin 
production it is tempting to postulate that TGFB inhibits 1,25-(OHlzD3-induced 
osteoclast formation via inhibition of 1,25-(OHlzD3-stimulated osteocalcin synthesis. 
Since osteopontin has been suggested to act as an anchor of osteoclasts to bone 
(46,47), our data on osteopontin support the idea of a negative interaction between 
TGFB and 1,25-(OHlzD3 in the regulation of osteoclast action and are thereby in line 
with the osteocalcin data. 
In conclusion the present study demonstrates a TGFB-induced dissociation 
between VDR level and 1,25-(OHlzD3 action in osteoblast-like cells. At the moment 
the significance of VDR up-regulation by TGFB remains unclear. Whether this is 
important for other 1,25-(OHlzD3 biological responses has to be established. More 
generally, the present study demonstrates the importance of the presence of locally 
produced growth factors for the eventual response of target tissues/cells to hormone 
treatment. 
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ABSTRACT 
Osteocalcin and osteopontin are non-collagenous proteins secreted by osteoblasts 
and regulated by a complex interplay of systemic and locally produced factors, including 
growth factors and steroid hormones. We investigated the mechanism by which 
transforming growth factor 13 (TGF13) inhihits 1,25-dihydroxyvitamin D3 (1,25{OH)zD3) 
enhanced expression of the osteocalcin (Oe) and osteopontin COP) genes. ROS 17/2.8 
cells, in which both genes are expressed, were transfected with reporter COll5trncts driven 
by native (i.e. wild-type) rat OC and mouse OP promoters. TGF,6 abrogated the 
1,25{OHhD3 enhanced transcription of both the OC and OP genes. The inhibitory 
TGF,6 response for each requires Vitamin D response element (VDRE) sequences, 
although there are additional contributions from proximal basal regulatory elements. 
These transcriptional effects were further investigated for contribution of the tralls-
activating factors, which interact with OC and OP VDREs, involving the vitamin D 
receptor (VDR) and retinoic X receptor (RXR). Gel mobility shift assays show that 
TGFIl significantly reduces induction of the heterodimeric VDR/RXR complexes in 
1,25{OHhD3 treated ROS 17/2.8 cells. However, Western blot and ligand binding 
analyses reveal that TGF13 does not affect nuclear availability of the VDR. We also 
show that activator protein-l activity is up-regulated by TGF,6; thus, activator protein-1 
binding sites in the OC promoter may potentially contribute to inhibitory effects of 
TGF,6 on basal transcription. Our studies demonstrate that the inhibitory action of 
TGF,6 on the 1,25(OH)zD3 enhancement of OC and OP transcription in osteoblastic cells 
results from modulations of protein-DNA interactions at the OC and OP VDRE, which 
can not be accounted for by changes in VDR protein levels. As OC and OP participate 
in bone turnover, our results provide insight into the contributions of TGF,6 and 
1,25{OHlzD3 to VDR mediated gene regulatory mechanisms operative in bone formation 
and/or resorption events. 
INTRODUCTION 
Osteocalcin (Oe) and osteopontin COP) are two major non-collagenous calcium 
binding proteins in bone (1). During development of the osteoblast phenotype 
osteopontin is expressed during the period of active proliferation, decreases 
postproliferatively and expression is upregulated in mature osteoblasts. In contrast, 
osteocalcin is expressed only postproliferatively in mature osteoblasts with the onset of 
68 
TGFfJ modulation of VDR/RXR complexes 
extracellular matrix mineralization (2). InROS 17/2.8 osteosarcoma cells, however, both 
osteocalcin and osteopontin are constitutively expressed. Some evidence points to the 
involvement of both proteins in bone turnover; for example, both proteins bind to 
hydroxyapatite and are regulated by 1,2S(OHh03 and TGFj3. In addition, osteocalcin 
contributes to recruitment and/or differentiation of osteoclasts (3-S) and osteopontin 
appears to be important for attachment of the osteoclasts to the hone matrix (6, 7). 
TGFj3 and 1,2S(OHh03 are involved in regulation of both bone formation and 
resorption. The steroid hormone 1,2S(OHh03 plays a principal role in calcium 
homeostasis and skeletal metabolism (8), as well as influences expression of genes 
related to establishment and maintenance of the bone cell phenotype (9). 1,2S(OHh03 
exerts its primary effect by binding to its nuclear receptor, the vitamin D receptor 
(VOR), which belongs to the steroid/retinoid/thyroid hormone receptor superfamily (10) 
and acts via binding to distinct vitamin ° response elements (YDREs). VOREs have 
been identified in several genes related to osteoblastic differentiation and function: 
human osteocalcin (11, 12), rat osteocalcin (13-IS), mouse osteopontin (16), rat 2S-
hydroxy- and 1,2S-dihydroxyvitamin 03 24-hydroxylase (17-20), calbindin D28k (21), and 
113 integrin (22). 
TGFIl is locally produced in bone by os teoblasts and osteoclasts and represents 
a member of the TGFIl/BMP superfaudly of polypeptide hormones, which play key roles 
in skeletal development and bone remodeling (23, 24). In mammals three isoforms of 
TGFj3 have been identified: TGFlll> TGFIl2 and TGFIl3 (2S, 26). TGFIl is present as 
a latent complex in bone and released from the extracellular matrix in an active form 
during bone resorption by osteoclasts (27). TGFIl modulates the expression of several 
markers of the osteoblast phenotype (28-3S). 
Recent studies suggest that regulation of bone metabolism by 1,2S(OHlzD3 and 
TGFIl is functionally coupled. For example, combined treatment with TGFIl and 
1,2S(OHhD3 of both human and rat osteoblast-like cells has been shown to affect 
parameters of osteoblastic differentiation and function (36-38). However, the mechardsms 
by which TGFIl and 1,2S(OHh03 together modulate the expression of osteoblast-related 
genes remains to be established. In this study we examined the antagordstic effects of 
TGFIl1 and TGFIl2 on the 1,2S(OHlz03 enhancement of osteocalcin and osteopontin 
gene transcription. We show that TGFj3 inhibition of 1,2S(OHlz03 stimulated 
transcription involves the selective down-regulation of VOR/RXR interactions with both 
the OC and OP YDREs. 
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MATERIALS AND METHODS 
Cell Cfllfllre 
ROS 17/2.8 osteosarcoma cells, kindly provided by Dr. G. Rodan and Dr. S, Rodan (Merck Sharp 
& Dohme Research Laboratories, West Point, PA) were maintained in Ham's F12 medium supplemented 
with 2 ruM L.glutamine, 100 IU JmI penicillin, 100 Ilg/mi streptomycin and 5% FCS at 37 °C under 95% 
air/5% CO2_ For the experiments, cells were seeded in 100 x 20 mill plastic dishes at 0.7 x 10
6 cells/plate 
in Ham's F12 medium containing 5% Fes and cultured for 24 h. Subsequently, medium was replaced by 
Ham's F12 with 2% charcoal-treated Fes and cells were cultured overnight and then incubated for 24 h with 
to,8 M 1,25(OHhD3 and/or 2.5 ng/ml of either TGFB1 or TGFB2, 1,25(OHhD3 was kindly provided by 
Dr. M. Uskokovic, Hoffman-La Roche Inc. (Nutley, NJ). TGFJ\ was purchased from R&D Systems 
(Minneapolis, MN). TGFB1 was kindly provided by Dr. J. Feyen, Sandoz Pharma LtD (Basel, Switzerland). 
Medium was analyzed for osteocalcin by RIA as previously described (39). 
Gel mobility shift assay 
Nuclear extracts were prepared as previously described (40).10 brief, cells were scraped in PBS and 
after centrifugation the cell pellet was reconstituted in a hypotonic lysis buffer (10 mM HEPES, pH 7.5, 10 
mM KCI and 0.2 mM EDTA) supplemented with 0.75 ruM spermidine, 0.15 ruM spermine, 1 mM EGTA, 
1 mM dithiothreitol and a broad spectrum of protease inhibitors: 0.2 mM PMSF, 70 Itg/ml TPCK, 10 Itg/ml 
trypsin inhibitor, 0.5 Itg/mlleupeptin and 1.0 Itg/ml pepstatin. Then 0.5% Nonidet P40 was added and cells 
were lysed using a dounce homogenizer. After centrifugation, nuclear extracts were obtained by incubating 
nuclei in a hypertonic nuclear extraction buffer (20rnM HEPES, pH 7.5, 420 ruM KCI, 25% glycerol and 0.2 
mM EDTA) supplemented with the sallle reagents previously mentioned for the hypotonic lysis buffer. 
Desalting was performed by dilution with hypertonic nuclear extraction buffer without KCI. 
For gel mobility shift assays the following oligonucleotides were synthesized: 
rat osteocalcin VDRE (14): 5'-CfGCACfGGGTGAATGAGGACATIACfGA-3'j 
mouse osteopontin VDRE (16): 5'-ACAAGGTICACGAGGTTCACGTCI'-3'j 
metallothionein II/activator protein-l (AP-l) consensus: 5'-AATICGTGACfCAGCGCGCG-3'j 
SP-1 consensus: 5'-CGGATGGGCGGGGCCGGGGATGGGCGGGGCCGG-3'. 
Gel-purified oligonucleotides were radiolabeled ,vith [-y32p} ATP as described previously (41). 
Protein/DNA binding reactions were performed by combining 10 It! of a 5 Itg protein mixture in a final KCI 
concentration of 100 mM with 10 III of a DNA mixture containing 1 fmolh" DNA, 0.2 Jlg/ltl nonspecific 
competitor DNA (poly(dI-dC)*(dI-dC» and 2 mM dithiothreitol for 15 min. Protein/DNA complexes were 
separated in a 4% polyacrylamide gel (acrylamide:bisacrylamide=SO:I) in O.5x TBE electrophoresis buffer. 
Gels were dried and exposed to x-ray IiIm. 
Transient trallsfection assay 
The OC chloramphenicol acetyilransferase (CAT) chimeric reporter gene constructs pOCZCAT and 
Bg/IICAT contain the osteocalcin promoter sequences -1097/ +23 and -348/ +23, respectively (42). The OP 
CAT chimeric reporter gene constructs pOP772CAT and pOP552CAT span nucleotides -772/+40 and -
552/ +41, respectively (16). The (VDREh-tk-luciferase chimeric rcporter construct, which was generously 
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provided by Dr. LJ. Sturzcl1becker (Hoffman-La Roche), contains three copies of the rat osteocaldn VDRE 
fused to thymidine kinase lucifcrasc. DEAE-dextran mediated transfcctions (43) were performed with cells 
plated at a density of 0,8 x 105 pcr well in 6-well plates. CAT and luciferase reporter gene constructs (5,tg) 
were either cotransfected with 2 Jig ROllS sarcoma virus LTR lucifcrase or pSV2CAT (used as an internal 
control for transfedion efficiency) 48 h afler plating. After transfcction, cells were fed with Ham's F12 
medium supplemented with 5% pes. Subsequently, 4 h after feeding, ceLis were incubated with TGFB l • 
TGFllz and/or 1,25(OHhD3 in Ham's F12 with 2% charcoal-treated pes. Cells were harvested after 
incubation for 24 h and CAT activity was determined (43). CAT and luciferase assays were normalized on 
the basis of luciferase activity and CAT activity, respectively, as well as protein content by Bradford assay 
(Pierce). Quantitation was performed by using a 6-emission analyzer (Betascope 603 Betagen). 
Northem blot allalysis 
RNA isolation, electrophoresis of total RNA (10 I1g) in formaldehyde gels, Northern blotting 
[Zeta probe membranes (Biorad)J, prehybridizations and hybridizations were performed as described 
previously (44). The sources of the foUmving probes used for hybridization are described by Shalhoub et 01. 
(44): osteocalcin, osteopontin, histone H4 , collagen type I, alkaline phosphatase, and vitamin D receptor 
probes. Values for mRNA were normalized to GAPDH and ribosolllal28S transcripts. For rehybridi7..<1tion, 
filters were washed for 2 It at 65 °C with 5 mM Tris (pH 8.0), 0,2 mM EDTA (pH 8,0), 0_05% 
sodiulllpyrophosphate and 0.1 x Denhardt's solution. 
Westem blot analysis 
Nuclear proteins were separated in 12% SDS-PAGE gels (acrylamide:bisacrylanlidc=30:1) (43) and 
transferred to Zctaprobe membrane followed by Western blot analysis (ECL Amersham). In brief, 5% 
blocking agent was used in PBS containing 0,1 % Tween-20. The blot was subsequently incubated with VDR 
antibody (IVG8Cll) in a 1:1000 dilution and incubated with the second antibody (peroxidase anti-mouse 
antibody at a 1:10,000 dilution). 
Preparations of cell extracts and [JHJ 1,25(OH)fJ J binding assay 
Vitamin D ligand binding assays were performed as described by Pols et 01. (45). In brief, after 
incubation with TGFI3 and/or 1,25-(OHhD3' cells were washed with 2% BSA in serum-free medium for 2 
h to remove residual unlabeled 1,25-(OHhD3' Then ceUs were extracted on ice in a hypertonic buffer 
consisting of 300 mM KCI, 10 mM Tris-HCI (pH 7.4), 1 mM EDTA, 5 mM dithiothreitol, 10 mM sodium 
molybdate and 0.1% Triton X-lOO. High-speed supernatants were obtained, and 250 It 1 aliquots were 
incubated overnight at 4 °C for single point assays with 0.25 nM eHJl,25(OHhD3 in the absence or 
presence of a 200-fold molar excess of unlabeled hormone, After removal of unbound ligand, receptor-
bound vitamin D was quantitated by liquid scintillation counting. 
D(lta analysis 
To assess significance of the interaction between two agents, tested data were analyzed with analysis 
of variance for two-way design (indicated by #). Other statistical analyses were performed using Student's 
t test (indicated by *) 
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RESULTS 
Effects of TGFfJl' TGFfJ2 and 1,25(OH)fJ3 on expression of genes related to osteoblast 
function and differentiation. 
As osteoblasts are responsive to TGFBj and TGFB2> and display three classes of 
TGFB receptors (46), we explored possible differential effects of these two major 
isoforms present in bone. Northern blot analysis reveals inhibitory effects ofhoth TGFilj 
and TGFil2 on basal osteocalcin gene expression (Fig. I). Steady state mRNA levels of 
osteopontin were not affected by either growth factor after 24 h of treatment. TIle 24·h 
time point was selected for our studies as this treatment interval facilitates assessment 
of the combined effects of TGFB and 1,2S·(OHhD3 on OC and OP gene expression. 
We have previously established that under our experimental conditions, 1,2S.(OHhD3 
enhancement of OC gene expression is maximal at 24 h after adminstration of the ligand 
(9). Also, although TGFB modulates parameters of 1,2S.(OHhD3·mediated gene 
expression as a component of an earlier response (i.e. 6 h), maximal effects of TGFB on 
OC gene expression are observed at the 24·h time point (37). 
The combined effects ofTGFB and 1,2S-(OHhD3 on OC and OP gene expression 
are also shown in Fig. 1. Both OC and OP mRNA levels were increased 6- to lO-fold 
after 24 h of 1,2S-(OHhD3 treatment. Both TGFBj and TGFB2 inhibited the 1,2S-
(OH)2D3-induced increases in OC or OP expression. However, the magnitude of the 
decrease was reproducibly greater for osteocalcin in multiple experiments, consistent with 
the influence of TGFB on basal level of OC gene expression. For 1,2S-(OHhD3-treated 
cells, the level of secreted OC in the medium, which reflects OC protein synthesis, 
parallels the changes in OC gene expression (Table I). For comparison, TGFil and 1,2S-
(OHhD3 effects on other bone-related proteins (e.g. alkaline phosphatase, collagen type 
1 and vitamin D receptor) and cell proliferation marker (histone H4) were determined. 
These genes display different patterns of expression after TGFB and 1,2S(OHhD3 
treatment, demonstrating the selective responsiveness of the OC and OP genes to these 
factors. 
Effects of combined treatment with TGFfJ and 1,25(OH)fJ3 on OC alld OP transcription. 
1,2S-(OHhD3 regulates OC and OP gene expression by specific interactions of 
VDR containing transcription factor complexes with defined VDREs in the promoters 
of both genes. To gain insight into the mechanism by which TGFB inhibits 1,2S-
(OHhD3 enhancement of OC and OP gene expression, we performed transient 
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TGFfi and/or 1,2S.(OHhD3 affect the expression 
of mRNAs related to osteoblast function and 
differentiation. Cells were cultured as described 
in Materials and Methods and incubated for 24 h 
with 2.5 ng/ml TOFO, (T,), 2.5 ng/ml TOFil, 
(T,) andlor 10-8 M 1,25-(OH),D3 (D) or vehicle 
(C). Northern blots were hybridized with the 
following probes: osteocalcin (OC), ostcopontin 
COP), histone H4 (H4), alkaline phosphatase 
CAP), collagen type I (COLL 1), vitamin D 
receptor (VDR), glyceraldehyde 6-phosphate 
dehydrogenase (GAPDH) and LS6 (285 
ribosomal RNA). A: Composite autoradiograms 
from representative experiments. B: Bar graphs 
(arbitrary absorbance units, A.U.) of DC, OP, 
VDR and 28S represent quantitation of mRNA 
levels by densitometric scanning of the 
autoradiogram. OC, OP and VDR mRNA levels 
are normalized for 28S. Similar results were 
obtained in multiple independent expcrimcnts. 
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TABLE 1 
Effect of either TGFB1 or TGFfi2 and 1,25-(OHhD3 on osteocalcin secretion in medium of ROS 17/2.8 
cells (ng/ml). 
control TGFB, 
control 2.76 ± 0.23 2.13 ± 0.44 2.26 ± 0.40 
1,25(OH)'D3 15.45 ± 2.15 3.44 ± 0.35 3.14 ± 0.08 
Cells were cultured as described (Materials and methods) and incubated for 24 h with 2.5 ngjml TGF1311 
2.5 ng/ml TOF02 and/or 10'8 M l,25.(OH}zD3_ Data arc expressed as mean ± SD. 
transfections assays in ROS 17/2.8 cells with OC and OP promoter CAT fusion 
constructs in the presence ofTGFIl and/or 1,25-(OHhD3' After transfection with an OC 
promoter construct of 1100 nucleotides, which contains the VDRE (pOCZCAT; Fig. 2A), 
we observed a 4- to 6-fold decrease in basal CAT activity in response to both TGFIl I and 
TGFE2. 1,25-(OHhD3 increased basal CAT activity 8-fold in 24 h. This increase was 
inhibited 20- to 30-fold after coincubation with either TGFIlI or TGFIl2. 11ms, in 
addition to a significant inhibition of basal transcription, both TGFE subtypes abrogated 
1,25(OH)P3 enhanced OC transcription. 
To ascertain the extent to which TGFf3 effects on OC depend on VDRE 
sequences, ROS 17/2.8 cells were transfected with a construct in which the VDRE was 
deleted (pBg/IICAT; Fig. 2B). As expected, the construct did not respond to 1,25-
(OH)zD3' TGFIl! or TGFIl2 either alone or in the presence of 1,25-(OHhD3 caused a 
4- to 6-fold decrease in CAT activity. This inhibitory effect of TGFf3 on basal OC gene 
transcription is consistent with the presence of a TGFf3 response element in the proximal 
promoter (47). Notably, the fold decrease resulting from coincubation of TGFE and 
1,25-(OH)zD3 was significantly less for the OC promoter CAT construct lacking the 
VDRE (4- to 6-fold; pBg/IICAT) as compared to the OC CAT construct containing the 
VDRE (20- to 30-fold; pOCZCAT). To assess the promoter selectivity ofTGFIl effects 
on transcription of bone-related genes, we performed similar experiments with CAT 
reporter gene constructs fused to the SV40 promoter (pSV2CAT) or lacking a promoter 
(pSVOCAT). TGFIl has only modest inhibitory effects on the virally derived SV40 
promoter (1.3-fold; data not shown). 
Similar to results with the OC promoter, transfection with the osteopontin 
promoter construct pOP772CAT (Fig. 3A), containing 772 nt of 5' flanking 
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Figure 2 
TGFB1 and TGFG2 antagonize basal and 1,25(OHhD3 stimulated DC transcription. RQS 17/2.8 cells were 
transiently transfected with the following osteocalcin promoter-CAT fusion constructs: A) pOCZCAT •. 
1097/+23, and B) pBglJICAT -348/+23. Cells were transfected and 4 h latcr incubated for 24 h in the 
absence (control) or presence of 2,5 ng/ml TGPHI (Tt ), or TGF62 (T2). These trcatment groups were 
coincuhated with either vehicle (e, 0) or l,25-(OHhD3 (D, 10-8 M). Upper portions of each panel show 
one representative autoradiogram of a CAT assay. The lower portion of each panel are bar graphs 
representing mean ± SD of duplicates and triplicates from three indcpcndent transfection experiments after 
quantitation using a l3-emission analyzer. CAT activity was corrected for transfection efficiency by luciferase 
activity. * P<O.OOl, ** P<O.OO5, *** P<O.Ol versus control. # P<O.01 calculated as significance of 
interaction. 
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sequences, showed a decrease in basal CAT activity after incubation with either TGFJl1 
or TGFJl2 (2-fold). 1,25-(OH}zD3 caused an II-fold increase in CAT activity, which was 
inhibited 7-fold by TGFB1 and TGFJl2. The OP construct lacking the YDRE 
(pOP552CAT; Fig. 3B) does not respond to 1,25-(OHhD3' We noted that a modest 
level of TGF(3 inhibition (2-fold) of OP basal promoter activity persists. Taken together, 
our results suggest that TGF(3 exerts a major effect on 1,25-(OH}zD3 mediated OC and 
OP transcription and requires a YORE containing promoter segment. 
To investigate directly the effect ofTGFJl and 1,25-(OHhD3 on YORE-mediated 
transcription, we transfected cells with the (YDREh-tk-Iuciferase reporter gene 
construct, which contains three copies of the rat OC YORE (Fig. 4). Treatment with 
1,25-(OH}zD3 increased basal luciferase activity approximately 4-fold in 24 h. This 
increase was inhibited 50% and 30% by TGFJl1 and TGFJl2, respectively, indicating that 
the inhibitory effect of TGFJl on 1,25-(OH}zD3 enhancement of OC transcription is at 
least partly mediated by the YORE. 
TGFJ3 and 1,25-(OH)fJ3 modulate protein/DNA interactions at VDREs 
To address directly the mechanism by which TGFJl abrogates 1,25-(OHhD3-
dependent enhancement of OC transcription, we examined protein/DNA interactions at 
YDREs. Gel shift assays were performed with nuclear proteins from ROS 17/2.8 cells 
treated with TGFB and/or 1,25-(OH}zD3' using labeled OC and OP YORE 
oligonucleotides. Fig. 5 shows the well-established induction of the YDR containing 
complexes at both OC and OP YDREs after treatment of ROS 17/2.8 cells with 1,25-
(OH}zD3 (16, 40, 48-50). Nuclear proteins from control or TGF(32-treated cells do not 
show YORE protein/DNA interactions. However, combined treatment of 1,25-(OHhD3 
with TGFJl caused a significant reduction of the YDR containing complex at both the 
OC and OP YDREs. Similar reductions in YORE complexes were observed in TGF(31 
treated cells (data not shown). This indicates that the inhibitory effects by TGFJl1 and 
TGF(32 on the 1,25-(OHhD3-induced increase in OC and OP transcription are at least 
in part due to decreased binding of transcription factors to the YDRE. 
Because both TGF(3 and 1,25-(OH}zD3 modulate expression of the fos and jun 
family of proto-oncogenes in osteoblasts (34, 51-53), we also examined the effects of 
these agents on AP-l activity in ROS 17/2.8 osteosarcoma cells. Gel shift assays were 
performed using AP-I and SP-l consensus sequences as the probes (Fig. 6). 
The AP-l complex was increased after incubation with either TGFJl or 1,25-(OHhD3' 
although the increase observed with TGFB was more pronounced than with 
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Figure 3 
TGF131 and TGF62 antagonize basal and 1,25(OH)2D3 stimulated OP transcription, ROS 17/2.8 cells were 
transiently transfected with the following ostcopontin promoter~CAT fusion constructs: panel A) 
pOP772CAT, -772/+40, panel B) pOP552CAT -552/+40. Cells were transfccted and 4 h latcr incubated 
for 24 h in the absence (control) or presence of 2,5 ng/ml TGFfH (T1), or TGFfi2 (T2). These treatment 
groups were co-incubated with either vehicle (e, 0) or l,2S-(OHhD3 (D, lO,8 M). Upper portion of each 
panel shows one representative autoradiogram of a CAT assay. The lower portion of each panel are bar 
graphs representing mean ± SD of duplicates and triplicates from tluce independent transfection 
experiments after quanlitation using a 8·emission analyzer. CAT activity was corrected for transfection 
efficiency by ludfcrase activity. * P<O.OOl, ** P<O.OO5 versus control. # P<O.Ol calculated as significance 
of interaction. 
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TGFJ31 and TGFfiz inhibit 1)25-(OH)zD3 enhancement of DC VDRE-mediated transcription. ROS 17/2.8 
cells were transiently transfcctcd with the (VDREh-tk-luciferase construct. Cells were trallsfcctcd and 4 h 
later incubated for 24 h in the absence or presence of2.5 ng/ml TGFEI and TGF02. These treatment groups 
were coincubated with either vehicle Of IJ25-(OH}zD3 (10-8 M). Bar graphs represent mean ± SD of 
luciferase activity. '!O P<O,05, ** P<O.OO5 versus control. # P<O.Ol, ## P<O,05 calculated as significance of 
interaction. 
1,25(OHlzD3. Combined treatment caused a further enhancement of the AP-l complex. 
No modulation of Spot binding activity was observed, which represents an internal 
control for protein quantitation. These findings indicate selectivity of the TGF{3- and 
1,25-(OHhD3-mediated signaling mechanisms that modulate nuclear transcription factor 
levels. 
VDR protein levels are not rate-limiting for VDRE interactions in the presence of TGFfJ and 
1, 25-(OH):f>3' 
Because changes in VDR mRNA levels were observed after treatment with 
TGFB1, TGFIl2 and 1,25-(OH)P3 (Fig. I), we studied the effects ofTGFIl1 and TGFJl2 
in the absence or presence of 1,25-(OH}zD3 on VDR protein levels, as a possible 
mechanism for the inhibitory effects ofTGFJl on VDR!RXR interactions at the OC and 
OP VDREs. We investigated the effect of TGFJl on homologous up-regulation of the 
VDR by western blot analysis. The results indicate that nuclear VDR levels are ordy 
detected after treatment with !,25-(OHhD3' and that neither TGF{311lor TGFJl2 affects 
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TGFfi modulates interactions of endogenous 1,25-
(OH}zD3 inducible VDR/RXR complexes from 
ROS 17/2.8 cells. Binding of nuclear proteins to 
the ac VDRE and OP VDRE was analyzed in 
gel mobility shift assays. Cells were incubated for 
24 h with vehicle (C), 2.5 nglml TGFfi, (T), 10-8 
M 1,25-(OH),D3 (D) or both (T+ D). Nuclear 
protein preparations were incubated with either 
radiolabcled OC- or op· VDRE. The vitamin D 
responsive complexes (V) for the DC- and op-
VDRE are indicated by the arrowhead. 
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Figure 6 
Selective enhancement of AP-l activity by TGFfi 
and 1,25-(OH}zD3. Gel mobility shift assays were 
performed with AP-l and SP-! consensus 
oligonucleotides, Nuclear extracts were identical 
10 those in Fig. 5. Abbreviations and symbols are 
as indicated in Fig. 5. The AP~l complexes (A) 
represent a composite of hcterodimers of the fos 
and jun family members and are indicated by the 
arrowhead. The triple arrowhead (S) indicates 
three specific complexes mediatcd by the SP~l 
family of transcription factors; the upper complex 
represents SP-l and the two lower complexes are 
SP-3 related proteins. 
the 1,25-(OHlzDJ dependent increase in VDR levels (Fig. 7A). Subtle variations in the 
1,25-(OHlzD3-treated lanes appear to refieci similar variations in the nonspecific band 
migrating slower than the VDR. The lack of an effecl by TGFIl on VDR protein levels 
in the presence of 1,25-(OHlzDJ is further corroboraled by quantitative analysis of VDR 
protein using immunoradiometric assays; homologous up-regulation of VDR number in 
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nuclear extracts after 1,2S-(OHhD3 treatment was not affected by eotreatment with 
either TGFB, or TGFB2 (data not shown)_ Ligand binding assays in whole cell extracts 
using isotopically labeled 1,2S-(OHhD3 (Fig. 7B) also demonstrate homologous up-
regulation of 1,2S-(OHhD3"receptor number, as reflected by a S-fold increase in ligand 
binding following 1,2S-(OH)zD3 treatment. Cotreatment with TGFB (24 h) does not 
affect the the homologous up-regulation of 1,2S-(OH)zD3-receptor number in the 
presence of 1,2S-(OH)zD3' TIlUs, the evidence presented in Fig. 7 indicates that TGF{3 
inhibition of protein/DNA interactions at the VDRE is not the consequence of a 
reduction in the level of VDR protein. 
We have found that TGFB alone causes a subtle enhancement of VDR levels in 
whole cell extracts after 24 h of treatment (P<O.OS). We have previously reported that 
the magnitude of this response is higher at 6 h after TGFB administration (37). TIle 
modestly elevated levels of VDR protein after 24 h of TGFB treatment therefore may 
represent a residual, and perhaps persistent, component of TGFB responsiveness. Our 
previous observation that TGFB enhances VDR levels in whole cell extracts as a 
component of an earlier response (i.e. 6 h )(37) and our current finding that show that 
TGFfl does not significantly influence homologously up-regulated levels of the VDR 
protein at 24 h are both consistent with a complex temporal regulatory mechanism for 
modulation of the VDR levels that may in part be compartmentalized. 
DISCUSSION 
In this study we focused on gene regulatory mechanisms that control OC and OP 
expression which are affected by the combined activities of 1,25-(OH)zD3 and TGFfl. 
TIle basis of our studies is supported by previous studies (36, 37), and our present 
findings which show that TGFB inhibits the 1,25-(OH)zD3-induced increase of both OC 
and OP mRNA levels. The physiological relevance of TGF{3 inhibition of the 1,25-
(OH)zD3 enhanced expression of osteoblast-related genes is exemplified by decreased 
secretion of the osteocalcin protein, a major functional product of osteoblasts. In 
addition, by directly comparing the actions of TGFB, and TGFflz. we show that these 
agents exert identical effects on regulation of OC and OP gene expression. TIlis finding 
is consistent with the observation that TGFBr and TGFflz-mediated cell signaling 
pathways operate via shared TGF{3 receptor classes (46). 
Using transfection assays with osseous cells and reporter gene constructs 
containing the native OC and OP gene promoters, we establish that 1,25-(OH}zD3 related 
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Homologous upregulation of VDR protein levels by l,25.(OH)zD3 is not affected by TGFO. Western hlot 
analysis (A) was performed with nuclear proteins from ROS 17/2.8 cells, which were separated in a 12% 
SDS·PAGE gel and transferred to a solid support. Detection of VDR levels was performed using the VDR 
antibody IVG8Cll, The abbreviations used are the same as indicated in Figs. 5 and 6, and the VDR protein 
(V) is indicated by the arrowhead. The subtle variations in the l,25.(OHhD3 treated lanes appear to reOect 
similar variations in the nonspecilic band migrating slower than the VDR. Ligand binding assays (B) using 
eHJl,25-(OHhD3 were carried out with cytosotic preparations from ROS 17/2,8 cells treated with 1,25-
(OH}zD3 and/or TGF/12' The values on the ordinate were calculated by dividing fmol eHJ 1,2S(OH}zD3 
bound per mg protein by the values obtained from untreated cells, Bar graphs represent mean ± SD of 
duplicates form two independent 1,2S-(OHhD3ligand binding experiments, * P<O.OS, ** P<O,OOO1 versus 
control. 
effects of TGFJ3 on expression of the OC and OP genes are mediated by transcriptional 
mechanisms. TGF{3 abrogates 1,25-(OHlzD3 enhancement of OC transcription, which 
requires presence of the OC VDRE within the promoter. However, TGF{3 also inhibits 
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basal OC transcription in the absence of 1,25-(OHhD3' which occurs irrespective of the 
presence of VDRE sequences. TGF{3 repression of basal OC gene transcription is 
mediated by a TGF{3 response element (TGRE) in the proximal promoter of the OC 
gene (47). Transcriptional repression involves binding of AP-l family members to the 
TGRE (47). Our results show that TGF{3 increases AP-l binding activity both in the 
presence or absence of 1,25-(OH}zD3 in ROS 17/2.8 cells. Thus, increased levels of AP-
I binding may contribute to inhibition of OC gene transcription. 
We note that TGF{3 also inhibits basal OP gene transcription. This inhibition of 
OP gene transcription, as monitored by reporter gene expression following treatment 
with TGF{3 for 24 h, is not reflected by changes in OP mRNA levels. It appears that 
TGF{3 dependent inhibition of OP transcription may be compensated by post-
transcriptional modulatory events, including mRNA processing, transport, and/or 
stability. Alternatively, the observed differences between TGFB effects on OP 
transcription and OP mRNA level may reflect differences in the regulation of the 
endogenous gene and the OP CAT chimeric reporter gene construct. Noda et al. (16) 
observed that TGFB increases OP mRNA levels, concomitant with stimulation of OP 
gene transcription, based on results from nuclear run-on assays following a 72 hr 
treatment with TGF{3. 111is apparent discrepancy in the observed effects of TGF{3 on 
OP gene expression may relate to differences in experimental design, as well as perhaps 
reflect chronic effects of TGF{3 on cell growth and differentiation of osteoblasts. 
We tested the hypothesis that transcriptional repression of 1,25-(OH}zD3-
enhanced OC and OP gene expression may be achieved by modulating protein/DNA 
interactions at the OC and OP VDREs. Transcriptional up-regulation of the OC gene 
by 1,25(OH}zD3 requires the positive cis-acting VDRE, which interacts with VDR/RXR 
heterodimers i1l vitro (49, 54-57) and i1l vivo (58). Our results show that TGF{3 inhibits 
the 1,25-(OH}zD3 enhancement of OC VDRE-mediated transcription and the 1,25-
(OH}zD3-dependent induction of VDR containing transcription factor complexes 
interacting with the OC- and OP-VDREs. 11ms, we propose that TGF{3 may directly 
influence OC and OP gene transcription by modulating 1,25(OH}zD3-dependent 
protein/DNA interactions at the OC and OP VDREs. This concept is supported by 
previous findings that another polypeptide regulator of OC transcription, TNF-Ci (59), 
influences 1,25(OH}zD3 regulated transcription by modifications of protein/DNA 
interactions at the VDRE. 
Regulation of the nuclear representation of VDR/RXR heterodimers may occur 
at multiple levels of control. For example, our results show that VDR mRNA levels are 
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increased in a 1,25-(OHhD3-dependent manner, which is reflected by increased VDR 
protein levels as monitored by Western blot analysis and 1,25-(OH}zD3 ligand binding 
assays, as well as induction of VDR/RXR heterodimer interactions with the VDRE. In 
coincubation experiments with 1,25-(OHhD3' TGFll reduces the 1,25-(OHhD3-
dependent increase in VDR mRNA, but this decrease is not paralleled by a reduction 
in VDR protein levels. This finding is consistent with the observation that stabilization 
of VDR protein by 1,25-(OH}zD3 ligand binding, contributes to the homologous up-
regulation of the VDR (60). Taken together, these data suggest that VDR mRNA levels 
are not rate-limiting for synthesis of VDR protein, and VDR protein levels are not rate-
limiting for formation of VDR/RXR heterodimers in cells treated with both TGF{l and 
1,25-(OH}zD3' Thus, the mechanism by which TGFJ:1 reduces VDR/RXR heterodimer 
interactions at VDREs appears to involve post-translational events, e.g. phosphorylation 
and/or protein/protein interactions, including effects of TGFll on nuclear availability of 
RXR proteins. 
Phosphorylation of the VDR influences VDRE binding activity and transcriptional 
activation function of VDR/RXR heterodimers (40, SO, 61, 62). Hyper-phosphorylation 
of the VDR correlates with decreased VDRE binding activity (SO, 61) and 
phosphorylation pathways involving protein kinase C may post-translationally modify 
VDR ill vivo. Because TGF{l-mediated signal transduction occurs via protein kinase C 
(63) and 1,25-(OH)P3 action also involves protein kinase C (61, 64), the possibility 
arises that TGFI3 may alter phosphorylation of the VDR with consequential repression 
of VDR/RXR binding activity and transcriptional activation. 
Accumulating evidence suggests that the functions of 1,25-(OHhD3 and TGFI3 in 
the regulation of bone metabolism and parameters of osteoblast differentiation are 
strongly interrelated (34, 36-38). TGFll is capable of increasing 1,25-(OHhD3 receptor 
number (65, 37). 1,25-(OH}zD3 stimulates homologous up-regulation of the VDR, which 
is required for the induction of VDR/RXR heterodimers, resulting in the transcriptional 
activation of 1,25-(OHhD3 responsive genes. 1,25-(OHhD3 also stimulates TGFI3 
synthesis and secretion by bone cells, as well as enhances TGF{l incorporation into bone 
(66,67). The inhibitory effect of TGFI3 on 1,25-(OHhD3-enhancement may provide a 
negative regulatory loop in the action of 1,25(OHhD3' 
The results presented here suggest that TGF{l influences OC and OP gene 
transcription. The effect of TGF{l on OC gene transcription may occur via a two-
pronged mechanism. First, TGF{l abrogates 1,25-(OHhD3 enhancement of OC 
transcription by down-regulating binding of VDR/RXR heterodimers to the OC VDRE. 
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Secondly, TGFIl also inhibits OC transcription in the presence or absence of 1,25-
(OHhD3' which occurs via AP-I binding sites (47,53), perhaps mediated by TGFIl 
enhanced levels of AP-l proteins. Similarities in the inhibitory effect of TGFI3 on 1,25-
(OHhD3-enhanced expression of two genes, OC and or, encoding proteins with distinct 
properties, are consistent with functional linkage of these proteins in bone turnover. 
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ABSTRACT 
A direct relationship between vitamin D receptor (VDR) level and target cell 
responsiveness to 1,25-dihydroxyvitamin D3 (1,25-(OHhD3) has been shown in 
osteoblast-like cell lines. However, we previously found an inverse relationship 
between the TGFfl-induced VDR up-regulation and subsequent 1,25·(OHhD3-induced 
biological responses. A clear inhibition of the 1,25-(OHhD3-induced stimulation of 
osteocalcin and osteopontin expression was observed. A biological response that has 
formerly been shown to be coupled to VDR level is 24-hydroxylase activity. This 
enzyme initiates the C24-oxidation of the side-chain, followed by cleavage and 
ultimate metabolic clearance of both 25-(OH)D3 and its metabolite 1,25-(OHhD3' 
With UMR 106 (rat) and MG 63 (human) osteoblast-like cells, we show that after 
preincubation with TGFfl, which causes an increase in VDR level, 1,25-(OHhD3 
induction of 24-hydroxylase activity is also stimulated. In addition, we provide 
evidence that variations in VDR level induced by other means (PTH, EGF, medium 
change) are also closely associated with 1,25-(OH)zD3-induced 24-hydroxylase activity. 
Furthermore, we show that in MG 63 cells, but not in UMR 106 cells, TGFfl itself 
was able to increase the activity of the enzyme 24-hydroxylase. As 24-hydroxylation is 
the initial step in the further C24-oxidation of 1,25-(OHhD3' our results indicate a 
close coupling of VDR level and the degradation of its ligand, 1,25-(OHhD3' This 
mechanism may provide an important regulatory feedback in the action of 1,25-
(OHhD3 at target tissue/cellleve!. 
INTRODUCTION 
For the maintenance of calcium homeostasis regulation of the formation and 
degradation of the biologically active form of vitamin D3, 1a,25-dihydroxyvitamin D3 
(1,25-(OHhD3), is important. After 25-hydroxylation of vitamin D3 in the liver, and 
hydroxylation at the CIa-position in the kidney, la,25-(OHhD3 is formed. Parathyroid 
hormone (PTH) and reduced plasma levels of calcium and phosphate are the most 
important stimulators of la-hydroxylase activity. In the kidney, 1,25-(OHhD3 inhibits 
its own synthesis, but stimulates in a number of target tissues, induding the kidney, 
the enzyme 24-hydroxylase (1). 24-Hydroxylase mediates the conversion of 1,25-
(OHhD3 to 1,24,25-(OHhD3' which is actually the initial step in a more extensive C-
24 and C-23 oxidation of the side chain (1,24,25-(OH)P3 ~ 24-oxo-l,25-(OH)zD3 ~ 
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24-oxo-l,23,2S-(OHhD3) and ultimately results in the production of calcitroic acid 
(2,3). In other words, the self-induced metabolism of 1,2S-(OHhD3 may provide a 
means to regulate its concentration at the level of its target tissues (3,4). 
A direct relationship between vitamin D receptor (VDR) level and target cell 
responsiveness (7) to 1,2S-(OHhD3' including regulation of the C24-oxidation 
pathway, has been shown in osteoblast-like cell lines (8-10). However, transforming 
growth factor-B (TGFB), a growth factor produced by bone cells and stored in the 
bone matrix, which increases VDR level in osteoblast-like cells (11,12), decreases the 
expression of osteocalcin and osteopontin in response to 1,2S-(OHhD3 (12,13). At the 
moment the biological significance of the TGFB-induced increase in VDR level is 
unknown. In the present study, we examined the coupling of VDR level to 24-
hydroxylase activity by studying the effect of TGFB-induced VDR up-regulation on 
subsequent 1,2S-(OHhD3 induction of the 24-hydroxylase activity. 
MATERIALS AND METHODS 
Materials 
[23,24-'H]-1,25-(OH),D, (120 Ci/mmol) and [26,27-'H]-25-(OH)D, (28 Ci(mmot) were 
obtained from Amersham International (Aylesbury, Buckinghamshire, UK). Non-radioactive 1,25-
(OHhD3 was generously provided by LEO Pharmaceuticals BV (Weesp, The Netherlands), and TGFI3 
type 2 by Dr. J. Feyen, Sandoz Pharma Ltd (Basel, Switzerland). Fetal calf serum (peS), penicillin, 
streptomycin and L-glutaminc were purchased from Flow Laboratories (Irvine, UK). aMEM medium was 
purchased from Sigma (St Louis, MO, USA). Bovine serum albumin (BSA) fraction 5 was obtained from 
TeN ImmunoBiologicals (Lisle, USA). All other reagents were of the best grade commercially available. 
Cell culture 
UMR 106 (rat) and MG-63 (human) osteoblast-like cells were maintained in aMEM medium 
supplemented with 2 mM L-glutamine, 0.1 % glucose, 100 IV jml penicillin, 100 IV jml streptomycin and 
10% PCS at 37°C under 95% airj5% CO2, Por the experiments, ceUs were seeded at 40,000 cellsjcm2 in 
aMEM containing 10% PCS and cultured for 24 h. Next, medium was changed to aMEM medium 
containing 2% charcoal-treated PCS (CT-PCS) and the cells were cultured for 16 hr. To investigate the 
effect of TGPI3, and changing the medium on VDR levels, respectively, 1 ngjml TGFfi was added to the 
cells cultured with 2% Cf-PCS containing aMEM, or medium was changed to serum free aMEM 
containing 0.1% BSA. 1,25-(OHhDJ binding assays were performed after various incubation periods. For 
investigation of the effects of altered receptor levels on subsequent induction of the C24-oxidation 
pathway by 1,25-(OHhD3 the following incubations were chosen: 1) preincubation with 1 ngjml TGFO for 
4 hr, thereby increasing VDR level, followed by addition of vehicle or several concentrations 1,25-
(OHhD3 for 1 hr, 2) no preincubation with TGFB, thereby maintaining a control VDR level, and 
subsequent coincubation of 1 ngj01I TGPO with vehicle or several concentrations of 1,25-(OHhD3 for 1 
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ht (Figure lA), 3) changing the medium to serum free aMEM containing 0.1% BSA, followed by either 0 
hr (control VDR level), 3 hr (increasing VDR level) or 24 he (decreasing VDR level) of incubation and 
subsequent addition of vehicle or several concentrations l,25-(OHhD3 for 1 hT (Figure IE). 
r'Hf-1,25-(OH)fJ3 billdillg assay 
l,2S-(OHhD3 ligand binding assays were performed as described by Pols et a!. (6). In brief, 
after incubation the cells were washed with aMEM containing 2% BSA at 37°C for 2 hours to remove 
residual unlabelled 1,25-(OHhDJ. Then cells were extracted on ice in a hypertonic buffer consisting of 
300 mM Kel, 10 mM Tris-Hel (pH 7.4), 1 mM EDTA, 5 mM dithiothreitol, 10 mM sodium molybdate 
and 0.1% Triton X-IOI), High-speed supernatants were obtained, and 250 J!I aliquots were incubated 
A 
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Figure 1 
Incubation protocols for determining the effects of pre-and co-incubations with several factors on 1,25-
(OHhD3 induction of the C24-oxidation pathway of vitamin D3. 
Cells were plated at a density of 40,OOO/cm2 and cultured for 24 hr in aMEM containing 10% FCS. Next, 
medium was changed to aMEM containg 2% charcoal treated FCS and cultured for 16 hr. Subsequently, 
A) cells were coincubated with 1 ng/ml TGFO and vehicle or several concentrations of 1,25-(OHhD3 for 
1 hr or cells were preincubated with 1 ng/ml TGFO for 4 hr followed by the addition of vehicle or several 
concentrations 1,25-(OHhD3 for 1 hr, or B) medium was changed to serum free aMEM containing 0.1 % 
BSA and cells were cultured for 0, 3 or 24 hr followed by the addition of vehicle or several concentrations 
1,25-(OHhD3 for 1 he. After incubation with 1,25-(OHhD3. cells were washed in aMEM containing 2% 
BSA at 37°C for 2 hr to remove unlabelled 1,25-(OHhD3' followed by the incubation of 10-8 M eHJ-25-
(OH)D3 in aMEM containing 0.1% BSA for 1 hr. Next, the cOIwersion of eH]-25.(OH)D3 to [3H1-24,25-
(OHhD3 was determined by HPLC. 
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overnight at 4°C for single point assays with 0,25 oM eHj-l,25-(OHhD3 in the absence or presence of a 
200·fold molar excess of unlabelled hormone. After removal of the unbound ligand, receptor-bound 1,25-
(OH)2D3 was quantitated by liquid scintillation counting. 
24-Hydroxylase assay alld defection of virum;" D metabolites 
Induction of the eM-oxidation pathway and 24-hydroxylase activity was determined by 
measuring the reduction in substrate <eHJ-25-(OH)D3) and/or the appearance of el-24,25-(OHhD3 as 
described previously (6). At the end of the incubation period, as described in cell culture, medium was 
removed and cells were washed with (¥MEM containing 2% nSA at 37°C for 2 hours to remOVe residual 
unlabeled 1,25-(OH)2D3 and subsequently incubated with 10-8 M (26,27)H]-25-(OH)D3 for 1 hour. Next, 
medium was collected, cells were scraped in PBS-Triton X-100 and pooled with the medium. Samples 
were extracted three times with diethylether. The ether-extractable fraction was subjected to high pressure 
liquid chromatography (HPLC). Injector, pumps and uv detector of the HPLC system were purchased 
from Millipore Waters (Milford, MA, USA). HPLC analysis was performed using either two 0.3 x 10 em 
SI columns (Chrompaek, Bergen op Zoom, The Netherlands) with hexane : isopropanol : methanol 
(96:3_2:0_8) as the solvent at a flow rate of 0.4 ml/min or two 0.3 x 10 cm Spherisorb 5 CN columns 
(Chrompaek, Bergen op Zoom, The Netherlands) with hexane:isopropanol:methanol (94:5:1) as the 
solvent at a flow rate of 0.6 lUI/min. The radioactive vitamin D3 metabolites were identified by their 
retention time after calibration with standard 25-(OH)D3 and 24,25-(OHhD3' 
DNA fll/d protein measurements 
Changes in DNA content were assessed by the fluorimetrical method of Johnson-Wint and 
Hollis (14). Protein concentration was measured according to the method of Bradford (15). 
RESULTS 
The effects of TGFj3 and medium change 01/ vitamin D receptor level 
Figure 2 illustrates the time-course of the 1 ng/ml TGFI3 effect on VDR level 
in UMR 106 (Figure 2A) and MG 63 (Figure 2B) cells. In both cell lines TGFIl has a 
maximal effect after4-6 hr of incubation, although a significant increase was already 
observed after 2 hr in UMR 106 and 4 hr in MG 63 cells. Figure 2C shows the effect 
of a medium change from "MEM containing 2% CT-FCS to serum free "MEM 
containing 0.1 % BSA. A doubling of VDR content was observed 3 hr after medium 
change, followed by a decline to levels significantly below control level at 24 hr. 111e 
up-regulation of VDR level was blocked by the addition of actinomycin D and 
cycloheximide (data not shown), indicating that the observed increase is due to 
increased VDR transcription and new protein synthesis. Finally, under all conditions 
tested no change in receptor affinity for 1,25-(OHhD3 was observed (data not shown). 
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Time course of the modulation of VDR level by TGFfi treatment and medium change. 
A) UMR 106 and B) MG 63 cells were incubated with 1 ngjml TGFB for several incubation periods and 
VDR levels were determined by l,25-(OH)zD3 binding assay. C) MediuDl of UMR 106 cells was changed 
from 2% charcoal-treated Fes to serum free aMEM containing 0.1% nSA and after several incubation 
periods VDR levels were determined by 1,25-(OH)zD3 binding assay. Data are expressed as 
treatment/control ± SD as determined by single point assays in duplicate of two separate experiments. >I< 
p<O,05, "'* p<O.OO5, +H p<O.OOl versus control. 
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The effect of TGFfJ pre- al/d co-incubation on 1,25-(OH)}J]"induced 24-hydrmylase 
activity 
The significance of TGFIl-induced VDR up-regulation for 1,25-(OH}zD3 
induction of 24-hydroxylase activity was studied by preincubating UMR 106 and MG 
63 cells with 1 ng/ml TGFIl for 4 hr, causing an up-regulation of VDR level, followed 
by the addition of several concentrations 1,2S-(OH)P3 (Figure lA). To prevent 
interference of homologous up-regulation of the VDR, which is the increase in VDR 
level induced by 1,2S-(OH}zD3' the incubations with 1,2S-(OH}zD3 were limited to 1 
hr. Induction of the 24-hydroxylase activity was measured by HPLC analysis as the 
conversion of eH]-2S-(OH)D3 to eH]-24,2S-(OH}zD3 during 1 hr of incubation. Prior 
to incubation with labelled 2S-(OH)D3' cell cultures were washed at 3rC for 2 hr in 
serum free medium containing 2% BSA to remove residual unlabelled 1,2S-(OH}zD3 
(Figure lA). For comparison, experiments were performed in which TGFJl was 
coincubated with 1,2S-(OH}zD3 for 1 hr. TGFll incubation for 1 hr does not 
significantly affect VDR content in UMR 106 and MG 63 cells (Figures 2A and B). 
Figures 3 and 4 illustrate the effects of pre- and co-incubation with TGFIl on 
1,2S-(OH}zD3-induced C24-oxidation in UMR 106 and MG 63 cells, respectively. 
Preincubation with 1 ng/ml TGFll strongly enhances the 1,25-(OHhD3-induced 
conversion of 25-(OH)D3 to 24,25-(OHhD3 (Figure 3A), concomitant with its 
stimulation of VDR level in UMR 106 cells (Figure 2). Also in MG 63 cells, 
preincubation with TGFll resulted in increased induction of 24-hydroxylase activity 
(Figure 4A). However, in contrast to UMR 106 cells, it is not clear whether this 
increase is fully related to an increased VDR level, because a 4 hr preincubation with 
TGFIl, followed by a control incubation (i.e. without 1,25-(OH}zD3) also induced 
24,2S-(OH}zD3 accumulation (Figure 4A). As to the difference in effects of TGFIl in 
UMR 106 and MG 63 cells (c.f. Figures 3A and 4A), the possibility exists that 24,25-
(OHhD3 is already converted to subsequent metabolites in the C24-oxidation pathway 
in MG 63 cells. Therefore, after incubation with TGFIl and 10-8 M 1,25-(OHhD3 in 
MG 63 cells, we also examined the loss of the eH]-2S-(OH)D3 substrate, which 
reflects the overall conversion into "catabolic" metabolites. Figure 5 shows that 
preincubation with TGFll results in an greater loss in [3H]-2S-(OH)D3 substrate than 
control incubation. This observation indicates that additional metabolites have been 
formed. But more importantly it suggests that a relationship exists between TGFll-
regulated VDR level and the induction of the C24-oxidation pathway in MG 63 cells. 
Coincubation with TGFIl did not significantly affect the induction of 24-
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[1 ,25·(OH),D31 (M) 
Preincubation, but not coincubation, with TGFfi enhances the induction of 24-hydroxylase activity by 1,25· 
(OH}zD3 in UMR 106 cells. 
UMR 106 ceUs were preincubated for 4 hr with 1 ng/tnl TGFB followed by the addition of vehicle or 
l,25-(OHhDJ for 1 he or coincubated with 1 ng/ml TGFfi and vehicle Of l,25-(OHhDj for 1 he as 
described in Figure 1A and the effect on C24-oxidation was determined by measuring the conversion of 
eH]-25-(OH)D,3 to eH]-24,25-(OHhD3' A) The effect of preincubation with TGFfi on the induction of 
C24-oxidalion by 1,25-(OH)2Dj. B) The effect of coincubation of TGFB and l,25-(OHhDj on C24-
oxidation. * p<O.05 versus control. # p<O.Ol, ## p<O.OO5 calculated as significance of interaction. 
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hydroxylase by 1,25-(OH)zD3 in UMR 106 and MG 63 cells (Figures 3B and 4B)_ In 
MG 63 cells, we show that coincubation of TGFIl and 1,25-(OHlzD3 also did uot 
affect the loss of eHl-25-(OH)D3 substrate (Figure 5). Incubation of MG 63 cells with 
TGFIl alone for I hr resulted in a small induction of 24-hydroxylase activity (Figure 
4B). 
The effects of other mediators 011 VDR level and their consequences for the induction of 
the C24-oxidation pathway by 1,25-(OH)P3 
In order to address the relationship between VDR level and the C24-
oxidation pathway more extensively, we examined the effect of changes in VDR by 
other means than TGFIl incubation on the induction of the C24-oxidation pathway. 
Preincubation for 4 hr with 10 nM PTH, which has previously been shown to increase 
VDR level after 4 hr of incubation in UMR 106 cells (17,18), also results in increased 
induction of the C24-oxidation pathway by 1,25-(OH)zD3 in UMR 106 cells (data not 
shown). 
Another way to modulate VDR number in UMR 106 cells is changing cell 
culture medium from CT-FCS to serum free (16). In this way we could time-
dependently either increase (3 hr) or decrease (24 hr) the VDR level (Figure 2e). 
The mechanism of and the factors involved in the medium change-induced modulation 
of the VDR are unknown. However, it provides an excellent tool to examine by one 
type of manipulation the significance of either an increased or decreased VDR level. 
Therefore, medium was changed from 2% CT-FCS "MEM to serum free "MEM 
containing 0.1 % BSA and after 0, 3, or 24 hr of incubation in this medium 1,25-
(OHlzD3 was added for 1 hr. Subsequently, cells were washed for 2 hr in MEM 
containing 2% BSA, followed by the incubation with 10-8 M [3Hl-25(OH)D3 for 1 hr 
(Figure Ie). Figure 6 shows a dose-dependent effect of 1,25-(OHlzD3 on the loss of 
eHl-25-(OH)D3 substrate. 111e increased receptor level at 3 hr after medium change 
is parallelled by an increased catabolism. Comparably, decreased receptor level at 24 
hr after medium change is parallelled by a reduced catabolism. 
In addition, we found that preincubation for 24 hr with 10 ng/mi epidermal 
growth factor (EGF), a growth factor which has previously been shown to decrease 
VDR level after 24 hr of incubation in the osteoblast-like cell line UMR 106 (19), 
results in a decreased induction of the C24-oxidation pathway by 1,25-(OHlzD3 in 
UMR 106 cells (data not shown). 
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The cffects of pre- and coillcubation with TGFJ3 in the absence or presence of 1,25-(OHhD3 on 24-
hydroxylase activity in MG 63 celis, 
MG 63 ceUs were either preincubated with 1 ng/ml TGFfi for 4 hr followed by the addition of vehicle or 
1,25-(OHhD). or cells were coincubatcd with 1 ng/ml TGFfi and vehicle or several concentrations of 
1,25-(OH)2D3 for 1 hr as described in Figure lA. The effect on C24-oxidation was determined by 
measuring the conversion of fH]-25-(OH)DJ to r3H]-24,25-(OHhD3' A) The effect on 1,25-(OHhDr 
induced formation of 24,25·(OHhD3 by preincubation with TGFB for 4 hr. B) The effect of 1,25-
(OHhD3 .induced formation of 24,2S.(OH)2D3 after coincubation with TGF6 for 1 hr. * p<O.05, ** 
p<O.01 versus control. 
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Figure 5 
The effects of pre- and coincubation with TGFfi on the 1,25-(OHhD3-induced C24-oxidatiol1 pathway. 
MG 63 cells were either preincubatcd with 1 ng/ml TGFfi for 4 he followed by the addition of vehicle or 
1,25-(OHhD3' Of cells were coincubated with 1 ng/ml TGF6 and vehicle or 10,8 M 1,25-(OHhD3 for 1 
he as described in Figure lA. The effect on C24-oxidation was determined by measuring the loss of eHJ-
25.(OH)D3 substrate. * p<O.05, H p<O.Ol versus control. 
DISCUSSION 
In general, tbe present study provides evidence for a close relationship 
between VDR regulation and the induction of 24-hydroxylase activity by 1,25-
(OHlzD3• Previous experiments in our laboratory have clearly indicated that 24-
hydroxylation only represents the initial step of the C24-oxidation pathway. 
Furtbermore, the present resuits underline the biological relevance of the TGFJ3-
induced increase in VDR level, which has previously been shown not to be related to 
two other responses to 1,25-(OH)zD3, osteocalcin and osteopontin expression (12,13). 
The observed relationship between VDR up-regulation and a subsequent higher 1,25-
(OHlzD3-induced 24-hydroxylase activity is not unique for TGFIl. We show tbat 
medium change- and PTH-induced (18) VDR up-regulation as well as medium 
change- and EGF-induced (19) down-regulation of the VDR is followed by enhanced 
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The effects of medium change on the 1,25-(OH)2D:J induction of the C24-oxidation pathway as measured 
by the loss of ['HI-25-(OH)D, substrate. 
Medium of UMR 106 cells was changed to serum free aMEM containing 0.1% BSA and cells were 
cultured for 0, 3 or 24 he followed by the induction of C24-oxidation by severa) concentrations of 1,25-
(OHhD3 for 1 he as described in Figure lB. Loss of eHJ-2S.(OH)D3 Was calculated from pmal [3H].25-
(OH)D,/106 cells. 
or reduced 1,25-(OHhD3 induclion of 24-hydroxylase activity, respeclively. These 
observalions fit with data obtained by others. Armbrecht et al. (20) also demonstrated 
a synergistic increase in 24-hydroxylase activity after combined treatment of PTH and 
1,25-(OHhD3 in osleoblast-like cells. Despite species differences with respect to the 
response to retinoic acid in VDR regulalion, a close parallel was observed between 
the regulalion of VDR level and the self-induced catabolism of 1,25-(OHhD3 in rat 
and mouse osteoblast-like cells (8). Dexamethasone induces an increase in VDR level 
and concomitantly increases 1,25-(OHhD3 induclion of 24-hydroxylase aclivity (9). 
Proliferalion-related variances in VDR level in mouse osteoblast-like cells were also 
coupled 10 the induclion of 24-hydroxylase activity by 1,25-(OHhD3 (11). Also in 
other lissues, VDR mRNA and 24-hydroxylase mRNA expression are concomitantly 
induced by 1,25-(OHhD3' which supports the relevance of the VDR for 24-
hydroxylase aclivity (21-27). 
lOa 
Consequences of VDR level for 24-hydrmylase activity 
In our experiments, incubation with 1,25-(OHhD3 for 1 hr followed by a 2 hr 
period of washing the cells with "MEM containing 2% BSA was enough to induce the 
24-hydroxylase activity. It remains unclear, whether the effect of 1,25-(OHlzD3 on 24-
hydroxylase in this short period is caused by enhancement of the expression of the 
gene or by enhancement of enzyme activity. Induction of gene transcription is a 
possibility, because two vitamin D responsive elements have been identified in the 
promoter of the 24-hydroxylase gene, which are involved in the transcriptional 
regulation of 24-hydroxylase by 1,25-(OHlzD3 (28-31). However, the time needed for 
the induction of 24-hydroxylase mRNA varies among cell lines and tissues from 1 hr 
(32) to 24 hr (33). 
An interesting observation in the present study is that in MG 63 cells TGFB 
incubation alone appeared to induce 24-hydroxylase activity. MG-63 cells may, unlike 
UMR 106 celis, contain the mediator(s) to induce C24-oxidation by TGFB. Induction 
of 24-hydroxylase activity by 1,25-(OHlzD3 has previously been shown to be partly 
mediated through protein kinase C in intestinal epithelial cells (34) and in renal cells 
(35). Furthermore, TGFB responses have also been reported to be mediated by 
protein kinase C (36-38). However, protein kinase C activity was not affected by 
TGFB in UMR 106 cells (39). 11ms, the possibility arises that in MG 63 cells TGFB 
induction of 24-hydroxylase activity may be mediated by protein kinase C. Despite the 
lack of knowledge on this mechanism, induction by TGFB results in an enhanced 24-
hydroxylase activity and thereby an increased degradation of biologically active 1,25-
(OHlzD3. We extrapolate the data obtained with labelled 25-(OH)D3 to 1,25-
(OHlzD3, because up to now 24-hydroxylase is considered the initial step in the C24-
oxidation pathway of both 1,25-(OH)P3 and 25-(OH)D3' 
In conclusion, we and others have provided evidence for the coupling of VDR level 
to the magnitude of induction of the C24-oxidation pathway by 1,25-(OH)2D3 in 
osteoblast-like cells. This strict coupling does not exist for several other bioresponses 
to 1,25-(OHlzD3, including osteocalcin, osteopontin (12,13) and inhibition of collagen 
synthesis (40), indicating that additional mechanisms compensate or overrule the 
effect of changed receptor level in the response to 1,25-(OHlzD3. The coupling of 
VDR level to the catabolic pathway of vitamin D3 may provide an important negative 
feedback mechanism in the regulation of biological responses to 1,25-(OHlzD3 at 
target cell level. 
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ABSTRACT 
Both locally produced factors and systemic factors are involved in the 
regulation of bone metabolism. Systemic factors have been shown to modulate the 
production of local factors, thereby regulating bone formation and resorption. 
However, the presence of locally produced factors may also have implications for the 
biological response to systemic factors. Previously, we have shown that the locally 
produced factor transforming growth factor fl (TGFfl) has an inhibitory effect on 1,25-
(OHhD3-stimulated osteocalcin and osteopontin expression after 24 hr. In this study 
we investigate the effects of two other locally produced growth factors, bone 
morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) on the 
action of 1,25-(OHhD3 on osteocalcin and osteopontin expression in the rat 
osteoblast-like cell line ROS 17/2.8. In contrast to TGFfl, both BMP-2 and IGF-I did 
not affect osteocalcin protein production and osteocalcin mRNA expression in 
absence or presence of 1,25-(OHhD3 after 24 hr. BMP-2, but not IGF-I, caused an 
increase in 1,25-(OHhD3-enhanced osteopontin mRNA expression. Previous 
experiments have shown that the inhibitory effects of TGFfl on 1,25-(OHhD3-
stimulated osteocalcin and osteopontin expression were at least in part due to 
decreased binding of nuclear proteins to the vitamin D response elements (VDREs) 
in the promoter regions of these genes. In this study, like TGFfl, BMP-2 appeared to 
decrease the 1,25-(OHhD3-induced binding of nuclear proteins to both the 
osteocalcin and osteopontin VDREs. This may suggest that the BMP-2 effect on 
osteopontin mRNA is due to stabilization of the mRNA or that other regulatory sites 
in the promoters of osteocalcin and osteopontin playa more prominent role in the 
regulation of gene transcription by BMP-2. IGF-I did not affect binding of nuclear 
proteins to the osteocalcin VDRE and slightly reduced binding of nuclear proteins to 
the osteopontin VDRE. In conclusion, this study shows growth factor-specific 
regulation of 1,25-(OHhD3-stimulated osteocalcin and osteopontin expression in the 
ROS 17/2.8 osteoblast-like cell line. 
INTRODUCTION 
In bone, several factors are locally produced and are present either in soluble 
form or bound to the bone matrix. Among the matrix bound factors are transforming 
growth factor fl (TGFfl), bone morphogenetic protein-2 (BMP-2) and insulin-like 
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growth factor I (!GF-I). TGF13 and BMP-2 belong to the TGF13 superfamily and are 
dimers of 25 kD and 30 kD, respectively. TGF13 is synthesized and secreted in a latent 
form, which can be activated by the low pH under the ruffled border of the osteoclast 
(1,2). BMP-2 is synthesized as a precursor molecule, which is posttranslationally 
modified before the active dimer is secreted (3). Both factors enhance bone formation 
if! vivo, although only BMP-2 is able to induce ectopic bone formation (3,4). IGF-I is 
a single-chain polypeptide, which is also known to affect bone metabolism (5). 
The seco-steroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH}zD3) is an 
important regulator of calcium homeostasis and bone remodeling (6). 1,25-(OH}zD3 
exerts its actions primarily through the vitamin D receptor (VDR). The VDR belongs 
to the steroid/retinoid/thyroid hormone receptor family and acts by binding to 
distinct vitamin D response elements (VDREs) in the promoter regions of vitamin D 
responsive genes, including the rat (7-9) and human (10,11) osteocalcin, the mouse 
osteopontin (12), rat 25-hydroxy- and 1,25-dihydroxy-24-hydroxylases (13-16), calbindin 
D28k (17), fl integrin (18) and carbonic anhydrase II (19). 
Osteocalcin and osteopontin are two major noncollagenous bone matrix 
proteins, which are highly expressed with the onset of matrix mineralization during 
the if! vitro formation of bone-like tissue by normal diploid rat osteoblasts (20). 
However, in ROS 17/2.8 osteoblast-like celis, both proteins are constitutively 
expressed. The precise function of osteocalcin and osteopontin is unknown, but they 
have been proposed to playa role in bone resorption and/or mineralization (21-27). 
Systemic hormones play a role in the regulation of the production of local 
factors by skeletal cells and it has been suggested that local factors are the mediators 
by which systemic factors exert their effects on bone. However, the presence of local 
factors may also influence the effect of systemic hormones on skeletal cells. We have 
previously shown that TGFJl inhibits the 1,25-(OH}zD3-enhanced expression of both 
osteocalcin and osteopontin (28,29). Furthermore, differential effects of TGFfl, BMP-
2 and IGF-I have been found in 1,25-(OHhD3- and PTH-stimulated bone resorption 
(Chapter 6). In this study, we investigated the significance of the local factors BMP-2 
and IGF-I, as compared to TGFJl, for the action of 1,25-(OHhD3 on osteocalcin and 
osteopontin expression in ROS 17/2.8 osteoblast-like cells. 
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MATERIAL~ AND METHODS 
Materials 
[23,24-3H]-1,25(OHhD3 (105.5 Ci/millol) was obtained from Amersham International 
(Aylesbury, Buckinghamshirc, United Kingdom) and non-radioactive l,25(OHhD3 was generously 
provided by LEO Pharmaceuticals BV (Wcesp, the Netherlands). TGFI3 type 2 was a generous gift of 
Dr. J. Feyen, Sandoz Pharma Ltd (Basel, Switzerland) and BMP-2 of Genetics Institute (Cambridge, 
MA, USA). IGF-I was purchased from GroPep (Adelaide, Auslralia). Fetal calf serum (peS), penicillin, 
streptomycin and glutamine were purchased from Flow Laboratories (lrvine, United Kingdom), and 
aMEM medium from Sigma (St Louis, MO, USA), The rat osteocalcin probe (0.52 kb) and the rat 
ostcopontin probe (1.3 kb) were generously provided by Dr. M, Noda (West Point, PA, USA) and rat 
osteocalcin antiserum by Prof. R, Bouillon (Leuven, Belgium), All other reagents were of the best grade 
commercially available, 
Cell culture 
ROS 17/2.8 cells were a gift from Dr. S.B. Rodan (Merck Sharp & Dohme Research 
Laboratories, Westpoint, PA, USA). For experiments, cells were seeded at 50,000 cells/cm2 and cultured 
for 24 hr with aMEM supplemented with 2 mM glutamine, 0.1% glucose, 100 U/ml penicillin, 100 U/ml 
streptomycin and 10% FCS. Next, medium was replaced by aMEM with 2% charcoal-treated PCS and 
cells were cultured for 16 ht followed by the incubation with 1 ng/ml TGFB, 10 ng/mi BMP-2 or 10 
ngJml IGF-I in the absence or presence of 10.9 M or 10-8 M 1,25·(OHhD3 for 24 h. 
Osfeocalcill assay 
Osteocalcin measurements in medium of ROS 17/2,8 cells were performed according to the 
method described by Verhaeghe et al (30), 
RNA isolatiol! and Nort"em blot alwlysis 
RNA isolation was performed according to the method of Chomszinski (31). Electrophoresis of 
total cytoplasmic RNA (20 pg) through a formaldehyde gel and Northern blotting (Gene Screen ftlters) 
were performed according to the method described by Davis et al (32). Northern blots were prehybri-
dized for 2 hours at 42°C in a buffer containing 50% forlllamide, 0.2% SDS, lx Denhardt's solution, 5x 
sse (lx sse =: 150 mM Nael and 15 mM Na citrate, pH 7.0), 20 mM NaH2P04, 6% dextran sulphate, 
1 pg/ml salmon sperm DNA and then hybridized for 16-24 h at 42°e with 32P_labelled cDNA probe, 
either the 0.52 kb rat osteocaJcin fragment or the 1.3 kb rat osteopontin fragment. Filters were washed 
using 2x sse and 0.5% sos, Ix sse and 0.5% Sos and O.5x sse and 0.5% SDS wasb buffers. Next, 
filters were exposed to X-ray film. 
Gel mobility shift assay 
Nuclear extracts were prepared as described by Shakoori et al (33). In brief, cells were scraped 
in PBS and after centrifugation the cell pellet was reconstituted in a hypotonic lysis buffer (10 mM 
HEPES, pH7.5, 10 mM KCI and 0.2 Il1M EOTA) supplemented with 0.75 mM spermidine, 0.15 IllM 
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spermine, 1 rnM EGTA, 1 mM DTT and a broad spectrum of protease inhibitors: 0,2 mM PMSF, 70 
Jig/mi TPCK, 10 Jig/rut trypsin inhibitor, 0.5 Jig/mlleupeptin and 1.0 flg/ml pcpstatin. 0.5% Nonidct P40 
was added and cells were lysed using a dounce homogenizer. After centrifugation nuclear extracts were 
obtained by incubating nuclei in a hypertonic nuclear extraction buffer (20mM HEPES, pH 7.5, 420 mM 
KCi, 25% glycerol and 0,2 mM EDTA) supplemented with the same reagents previously mentioned for 
the hypotonic lysis huffer. Desalting was performed by dilution with hypertonic nuclear extraction buffer 
without KCI. 
For gel mobility shirl assays the following oligonucleotides were synthesized: 
rat ostcocalcin VDRE (8): 5'-CfGCACTGGGTGAATGAGGACATIACTGA-3'; 
mouse osteopontin YORE (12): S'-ACAAGGTTCACGAGGTICACGTC"'T~3'; 
SP-1 consensus: S'·CGGATGGGCGGGGCCGGGGATGGGCGGGGCCGG·3'. 
Gel·purified oligonucleotides were radiolabelled with [y32p] ATP as described by van Wijnen et 
al (34). Protein/DNA binding reactions were performed by combining 10 Itl of a S Jtg protein mixture in 
a final KCi concentration of 100 mM with 10 Jt! of a DNA mixture containing 1 fmol/pl DNA, 0.2 pg/pi 
nonspecific competitor DNA (poly(dI·dC)*(dI·dC» and 2 mM dithiothreitol for 15 min. Protein/DNA 
complexes were separated in a 4% polyacrylamide gel (acrylamide:bisacrylamide :=: 80:1) in 0.5x TBE 
electrophoresis buffer. Gels were dried and exposed to X.ray film. 
RESULTS 
The effects of TGFjJ, BMF-2 alld JGF-J all 1,25-(OH)2P3 stimulatioll of osteocalcill 
production. 
ROS 17/2.8 cells were incubated with I ng/m1 TGFIl, 10 ng/ml BMP-2 or 10 
ng/m1 IGF-I in the absence or presence of 10-9 M 1,25-(OH)P3 for 24 hr. These 
conditions were chosen, because 1,25-(OHhD3 has previously been shown to 
stimulate both osteocalcin and osteopontin expression, which was reduced by TGFIl, 
within 24 hr and these concentrations have previously been shown to be effective in 
cell culture experiments (27,35,36). As is depicted in Figure I, basal osteocalcin 
production was marginally reduced by TGFIl, and not affected by BMP-2 and IGF-I. 
The 1,25-(OHhD3 enhancement of osteocalcin production was reduced by TGFll, but 
not by BMP-2 and IGF-I. 
The effects of TGFjJ, BMF-2 alld JGF-J all the 1,25-(OH)2P3 induced illcrease ill 
osteocalcin and osteoponlin mRNA e)..pressioll. 
Figure 2 shows a Northern blot of the effects of 10 ng/ml IGF-I, 10 ng/m1 
BMP-2 and 1 ng/ml TGFIl on osteocalcin and osteopontin mRNA in the absence or 
presence of 10-9 or 10.8 M 1,25-(OHhD3 for 24 hr. IGF-I did not affect the 10-9 M 
1,25-(OHhD3 induced increase in osteocalcin and osteopontin mRNA, and slightly, 
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Figure 1 
The effects of TGFO, DMP-2 and lOP-Ion basal and l,25-(OHhD3-stimulated osteocalcin protein 
production in ROS 17/2.8 cells. ROS 17/2.8 cells were cultured as described in Materials and Methods 
followed by the incubation of 1 ng/rut TGFB, 10 ngJml BMp·2 and 10 ng/ml IGF-I in the absence or 
presence of 10.9 M 1,2S-(OHhD3 for 24 hr. Ostcocalcin level was measured in the medium and is 
depicted as treatment/control. Data are presented as mean ± SD of three independent experiments. '" 
p<O.OOl, H p<O.05 versus control. # p<O.Ol calculated as significance of interaction. 
although not significantly, enhanced the 10-8 M 1,25-(OH}zD3 induced increase in 
osteocalcin and osteopontin mRNA. BMP-2 caused an increase in 1,25-(OH}zD3 (10-8 
M) enhancement of osteopontin mRNA, although 1,25-(OH}zD3 stimulation of 
osteocalcin expression was not affected. TGFB reduced the 1,25-(OH}zD3 (10-9 M, 10-
8 M) induced increase in both osteocalcin and osteopontin mRNA. 
The eifects of TGFfJ, BM?-2 and IGF-I on 1,25-(OHhD3 induction of protein/DNA 
interactions at the osteocalcill and osteopontin VDREs. 
Because BMP-2 increased the 1,25-(OH}zD3-stimulated osteopontin expression 
in contrast to the inhibitory effect of TGFIl, we were interested in the mechanism 
whereby this effect was caused. Previously, we have shown that TGFB causes at least 
part of its inhibitory effects on 1,25-(OHlzD3-stimulated osteocalcin and osteopontin 
expression by reducing the binding of nuclear protein complexes to the VDREs in the 
promoters of the osteocalcin and osteopontin genes. To compare the effects of BMP-
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Figure 2 
The effects of TGFJ3, BMp·2 and IGF-I on 
basal and 1,25-(OH)zD3-stimulated ostcocalcin 
and osteopontin mRNA expression in ROS 
17/2.8 ceUs. ROS 17/2.8 cells were cultured as 
described in Materials and Methods followed by 
the incubation with 1 ng/rut TGFO (T), 10 
ng/ml BMP-2 (B) or 10 ng/mIIGF-1 (I) in the 
absence or presence of 10,9 M (D2) or 10,8 M 
(Dl) 1,25-(OH)2D3 for 24 hr. RNA was isolated 
and Northern blots were hybridized with 32p_ 
labeled rat ostcocalcin (OC) and osteopontin 
(OP) probes, A representative Northern blot is 
shown in panel A. 28S and 18S RNAs, stained 
by ethidium bromide, represent an internal 
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control for RNA quantitation. Panel B shows 
bar graphs of the optical density (OD) 
measurements of osteocalcin and osteopontin 
mRNA expression depicted in panel A. 
2 and IGF-I on the binding of nuclear proteins 10 the osteocalcin and osteopontin 
VDREs with TGFIl, ROS 17/2.8 cells were incubated for 24 hr with I ng/ml TGFIl, 
10 ng/ml BMP-2 and 10 ng/ml IGF-I in Ihe absence or presence of 1,25-(OHhD3' 
followed by the extracIion of nuclear proteins. Subsequently, nuclear extracts were 
incubated with labeled oligonucleotides containing either the osteocalcin or 
osteoponIin VDRE. No effects were observed by either growth factor on basal 
protein/DNA binding at both Ihe osteocalcin and osteopontin VDRE. 1,25-(OHhD3 
induced binding of nuclear proteins to the osteocalcin and osteopontin VDRE. Like 
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Figure 3 
The effects of TGFO, BMp·2 and IGF·! on the 
l,25-(OHhD3-induced binding of nuclear 
protein complexes to the ostcocalcin and 
osteopontin VDREs. ROS 17/2.8 cells were 
cultured as described in Materials and Methods 
followed by the incubation of 1 ng/ml TGFfi 
(T), 10 ns/ml BMP·2 (B) and 10 ng/ml IGF·I 
<I) in the absence or presence of 10-9 M (D) 
1,25-(OH)zD3 for 24 hr. Nuclear proteins were 
isolated and incubated with 32P_labcllcd 
oligonucleotides containing the ostcocalcin (OC) 
VDRE, ostcopontil1 (OP) YDRE or sPot 
consensus. The vitamin D inducible nuclear 
protein complexes (V) and complexes 
containing nuclear proteins that specifically bind 
the consensus SPot oligonucleotide (S) are 
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indicated by arrowheads. Binding to the SP-l 
consensus oligonucleotide represents an internal 
control for protein quanlitalion. 
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TGFB, BMP-Z inhibited the I,Z5-(OHh03 induced binding of nuclear proteins to the 
osteocalcin and osteopontin YORE. IGF-I slightly reduced binding of nuclear 
proteins to the osteopontin YORE, but did not affect binding to the osteocalcin 
YORE. SP-I oligonucleotide binding activity served as an internal control for protein 
quantitation. 
DISCUSSION 
In this study we examined the specificity of three growth factors produced by 
bone cells and present in the bone matrix for the rapid (Z4 hI') regulation of I,Z5-
(OHlz03 responses in osteoblasts. As we have previously shown and confirm in the 
present study, within Z4 hI' TGFB inhibits 1,Z5-(OHh03 enhanced osteocalcin and 
osteopontin expression (Z8). I,Z5-(OHlz03-induced binding of nuclear proteins to the 
osteocalcin and osteopontin YORE was reduced after TGFB incubation, which 
suggests that the inhibitory effects of TGFIl are at least in part due to reduced 
binding of nuclear proteins to the YOREs in the promoter regions of these genes 
(Z9). The present study demonstrates that these effects on osteocalcin 
(protein/mRNA) and osteopontin (mRNA) are TGFB-specific. Previously, no 
differences in regulation of I,Z5-(OHlz03 action between TGFB1 and TGFB2 (71 % 
amino acid sequence homology) were observed (Z9). However, as we show here, 
another member of the TGFB superfamily, BMP-2 (35 % amino acid sequence 
homology with TGFB) differentially affects the action of I,Z5-(OH)203' I,Z5-
(OH)203-induced osteocalcin production as well as osteocalcin mRNA expression 
were not affected by BMP-Z. Yamaguchi and colleagues reported an increase in both 
basal and I,Z5-(OHlz03-induced osteocalcin mRNA expression in osteoblasts after 6 
to 9 days of incubation with BMP-Z (35). Considering the long period of these 
incubations, these changes in osteocalcin expression are probably indirectly due to 
effects on differentiation of the osteoblasts (ZO,35,37). In contrast to osteocalcin, 
BMP-Z caused an enhancement of I,Z5-(OHlz03-induced increase in osteopontin 
mRNA expression. Using gelshift analysis we examined the effect of BMP-Z on 1,25-
(OHlz03-induced nuclear protein binding to the osteopontin YORE. Surprisingly, in 
contrast to the enhancement of the I,Z5-(OHh03 effect on osteopontin mRNA a very 
strong inhibition by BMP-Z of I,Z5-(OHlz03-induced binding of nuclear proteins to 
the osteopontin YORE was obselved. Also, BMP-Z strongly inhibited I,Z5-(OHlz03-
induced binding of nuclear proteins to the osteocalcin YORE, while it did not affect 
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1,2S-(OHhD3-induced osteocalcin mRNA and protein expression. Both the 
osteopontin and osteocalcin VDRE have been identified as functional elements (7-
9,12). Taken together, these data demonstrate a dissociation between binding of 
nuclear proteins to (functional) response elements and the eventual responses at 
mRNA or protein level. This indicates that in the regulation by BMP-2 other 
mechanisms than nuclear protein binding to the VDRE may play a more prominent 
role, which overcome the reduced binding of nuclear proteins to the VDRE in the 
regulation of transcription of the osteocalcin and osteopontin genes. BMP-2 may 
affect binding of nuclear proteins to other regulatory sites in the promoter region of 
these genes or may have more prominent effects at the mRNA level. Further studies 
on the effects of BMP-2 on transcription of the osteocalcin and osteopontin genes will 
give an indication at which level osteopontin mRNA expression is regulated. At the 
moment the physiological significance as well as precise mechanism underlying the 
observed discrepancy in BMP-2 effects between nuclear protein binding to VDRE 
and mRNA expression induced by 1,2S-(OH}zD3 remain unclear. 
Data obtained with IGF-I support the growth factor specificity of the 
regulation of 1,2S-(OH}zD3-stimulated osteocalcin and osteopontin expression. IGF-I 
did not affect basal and 1,2S-(OHhD3 stimulated osteocalcin protein level. IGF-I 
slightly enhanced the 10.8 M 1,2S·(OHhD3-induced increases of both osteocalcin and 
osteopontin mRNA, although not significantly. Previously, in human osteoblasts (38), 
in rat fetal calvaria (39) and in the human osteoblast-like cell line MG 63 (36) IGF-I 
was shown to stimulate both basal and 1,2S-(OHhD3-enhanced osteocalcin synthesis. 
In rat calvaria IGF-I stimulated osteocalcin synthesis after 24 hr of incubation. 
However, both human osteoblasts and MG 63 cells only responded to IGF-I after 48-
96 hr of incubation (36,38). In our experiments, 24 hr of incubation may be too short 
to observe an effect of IGF-I on osteocalcin protein level, but we did observe a small 
stimulatory effect on 1,2S-(OH}zD3-stimulated osteocalcin and osteopontin mRNA 
expression. Pirskanen et al reported that the effect of IGF-I on the 1,2S-(OHhD3 
induced increase in osteocalcin mRNA was due to a stabilization of mRNA and not 
to effects on the binding of nuclear proteins to the human osteocalcin VDRE (37). 
Our experiments also showed that 1,2S-(OHhD3-induced binding of nuclear proteins 
to the osteocalcin VDRE is not affected by IGF-I. The data obtained with the 
osteopontin VDRE and IGF-I show, like BMP-2 although less explicit, a dissociation 
between effects on mRNA, which was marginally enhanced by IGF-I, and nuclear 
protein binding to the VDRE, which was marginally reduced by IGF-I. 
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Finally, the present study demonstrates specificity of interaction of TGFB, its 
stmcturally related BMP-2, and IGF-I with 1,2S(OHlzD3 in osteoblasts. These data 
are in line with the growth factor-specific results we obtained in ill vitro bone 
resorption studies (Chapter 6). 11lOse studies show that 1,2S-(OHlzD3-stimulated 
bone resorption is strongly inhibited by TGFll and IGF-I, whereas it is enhanced by 
BMP-2. Furthermore, the present study shows a dissociation between the effects of 
BMP-2 and IGF-I on the 1,2S-(OH)P3-induced binding of nuclear proteins to 
osteocalcin and osteopontin VDREs and the regulation of 1,2S-(OHlzD3-stimulated 
osteocalcin and osteopontin mRNA expression by these factors. Additional studies to 
address this dissociation more specifically are in progress. 
REFERENCES 
1 Massague J 1990 The transforming growth fador-13 family. Annu Rev Cell Bioi 6:597·641 
2 Ol'efTo ROC, Mundy GR, Seyedill SM, BOllen-aid LF 1989 Activation of bone-derived latent 
TGP beta complex by isolated osteoclasts. Biochem Biophys Res Commun 158:817-823 
3 Wozney JM 1989 Bone morphogenetic proteins. Progress Growth Factor Res 1:267-280 
4 Rosen V, Thies RS 1992 The BMP proteins in bone formation and repair. Trends Genetics 8:97-
102 
5 Jones JI, Clemmons DR 1995 Insulin-like growth factors and their binding proteins: biological 
actions. Endocrine Rev 16:3·34 
6 DeLuca HF 1988 The vitamin D story: a collaborative effort of basic science and clinical 
medicine, FASEB J 2:224-236 
7 Demay l\-'JB, Gerardi J1\'I, DeLuca HF, Kronenberg HM 1990 DNA sequences in the rat 
osteocalcin gene that bind the 1,25·dihydroxyvitamin D3 receptor and confer responsiveness to 
1,25-dihydroxyvitamin D 3, Proc Natl Acad Sci USA 87:369·373 
8 Mal'kose ER, Stein JL, Stein GS, Linn JB 1990 Vitamin D-mediated modifications in protein-
DNA interactions at two promoter elements of the osteocaicin gene, Proc Natl Acad Sci USA 
87:1701-1705 
9 Tel'peoiog CM, Hausslel' CA, Jurullm PW, Gnlllgan MA, Komm BS, Haussler MR 1991 The 
vitamin D-rcsponsive element in the rat bone Gla protein gene is an imperfect direct repeat that 
cooperates with other cis-acting elements in 1,25-dihycroxyvitamin D3 mediated transcriptional 
activation. Mol Endocrinol 6:557-562 
10 Kernel' SA, Scott RAJ Pike JW 1989 Sequence elements in the human osteocalcin geneconfer 
basal activation and inducible response to vitamin D3. Proc Natl Acad Sci USA 86:4455-4459 
11 Ozono K, Llao J, keener SA, Scott RA, Pike JW 1990 The vitamin D-responsive element in the 
human ostcocalcin gene. J Bioi Chern 265:21881-21888 
12 Noda 1\1, Vogel RL, Craig AM, Prahl J, DeLuc", HF, Denhardt DT 1990 Identification of a DNA 
sequence responsible for binding of the 1,25-dihydroxyvitamin D3 reccptor and 1,25-
dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (Spp-l or ostcopontin) 
gene expression, Proc Natl Acad Sci USA 87:9995-9999 
13 Obymna Y, Ozono KJ Uchida MJ Shinki TJ Kato S, Suda TJ Yamamoto 0, Noshiro M, ({ato Y 
115 
Chapter 5 
1994 Identification of a vitamin n-rcsponsive element in the 5'·flanking region of the rat 25-
hydroxyvitamin D3 24-hydroxylase gene. J Bioi Chem 269:10545-10550 
14 Hahn eN, Kerry OM, Ohmdahl JL, May BK 1994 Identification of a vitamin D responsive 
element in the promoter of the rat cytochrome P450M gene. Nucl Acids Res 22:2410-2416 
15 ZICl'old C, Darwish HM, DeLuca HF 1995 Two vitamin D response elements fUllction in the rat 
l)25-dihydroxyvitamin D3 24-hydroxylasc promoter. J Bioi Chern 270;1675-1678 
16 Knhlen JP, Carlberg C 1994 Identification of a vitamin D receptor homodimcr-type response 
element in the fat calcitriol 24-hydroxylase gene promoter. Biochem Biophys Res Commun 
202: 1366-1372 
17 Gill RK, Christakos S 1993 Identification of sequence elements in mouse calbindin-028k gue 
that confer 1,25-dihydroxyvitamiu 03- and butyrate-inducible responses, Proc Natl Acad Sci USA 
90:2984-2988 
18 Cao X, Ross FP, Zhung L, MacDonald PN, Chappel J, Teltelhuum SL 1993 Cloning of the 
promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxvitamin 
03' J Bioi Chem 268:27371-27380 
19 Quelo I, Kallien JP, Rasch! A, Jurdlc P, Carlbel'g C 1994 Identification and characterization of a 
vitamin DJ response element of chicken carbonic anhydrase-H, DNA Cell Bioi 13:1181-1187 
20 Stein GS, Liun JD 1993 Molecular mechanisms mediating proliferation/differentiation 
interrelationships during progressive development of the osteolast phenotype, Endocrine Rev 
14:424-442 
21 Glowacki J, Liun JB 1987 Impaired recruitment and differentiation of osteoclast progrutors by 
ostcocalcin-deplete bone implants, Cell Diff 21:247-254 
22 Chenu C, Colucci S, Grano M, Zlgrlno P, BaraUolo R, Zambonln G, Baldini N, Vergnaud P, 
Delmas PD, Zallone AZ 1994 Ostcocalcin induces chemotaxis, secretion of matrix proteins, and 
calcium-mediated intracellular signaling in human osteoclast-like cells, J Cell Bioi 127:1149-1158 
23 Relnholt FP, Hultcnby K, Oldbel'g A, Heinegurd D 1990 Osteopontin v a possible anchor of 
osteoclasts to bone, Proe Natl Acad Sci USA 87:4473-4475 
24 Floi·cs ME, NOl'gm'dd M, Helnegard D, Relnholt FP, Andrssoll G 1992 RGD-directed 
attachment of isolated rat osteoclasts to osteopontin, bone sialoproteill, and fibronectin, Exp Cell 
Res 201:526-530 
25 Boivin G, Morel G, Llan JB, Antoinc-Tcrr'Jer C, Dubois PM, Meuniel' PJ 1990 Localization of 
endogenolls osteocalcin iu neonatal rat bone and its absence in articular cartilage: effect of 
warfarin treatment. Virchows Archiv Path Anat 417:505-512 
26 Sodck J, Chen J, Knsugal S, Nngutll T, Zhang Q, McKee M.D., Nllnci A 1992 Elucidating the 
function of bone sialoprotcin and osteopontin in bone formation, In: Chemistry and Biology of 
Mineralized Tissues (edited by Slavkin H, Price P) pp 297-306, Amsterdam: Elsevier, 
27 Roach HI 1994 Why does bone matrix contain non-collagenous proteins? The possible roles of 
osteocalcin, osteoneetin, osteopontin and bone sialoprotein in hone mineralisation and 
resorption, Cell Bioi Int 18:617-628 
28 Stual A, Birkenhagel' JC, Pols HAPJ Buurman CJ, Vlnk-van Wijngaarden T, Kleinekoort WMC, 
van den Bernd GJCM, JPTM van ueuwen 1994 Transforming growth factor /3-induced 
dissociation between vitamin D receptor level and 1,25-dihydroxyvitamin DJ action osteoblast-
like cells, Bone Miner 26:27-42 
29 Stanl A, van WiJnen AJ, Deslll RK, Pols HAP, 81rkenhfigel' JC, DeLuca UF, Denhardt DT, 
116 
Growth factor specificity ill modulation of 1,25-(OH)~3 action 
Stein JL, van Leeuwen JPTr.'1, Stein GS, Lian JB 1996 Antagonistic effects of transforming 
growth factor~13 on vitamin D3 enhancement of osteocalcin and osteopontin transcription: 
reduced interactions of vitamin D rcceptor/retilloic X receptor complexes with vitamin D 
response elements. Endocrinology 137: in press 
30 Verhaeghe J, Van Herck E, Van Brcc R, Van Assche FA, Bouillon R 1988 Osteocalcin during the 
reproductive cycle in normal and diabetic rats, J Endocrinol 120:143·151 
31 ChoDlczlnskl P, Saecelll N 1987 Single-step method of RNA isolation by acid guanidium 
thiocyanate-phenol-cholrogorm extraction. Anal Biochem 162:156-159 
32 Davis LG, Dlbncl' fI.'1D, BaHey JF 1986 Basic methods in molecular biology. Amsterdam: 
Elsevier Science Publishers 7.54-7.55 
33 Shukoorl AR, van Wljnen AJ, Rortell R, Owen TA, Stein JL, Llun JR, Stein GS 1994 Variations 
in Vitamin D rcceptor transcription factor complexes associated with the osteocalcin gene 
vitamin D responsive element in osteoblasts and osteosarcoma cells. J Ccll Biochem 55:1-12 
34 vun WIjnen AJ, Viln den Ent FMI, Linn JO, Stein JL, Stein GS 1992 Overlapping and CpG 
methylation.sensitive protein-DNA interactions at the histone H4 transcriptional cell cycle 
domain: disticntions between two human H4 gene promoters. Mol Cell Bioi 12:3273-3287 
35 Yllnmguchl A, Kntagirl T, Ikeda T, Wozney Jl\1, Rosell V, Wilng EA, Knhn AJ, Suda T, Yoshiki 
S 1991 Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation 
and inhibits myogenic differentiation in vitro. J Cell Bioi 113:681-687 
36 Pirsknnen A, Jiifiskelfilnen T, Maenpaii PH 1993 Insulin-like growth factor-1 modulates steroid 
hormone effects on osteocalcin synthesis in human MG-63 osteosarcoma cells. Eur J Biochem 
218:883-891 
37 Himkl Y, Inoue II, Shlgeno C, Sanma Y,fientz H, Rosen DM, Asada A, Suzuki F 1991 Bone 
morphogenetic proteins (BMP.2 and BMP.3) promote growth and expression of the 
differentiated phenotype of rabbit chondrocytes and osteoblastic MC3T3-EI cell,; in vitro. J Bone 
Miner Res 6:1371-1385 
38 Chenu C, Vnlentin-Opran A, Chavassleux P, Saez S, Meunier PJ, Dellllils PD 1990 Insulin like 
growth factor I hormonal regulation by growth hormone and by 1,25(OH}zD3 and activity on 
human osteoblast-like cells in short-term cultures. Bone 81·86 
39 Cunalis E, Lhm JB 1988 Effects of bone associated growth factors on DNA, collagen and 
osteocalcin synthesis in cultured fetal rat calvaria. Bone 9;243-246 
117 

CHAPTER 6 
DIFFERENTIAL EFFECTS OF THE LOCALLY PRODUCED FACTORS 
TGFIl, BMP-2 AND IGF-I ON THE ACTION OF SYSTEMIC FACTORS 
DURING IN VITRO BONE RESORPTION 
A. Staal, RA.P. Pols, J.e. Birkenhager, W.M.e. Geertsma-K1einekoort, G.J.e.M. van 
den Bernd, e.J. Buurrnan, P. Derkxl, V. Everts2, J.P.T.M. van Leeuwen 
1 Department of Pathology, Erasmus University Medical School, Rotterdam, The Netherlands 
2 Department of Cell Biology and Histology, Academic Medical Center, Amsterdam, The Netherlands 
Submitted for publication 
Chapter 6 
ABSTRACT 
Besides systemic calciotrophic hormones, a wide variety of locally produced 
factors has been shown to affect bone metabolism. Therefore, it is conceivable that 
systemic and local factors may interfere in their actions on bone. The factors 
transforming growth factor B (TGFJ:l), bone morphogenetic protein-2 (BMP-2) and 
insulin-like growth factor-I (IGF-I) are produced by bone cells and are stored in the 
bone matrix. In the present study we investigated the effects of TGFB, BMP-2 and 
IGF-I on the bone resorptive action of the systemic factors 1,2S-dihydroxyvitamin D3 
(1,2S-(OH}zD3) and parathyroid hormone (PTH). Our results show that TGFB 
inhibits 1,2S-(OH}zD3-enhanced bone resorption, but not PTH-enhanced bone 
resorption, whereas IGF-I inhibits both PTH- and 1,2S-(OH}zD3-enhanced bone 
resorption. BMP-2 has, depending on its concentration, a stimulatory effect on 1,2S-
(OH}zD3-enhanced bone resorption (10-100 ng/ml), or has at 1000 ng/ml a strong 
stimulatory effect on basal bone resorption and no further effects on 1,2S-(OH}zD3 
and PTH action. 
In these bone resorption studies the factors were exogenously added to these 
cultures. Analysis of the distribution of these growth factors in the bone matrix 
demonstrated that in adult human bone the presence of TGFJ:l type 2, TGFB type 3, 
BMP-2 and IGF-I appears to be restricted to specific areas in bone, and are not 
present throughout the bone. This suggests that these factors may control the 
response to systemic factors at particular sites in bone. 
Furthermore, the effects of local and systemic factors on osteocalcin and 
collagenase were studied as possible mediators involved in the regulation of bone 
resorption. Remarkably, 1,2S-(OH}zD3 has, in contrast to its stimulatory effect on 
bone resorption, an inhibitory effect on the osteocalcin protein levels in fetal mouse 
long bones. In addition, this inhibitory effect of 1,2S-(OH}zD3 is also observed in the 
mouse osteoblast-like cell line MC3D. 1,2S-(OH}zD3 does not affect collagenase 
activity. In conclusion, 1,2S-(OH}zD3 - and PTH-stimulated bone resorption is 
regulated in a growth factor-specific manner by TGFB, BMP-2 and IGF-I, 111is 
regulation is independent of effects on osteocalcin and collagenase activity. The 
distribution of these growth factors in bone suggests that they may control the 
response to systemic factors at particular sites in bone. Finally, in contrast to human 
and rat, in mouse 1,2S-(OH}zD3 does not appear to stimulate osteocalcin production. 
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INTRODUCTION 
The steroid hormone 1,2S-(OH)zD3 and the polypeptide hormone parathyroid 
hormone (PTH) are important systemic regulators of calcium homeostasis and 
skeletal metabolism (1,2)_ In response to a decrease in serum calcium concentration 
1,2S-(OHhD3 stimulates calcium absorption in the intestine and stimulates bone 
resorption_ PTH increases serum calcium levels by increasing both renal calcium 
reabsorption and bone resorption_ 
In addition, also locally produced factors affect bone metabolism_ Among 
these, members of the transforming growth factor II (TGFll) superfamily and insulin-
like growth factors (IGFs) affect osteoblast cell replication and differentiation (3)_ 
TGFll is a stimulator of bone formation, which is locally produced by osteoblasts (4) 
and osteoclasts (5) and is secreted and stored in an inactive form in bone (6,7)_ TGFll 
can be released from the extracellular matrix during bone resorption by osteoclasts 
(S) and it modulates the expression of several markers of the osteoblast phenotype (8-
IS)_ Bone morphogenetic protein-2 (BMP-2), another member of the TGFll 
superfamily present in the bone matrix, stimulates (ectopic) bone formation (16) and 
is a potent inducer of differentiation of osteoprogenitors and immature osteoblasts 
(17,18)_ The unrelated IGFs are produced by osteoblasts and stored in the bone 
matrix_ IGF-I stimulates the proliferation and/or differentiation of osteoblasts and 
osteoclast progenitors (19-21)_ IGFs can bind to IGF-binding proteins, the IGFBPs, 
which may either enhance or limit the effects of IGFs (22)_ Data have become 
available indicating that systemic hormones affect the synthesis of local factors, which 
may be the mediators of their effects on bone metabolism (23-25)_ However, the 
presence of local factors may also regulate the eventual response to systemic 
hormones at target tissue/cell level (26-28)_ 
These observations on synthesis of these growth factors by osteoblasts, their 
presence in bone matrix, their effects on bone cells, and their interactions with 
systemic regulators of bone metabolism at osteoblast level led to the following 
hypothesis_ Locally produced growth factors present in the bone matrix and 
potentially released during bone resorption regulate the eventual bone resorptive 
response to 1,2S-(OHhD3 and PTH. This hypothesis was tested in the present ill vitro 
study by examing the effect of exogenously added TGFll, BMP-2, or IGF-I on 1,2S-
(OHhD3 and PTH stimulation of bone resorption_ In relation to this hypothesis the 
distribution of these locally produced growth factors was examined in adult human 
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bone. In addition, in an attempt to elucidate the mechanism of the interrelated 
regulation of bone resorption by local and systemic factors, their effects on 
osteocalcin and collagenase were assessed. 
MATERIALS AND METHODS 
Materials 
1,25.(OHhD3 was kindly provided by LEO Pharmaceuticals BV (Weesp, The Netherlands). Rat 
PTH was purchased from Bachem Fernchemikalien AG (Bubendorf, Switzerland). TGFB type 2 was 
generously provided by Dr. J, Feyen, Sandoz Ph arm a Ltd (Basel, Switzerland) and BMP-2 by The 
Genetics Institute, Cambridge, MA, USA. IGP-I and des-IOP-I were purchased from GroPep Ltd, 
Adelaide, Australia. 45Ca was purchased from Amcrsham International (Aylesbury, Buckinghamshire, 
UK). Fetal calf serum (FeS), Biggers-Gwatkin·Judah (BGJ) medium, penicillin, streptomycin and 
glutamine were from Flow Laboratories (Irvine, UK), The rabbit polydonals against human 
transforming growth faclor-[32 and 03 (TGF02 and TGF03) were purchased from Santa Cruz Biotech-
nology, California, USA and against human insulin-like growth factor-I (IGF-I) was obtained from 
GroPep, Adelaide, Australia. The mouse monoclonal antibody h3b2/17.S.l against BMP-2 was kindly 
provided by The Genetics Institute, Cambridge, MA, USA. All other reagents were of the best grade 
commercially available. 
BOlle resorption assay 
The effects of systemic and local factors on bone resorption were assessed by measuring the 
percentage of 4SCa release from prelabelled 17-day old fetal mouse radii and ulnae after 3 and 6 days of 
culture which is based on the method described by Raisz (29). Mice were injected subcutaneously with 30 
ttCi of 4SCa on day 16 of gestation. Fetal mice were removed on day 17 and labeled radii/ulnae were 
dissected. Subsequently, radii/ulnae were cultured in 400 Itt of BGJ medium with 5% charcoal-treated 
FCS at .37°C for 24 hr to reduce free exchangeable calcium. Then medium was refreshed and cells were 
incubated with or \vithout systemic factors (l,25-(OHhD3 and PTH) in the absence or presence of 
growth factors (TGF8, BMP-2 and IGF-l). After 3 days medium was removed and replaced by medium 
containing the same test compound(s). After another .3 days medium was removed and radii/ulnae were 
decalcified with 5% formic acid. The amount of 4SCa was determined in medium collected after .3 and 6 
days, as well as in the 5% formic acid extracts using a liquid scintillation counter and used to calculate 
the total 4SCa content and the cumulative amount of 4SCa released from radii/ulnae. 
Afollse osleocalcill assay 
Osteocalcin levels were measured in medium and extracts of fetal mouse long bone cultures and the 
osteoblast-like cell line MC3T3 according to the method of Prof R, Bouillon (personal communication; 
30), Extracts of fetal mouse long bones were prepared either by the addition of 5% formic acid to 
radii/ulnae for 24 hr, sonification and neutralization (pH 7.4) by the addition of NaOH or by the 
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addition of a 6 M guallidine~HClfO.1 M Tris-buffer (pH 8.0) followed by sanification. MC3T3 cells were 
cultured in aMEM containing 10% pes for 2 weeks till confluency and were subsequently incubated with 
1,25.(OHhD3 for 48 hr. MC3T3 cells were extracted by the addition of a 6 M guallidinc-HCljO.l M 
Tris-buffer (pH 8.0) followed by sanification. 
Ertractioll of [eta/mollse IOllg bOlles for collagenase assay 
Extracts from long bone cultures were prepared according to the method described by Eeckbout 
et al (31); 0.1 ml CNTN buffer (lOmM Cacodylate/HCI (pH 6.0), 1 M NaCI/Triton X-lOO (0.1 mg/ml), 
I ItM ZnCI2/NaN3 (0.1 mg/llll» was added to radii/ulnae, sonificated and agitated by gentle oscillation 
at 4°C for 24 hr. Next, samples were centrifuged and supernatants were assayed for collagenase activity. 
Collagenase assay 
CoUagenase activity was measured as previously described (32). In brief, latent coUagenase was activated 
using p-aminophenylmercuric acetate (APMA, 0.1 111M); enzyme activity was inhibited by 
ethylenediaminetetraacetic acid (EDTA, 3 mM). 20 Itl medium and 180 ttl buffer (50 mM Tris, 10 mM 
CaCI2• 0.1 M NaCI, pH 7.6) in the absence or presence of APMA and/or EDTA was added to 25 Jtg e4q-labeled fibrillar collagen (2,500 dpm) and incubated for 24 hr at 35°C, Each sample was assayed in 
triplicate. FoUowing the incubation period the non-digested collagen was precipitated \vitlt 90% ethanol 
(4°C). and the radioactivity of the supernatant counted using a Packard scintillation counter with 92% 
efficiency for r14q, After subtraction of background the data were expressed as units collagenase/well, 
one unit collagenase being defined as the amount of collagenase degrading 1 Jtg collagen/min at 35°C. 
111,",lIIIO/I;s(ochenl;stry 
Bone biopsies and fixation: A human bone specimen (Os Naviculare) obtained during orthopaedic 
surgery was fixed for 24 hrs in 4% phosphate-buffered formaldehyde pH 6,9 under vacuum and dehydra-
ted in ascending ethanols for one night prior to a three steps impregnation in methylmethacrylate 
(MMA) monomer (Merck) for at least 10 hours. Specimen block was impregnated in: 80% (vol/vol) 
stabilized MMA, 0,4% Perkadox (Akzo Chemicals Netherlands), 20% (vol/yol) Plastoid N (Rohm 
Pharma Germany) for 2 bours under vacuum and embedded at 37"C overnight. Sections (5 11m) were cut 
using a Reichert-Jung Polycut S sliding microtome equipped \vith a Reichert-Jung tungsten carbide knife 
40° and mounted on gelatin-chromium-alum coated slides, 
Immunohistology: Sections were deacrylated in a 1:1 mixture of xylene and chloroform for 30 minutes 
and next dipped in xylene, rehydrated, decalcified with 1% acetic acid for 10 minutes, and rinsed two 
times with distilled water. Endogenous peroxidase activity was inhibited by a 10:1 mixture of methanol 
and 30% H 20 2 for 25 minutes, followed by two water washes, Sections were incubated with primary 
antibody (1:400 - except BMP2 H3B2 1:20) in 0,02 % TPBS (PBS pH 7.4 containing 0.1 % Triton X-IOO 
and 1.5 % BSA) for 1 hour and washed for 5 minutes with three changes of 0,1% TPBS. Primary 
antibody was detected using a Biogenex Stravigcn Multilink HRP kit (San Ramon, CA, USA). Sections 
were counterstained with a standard hematoxilill-cosin (HE) method, Control sections were stained, by 
replacing primary antibody by PBS and showed no background staining, 
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IPTHI (M) 
The effects of the systemic factors J,25-(OHhD3 and PTH on bone resorption in fetal mouse long bones. 
Prelabelled fetal mouse radii/ulnae were incubated with the indicated concentrations A) 1,25-(OHhD3 
and B) PTH for 6 days and the release of 45Ca into the mediulll was determined. % 45Ca release is a 
measure for bone resorption and was assessed as described in Materials and Methods. Data arc 
presented as mean ± SD of 12 cultures. * p<O.OO5, H p<O.OOOl versus control. 
RESULTS 
Effects of local factors on the l,25-(OH)!Y3 alld PTH enhallcemellt of bOlle resOIption 
The systemic factors PTH and 1,25-(OHlzD3 stimulate bone resorption, 
measured as % 45Ca release into the medium, in a dose dependent way in fetal 
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mouse radii/ulnae after 3 (data not shown) and 6 days of incubation (Figure 1). TIle 
effects were most pronounced after 6 days of incubation. Maximal stimulation of bone 
resorptiOl\ was observed at 10-8 M_W-7 M for 1,25-(OHlzD3 and PTH. 
Incubation of fetal mouse long bones with the locally produced factor TGFfl 
caused a small, but significant inhibition of basal bone resorption after 6 days (Figure 
2). Maximal induction of bone resorption by 1,25-(OHhD3 (10-8 M) was reduced 
after coincubation with TGFIl in a dose-responsive way with I, 10 and 100 ng/ml 
TGFIl (Figure 2A). However, co incubation with 1000 ng/ml TGFfl did not affect the 
1,25-(OHlzD3 enhancement of bone resorption. After 3 days of incubation the effects 
were less pronounced, but similar, compared to 6 days of incubation (data not 
shown). TGFfl did not affect PTH enhanced bone resorption neither after 3 nor after 
6 days (Figure 2B). 
BMP-2, which belongs to the TGFfl superfamily, had a completely different 
effect on 1,25-(OHhD3-stimulated bone resorption (Figure 3). After 6 days of 
incubation, BMP-2 did not affect basal bone resorption at concentrations of I and 10 
ng/ml. However, 100 ng/ml BMP-2 caused a small reduction in basal bone 
resorption, whereas 1000 ng/ml BMP-2 increased bone resorption to similar levels as 
10.8 M 1,25-(OHhD3 and 10.8 M PTH. 1,25-(OHhD3 stimulation of bone resorption 
was enhanced in a synergistic manner after coincubation with the concentrations 10 
and 100 ng/ml of BMP-2 (Figure 3A), whereas coincubation of 1000 ng/ml BMP-2 
and 1,25-(OHhD3 led to a similar level of bone resorption as determined after 
incubation with either BMP-2 or 1,25-(OHhD3 alone (Figure 3A). This was also 
observed after combined treatment of 1000 ng/ml BMP-2 with PTH (Figure 3B). 
BMP-2 at concentrations effective in combination with 1,25-(OHhD3 did not affect 
the PTH-induced increase in bone resorption (Figure 3B). These effects of BMP-2 
were also observed after 3 days of incubation, however less pronounced than after 6 
days of incubation (data not shown). IGF-I did not affect basal bone resorption of 
fetal mouse radii/ulnae after 3 and 6 days. However, in combination with 1,25-
(OHlzD3 IGF-I caused a dose-responsive inhibition of the 1,25-(OHhD3 stimulation 
of bone resorption (Figure 4A). In contrast to TGFIl and BMP-2, IGF-I inhibited 
PTH-stimulated bone resorption (Figure 4B). However, the PTH-stimulated bone 
resorption is about 10 times less sensitive to IGF-I than the 1,25-(OHhD3-stimulated 
bone resorption (Figure 4). TIle effects of IGF-I on 1,25-(OHhD3- and PTH-
stimulated bone resorption were also observed after 3 days of incubation, however, 
less pronounced than after 6 days (data not shown). 
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The effects of TGFB on i,25-(OHhD3- and PTH-stimulated bone resorption in fetal mouse long bones. 
Prelabelled radii/ulnae were incubated with several concentrations of TGFB (0-1000 ng/ml) in the 
absence or presence of A) 10-8 M 1,25.(OH}2D3' Of B) to-8 M PTH for 6 days. % 45Ca release is a 
measure for bone resorption. Data arc presented as mean ± SD of 12 cultures. >I< p<O.Ol, ** p<O.OOOl 
versus control. # p<O.05, ## p<O.OOOI calculated as significance of interaction. 
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Figure 3 
Effects of BMP-2 on 1,25-(OH}2Dr and PTH-stiruulated bone resorption in fctal mouse long bones. 
Prelabelled radii/ulnae were incubated with several concentrations of BMP-2 (0-1000 ng/ml) in the 
absence or presence of A) 10-8 M 1,25-(OHhD3' or B) 10-8 M PTH for 6 days. % 45Ca release is a 
measure for bone resorption. Data arc presented as Olean ± SD of 12 cultures. '" p<O,05, ** p<O.OOOl, 
H+ p<O.OO5 versus control. # p<O.05 ## p<O.OOOl, ### p<O.OO5 calculated as significance of 
interaction. 
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The effects of IGF-I on l,25-(OHhDr and PTH-stimulated bone resorption in fctal mouse long bones. 
Prelabcllcd radii/ulnae were incubated with several concentrations of IGF-I (0-1000 ng/ml) in the 
absence or presence of A) 10-8 M 1.25-(OHhD3' or B) 10-8 M PTH for 6 days. % 45Ca release is a 
measure for hone resorption. Data are presented as mean ± SD of 12 cultures. + p<O.OOOl versus 
control. # p<O.OOOl, ## p<Q,005 calculated as significance of interaction. 
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The effects of locally produced factors and 1,25-(OH)P3 on osteocalcin contellt alld 
release into medium of cultured fetal mouse 10llg bOlles 
Osteocalcin has been suggested to play an important role in bone resorption by 
enhancing the recruitment and differentiation of osteoclast precursors (33,34). 1,25-
(OH)zD3 is a potent stimulator of osteocalcin production by osteoblasts. Moreover, 
we have recently demonstrated that TGFB potently inhibits 1,25-(OH)zD3-stimulated 
osteocalcin production in both human and rat osteoblastic cells (27,35). Especially 
1,25-(OH)zD3-enhanced bone resorption was affected in the presence of the three 
growth factors. Therefore, we examined whether a relationship exists between the 
effects of TGFJl, BMP-2 and IGF-I on 1,25-(OH)P3-enhanced bone resorption and 
their effects on osteocalcin production in fetal mouse long bones. Osteocalcin protein 
levels were measured in the medium and extracts of cultured long bones after 3 and 6 
days of incubation with the various growth factors in the absence or presence of 1,25-
(OH)zD3' Surprisingly, 1,25-(OH)zD3 itself caused a dose-dependent reduction of the 
osteocalcin level in the medium of fetal mice long bones both after 3 and 6 days of 
incubation, whereas bone resorption is enhanced by 1,25-(OHhD3 (Figure I). Figure 
5 shows the cumulative effect of 1,25-(OH)zD3 on osteocalcin level in the medium 
after 6 days. In extracts, using two different extraction methods, the amount of 
osteocalcin was detectable, but low and no significant change was observed after 
incubation with 1,25-(OHhD3 (data not shown). TGFJl alone strongly reduced basal 
osteocalcin levels in long bone cultures. After coincubation of TGFB and 1,25-
(OH)zD3 osteocalcin levels were reduced to a lesser extent than after incubation with 
TGFJl alone, but were lower than after incubation with 1,25-(OH)zD3 alone (Figure 
6A). IGF-I affected neither basal nor 1,25-(OHhD3-reduced osteocalcin levels 
(Figure 6B). BMP-2 did not affect basal osteocalcin levels in the medium of fetal 
mouse long bone cultures. However, BMP-2 further enhanced the 1,25-(OH)zD3-
induced reduction in osteocalcin levels (Figure 6C). 
The inhibitory effect of 1,25-(OH)zD3 on osteocalcin levels in medium of fetal 
mouse long bone cultures is contradictory to the stimulatory effect of 1,25-(OH)zD3 
on osteocalcin production in rat and human osteoblast-like cells. To address the 
possibility of species specificity, we investigated the effect of 1,25-(OH)zD3 on 
osteocalcin production in the neonatal mouse osteoblast-like cell line MC3T3. Similar 
to the fetal mouse long bone cultures, 1,25-(OH)zD3 reduced osteocalcin levels in 
medium as well as in cellular extracts of MC3T3 cells (Figure 7). 
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Figure 5 (1 ,25-(OH),D,1 (M) 
The effect of l,25.(OH)2D3 on ostcocalcil1 level of fctal mOllse long bones. Fetal mouse radii/ulnae were 
incubated with several concentrations of l,25·(OHhD3 and ostcocalcin levels were measured in the 
medium after 6 days. Data are presented as mean ± SD of 6 cultures, .. p<O.05 versus control. 
The effects of TGFfJ and 1,25-(OH)fJ3 all collagenase level in fetal mouse long bones 
In addition to the investigation of osteocalcin as a possible mediator of the 
regulation of bone resorption, we studied the regulation of the activity of collagenase, 
an enzyme demonstrated to be involved in bone matrix degradation (36) by 1,25-
(OHhD3 in fetal mOllse long bone cultures. 1,25-(OHhD3' however, did not affect 
collagenase activity in these cultures (Table I). Additionally, we investigated the 
effects of one of the locally produced growth factors, TGFJl, on collagenase activity. 
Collagenase activity was not affected by TGFJl (Table I). These observations do not 
support a role of this enzyme in the inhibitory effects of TGFJl on basal and 1,25-
(OHhD3-enhanced bone resorption. 
Localization of locally produced factors in nonnallllilnall bone 
As interactions between local factors and systemic factors occur in the 
regulation of bone resorption, it is of interest to determine the presence and 
localization of these locally produced factors in normal bone. The purpose of this 
examination was not to determine their precise localization in relation to known bone 
histological and histomorphometric parameters, but to assess whether these factors 
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The effects of TGFO, nMP~2 and IGP-J in the absence or presence of 1,25-(OH)2D3 on ostcocalcin level 
in the medium of fetal mouse long bones. Fetal mouse long bones were incubated with A) 10 ng/ntl 
TGFJ3, B) 100 ng/ml IOF-I, and C) 10 or 1000 ng/ml BMP-2 in the absence or presence of 10,8 M 1,25-
(OHhD3 for 6 days. Osteocalcin level was measured after 6 days. Data are presented as mean ± SD of 
7 cultures ... p<O,QOOl, ++ p<O.05 versus control. # p<O,OOl, ## p<O.05 significance of interaction. 
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The effect of 1,25-(OHhD3 on ostcocalcin level in the mouse osteoblast-like cell line MC3T3. MC3T3 
cells were cultured for 2 weeks till conflucncy followed by the incubation with 10-10 M or 10.8 M 1,25· 
(OHhD3 for 48 hr. Osleocalcin levels were measured in medium as well as cell extracts of MC3T3 cells. 
Data arc presented as mean ± SD of 2 cultures. " p<O.05 versus control. 
TABLE I 
The effects of TGFI3 and 1,25-(OH)2D3 on collagenase activity in fctal mouse long bones after 6 days. 
control 
1,2S-(OH),D, 
TGFB 
1,2S-(OH),D, + TGFB 
collagenase 
activity (Units) 
6.98 ± 0.84 
7.07 ± 1.30 
7.07 ± 3.07 
7.07 ± 2.8 
Fetal mouse radii/ulnae were incubated with 10 ng/rol TGF6 and 10-8 M 1,25-(OH)zD3 for 6 days. A 
medium change was performed after 3 days. Collagenase was determined in radii/ulnae extracts after 6 
days of incubation. 
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are diffusely present throughout bone or whether their presence is restricted to 
particular sites. We investigated the localization of TGFIl type 2, TGFIl type 3, BMP-
2 and IGF-I in human adult bone by immunollistochemistry. As shown in Figure 8, all 
factors are highly expressed in particular areas and are not diffusely present 
throughout bone. 
DISCUSSION 
The data obtained in the present study clearly support the hypothesis that growth 
factors present in the bone matrix regulate bone resorption stimulated by 1,25-
(OHhD3 and PTH. The 1,25-(OHhD3- and PTH-enhanced bone resorption is 
regulated in a growth factor specific manner. Moreover, the effects of TGFIl, BMP-2, 
and IGF-I are hormone specific. We observed that TGFIl inhibits 1,25-(OHhD3- but 
not PTH-stimulated bone resorption in fetal mouse long bones. BMP-2 stimulated 
1,25-(OHhD3-induced bone resorption whereas the effect of PTH on bone resorption 
was not affected. IGF-I inhibited both 1,25-(OHhD3- and PTH-enhanced bone 
resorption although with different sensitivities. These data implicate that growth 
factors are involved in the control of the extent of bone resorption in response to 
1,25-(OHhD3 and/or PTH. To gain insight into the localization of these growth 
factors in the bone matrix, the presence and distribution of TGFIl type 2, TGFIl type 
3, BMP-2 and IGF-I in adult human bone were examined. Immunohistochemical 
analysis revealed that the presence of these growth factors is restricted to specific 
sites and that they are not diffusely present throughout the bone. Thus, the amount 
and type of growth factor present in the bone matrix may eventually cause less or 
more profound resorption in response to 1,25-(OHhD3 and/or PTH at particular 
sites. For example, 1,25-(OHhD3-induced bone resorption at a TGFIl-positive site 
may be limited whereas at a TGFIl-negative site resorption can go on. The proposed 
model requires that growth factors should be released from the bone matrix during 
resorption and must still be biologically active or in a configuration that can be 
activated. This seems not unlikely because TGFIl is stored in a latent form in the 
bone matrix (37,38) and IGF-I binds to IGF-BPs which are capable of binding the 
extracellular matrix (21,39,40). These features can have protective effects for the 
growth factor which may result in the eventual release of active growth factors. This is 
supported by the ill vitro obselvation that several factors that stimulate bone 
resorption at the same time enhance TGFIl activity in the culture medium (41). This 
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Figure 8 
Presence and distribution of TGFfi type 2, TGFB type 3, BMp·2 and IGF-I in normal human adult bone. 
Immunohistochemical analysis was performed as described in Materials and Methods, using antibodies 
specific for A) TGFfi type 2, B) TGFI3 type 3, C) BMP-2 and D) IOF·1, Arrows indicate the presence of 
the various growth factors. 
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indeed suggests that TGFJl, but possibly also the other growth factors, may serve as a 
local feedback regulatory mechanism for bone resorption. 
The present results about differential regulation of 1,25-(OHhD3 and PTH 
stimulation of bone resorption by the growth factors tested point to different bone 
resorptive mechanisms for 1,25-(OHlzD3 and PTH. This supports the observation that 
1,25-(OHlzD3• unlike PTI-I, affects precursors of the osteoclast lineage (42-44). Our 
data that TGFJl inibits 1,25-(OH)zD3 but not PTH stimulation of bone resorption 
seems to be in line with these observations because TGFIl is a potent inhibitor of 
1,25-(OHlzD3-induced osteoclast-like cell formation in long-term human bone 
marrow cultures, both by inhibiting proliferation and differentiation of early 
precursors as well as by inhibiting fusion of mononuclear cells to form osteoclasts 
(45). In addition, in fetal rat long bones TGFJl inhibition of 1,25-(OHlzD3-stimulated 
bone resorption was suggested to occur via inhibition of osteoclast precursor 
proliferation (46). 
To gain more insight into the mechanisms whereby TGFJl, BMP-2 and IGF-I 
affect 1,25-(OHlzD3-stimulated bone resorption we investigated the effects on 
osteocalcin production and collagenase activity in fetal mouse long bone cultures. 
Previously, osteocalcin has been suggested to play a stimulatory role in bone 
resorption by enhancing the recruitment and/or differentiation of osteoclasts (33,34). 
11,is is supported by evidence that osteocalcin deficiency leads to an increase in the 
amount of bone matrix deposition resulting in a 50% increased cortical thickness, 
replacement of the growth plate and epiphysal cartilage by newly formed bone and a 
significant increase in bending strength of long bones (47). In rat and human 
osteoblast-like cells osteocalcin production is strongly stimulated by 1,25-(OH)2D3' 
and this stimulation has been shown to be inhibited by TGFJl (26,27,35,48). This 
observation in rat osteoblast-like cells parallels the regulation of fetal rat long bone 
resorption by 1,25-(OHlzD3 and TGFIl. However, in fetal mouse long bones we 
observed an inhibitory effect of 1,25-(OI-IlzD3 on osteocalcin content, in contrast to 
the stimulatory effect of 1,25-(OHlzD3 on fetal mouse bone resorption. TGFIl alone 
strongly reduced basal osteocalcin level and in combination with 1,25-(OHlzD3 
osteocalcin level was reduced to a lesser extent than after incubation with TGFJl 
alone. To investigate whether the difference between the effects of 1,25-(OI-IlzD3 in 
rat/human osteoblast-like cells and fetal mouse long bones was due to a species 
difference, a difference between isolated osteoblasts and long bone culture or a 
difference between fetal and non-fetal regulation, we also studied the effect of 1,25-
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(OH}zD3 on osteocalcin production in the neonatal mouse osteoblast-like cell line 
MC3T3. Like in fetal mouse long bone cultures, in MC3T3 cells osteocalcin 
production was reduced in the presence of 1,25-(OH}zD3' However, Gundberg et al. 
showed in an ill vivo study that administration of 1,25-(OH}zD3 to mice increased 
serum osteocalcin level (49). Combining this observation with our data suggests that 
this is due to release from bone matrix during resorption rather than new synthesis in 
response to 1,25-(OH}zD3' The difference between rat/human and mouse suggests 
species specificity in the regulation of osteocalcin production by 1,25-(OH}zD3' This is 
supported by data of Sztajnkrycer et al. (50), who reported that in ROS 17/2.8 cells 
stably transfected with the mouse osteocalcin genes, 1,25-(OH}zD3 also reduced 
mouse osteocalcin production, whereas the endogenous rat osteocalcin gene was 
stimulated by 1,25-(OH}zD3' Kesterson et al. (51) introduced the human osteocalcin 
gene promoter fused to the chloramphenicol acetyl transferase gene into the germ line 
of mice and showed reduction of CAT activity after a low vitamin D3 diet, while 1,25-
(OH}zD3 supplementation restored and enhanced CAT activity over control values. 
These data show that the differences observed between rat/human and mouse are not 
due to differences in the availability of factors important for the regulation of the 
osteocalcin gene. Remarkable is the difference in the 5' half site of the vitamin ° 
responsive elements (VDREs) between the rat (GGGTGAnnnAGGACA; 52-54), 
human (GGGTGAnnnGGGGCA; 55,56) and mouse (GGGCAAnnnAGGACA; 57) 
VDREs of the osteocalcin genes. Underlined are the nucleotides in the mouse VDRE 
that differ from both the rat and human genes. This dinucleotide difference in the 
VDRE may lead to a change in its ability to bind nuclear proteins and thus, 
eventually in a change in regulation of transcription. Irrespective of the lack of 
koowledge on the precise mechanism, our data do not support a major role for 
osteocalcin in the 1,25-(OH}zD3 regulation of bone resorption in fetal mouse long 
bones. 
Another candidate protein that could be the mediator in the inhibitory effect 
of TGFJl on 1,25-(OH}zD3 enhancement of bone resorption is collagenase (58,59). 
Collagenase has been shown to be an important mediator in calvarial bone resorption 
(60). In osteoblast-like cells collagenase activity is stimulated by 1,25-(OH}zD3 and 
PTH (61-64). In mouse calvarial osteoblast cultures TGFIl has been shown to inhibit 
1,25-(OH}zD3 stimulated collagenolysis (65). However, in our study in fetal mouse 
long bones, we did not observe changes in collagenase activity after incubation with 
1,25-(OH}zD3 for 6 days. Collagenase does not seem to play a role in the 1,25-
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(OH}zD3 enhancement of resorption. The discrepancy between our results and 
previous reports may be caused by differences in the regulation of collagenase activity 
between calvaria and long bones. Furthermore, a time-related aspect may be 
important. The regulation of the production of tissue inhibitor of metalloproteinase-I, 
an enzyme reducing the activity of collagenase, may provide a feedback mechanism, 
whereby after 6 days 1,25-(OH}zD3- or TGFl.I-induced changes are counteracted. 
In conclusion, this study shows growth factor specificity in the regulation of 
1,25-(OH}zD3 and PTH enhanced bone resorption as well as hormone specificity, as 
shown by the differential effects of each growth factor on 1,25-(OHhD3 and PTH 
stimulation of bone resorption. Furthermore, we show that the expression of TGFl.I 
type 2, TGFl.I type 3, BMP-2 and IGF-I is restricted to specific sites in bone. Together 
with the bone resorption results, this suggests that locally produced factors define the 
action of systemic factors and are thereby important in the regulation of the 
architecture of bone. However, tbe mechanism by whicb 1,25-(OH}zD3- and PTH-
enbanced bone resorption is regulated by TGFfi, BMP-2 and IGF-I remains unclear. 
The present data on osteocalcin and collagenase activity do not support a major role 
for tbese proteins in the regulation of bone resorption at least in the model system 
used in this study. 
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ABSTRACT 
The j",2S-dihydroxyvitamin D3 (VD3)-dependent stimulation of osteocalcin (OC) 
and osteopontin (OP) gene transcription in bone tissue is mediated by interactions of 
trans-activating factors with distinct VD3 responsive elements (VDREs). Sequence 
variation between the OC- and OP-VORE steroid hormone half-elements provides the 
potential for recognition by distinct hormone receptor homo- and heterodimers. 
However, the exact composition of endogenous V03 induced complexes recognizing the 
OC- and OP-VOREs in osteoblasts has not been definitively established. To determine 
the identity of these complexes, we performed gel shift immuno-assays with nuclear 
proteins from ROS 17/2.8 osteoblastic cells using a panel of monoclonal antibodies. We 
show that VD3 inducible complexes interacting with the OC- and OP-VDREs represent 
two distinct heterodimeric complexes, each composed of the Vitamin D Receptor (VDR) 
and the Retinoid X Receptor 01 (RXR). While the OC- and OP-VDR/RXROI 
heterodimers are immunoreactive with both RXR" and VDR antibodies (i.e., 9a7"( and 
VD2F12), ordy the OC-VDRE complex is recognized by a specific monoclonal antibody 
(IVG8Cll) which contacts an epitope in the VDR DNA binding domain (amino acids 
57-164). By systematically introducing a series of point-mutations in the OC-VDRE, we 
find that two internal nucleotides of the proximal OC-VORE half-site (nt -449 and -448 
\S'-AGGACA) determine differences in VDR immunoreactivity. 111is result provides a 
novel line of evidence for polarity of VOR/RXR" binding to OC- and OP-VDREs, with 
the proximal half-elements being recognized by the VDR, and further suggests that the 
DNA binding domain of the VDR adopts different protein conformations when 
contacting distinct VDREs. Distinctions between the OC- and OP-VDR/RXR" 
complexes may reflect specialized requirements for VD3 regulation of OC and OP gene 
expression in response to physiological cues mediating osteoblast differentiation. 
INTRODUCTION 
J",2S-dihydroxyvitamin 0 3 (V03) is essential for the maintenance of calcium 
homeostasis and skeletal development and exerts most of its effects through the vitamin 
D receptor (VOR)(l). VDR containing transcription factor complexes trans-activate 
osteoblast related genes via" VD3 responsive cis-acting elements (VOREs). 
Transcriptional regulation of the VD3 responsive osteocalcin (OC) and osteopontin (OP) 
genes, which encode major non-collagenous proteins in bone, functionally contributes to 
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bone formation and resorption. The well-characterized VDREs located in the promoters 
of the OC and OP genes represent important paradigms for understanding VD3 
mediated transcriptional mechanisms in bone tissue. 
The VDR belongs to the superfamily of nuclear steroid hormone receptors (1-4) 
which also includes retinoic acid receptors (RAR and RXR), thyroid hormone receptors 
(TR) and several orphan receptors. The VDR is capable of forming homodimers, as well 
as heterodimers with RXR Ol and RXR {3 (S-lO), that bind to direct repeats of hexameric 
half elements (e.g., S'-PuG(G/T)TCA) with distinct spacing requirements (II-IS). In 
addition, in vitro binding site selection experiments have revealed that VDR/VDR 
homodimers and VDR/RXR heterodimers have different nucleotide preferences within 
the VDRE hexamers (14,IS). Moreover, distinct VDREs, which have the potential to 
interact with different receptor homo- and hetero-dimers, have been identified in the 
promoters of several genes; including the human (16,17) and rat osteocalcin (18-21), 
mouse osteopontin (22), rat 2S-hydroxyvitamin D3 and 1,2S-dihydroxyvitamin D3 24-
hydroxylase (23-26), as well as the mouse calbindin D28k (27) and chicken {33 integrin 
(28) genes. 
Several studies have established the potential for functional interactions between 
distinct VDR and/or RXR complexes at the OC- and OP-VDREs. For example, 
heterodimerization of the VDR with RXR-related auxiliary nuclear factors is required 
Table 1 
rat DC-VDRE 5'-GGGTGA ATG AGGACA-3' 
mouse op· VDRE 5'-GGTICA CGA GGTICA-3' 
human oc-YDRE 5'·GGGTGA ACG GGGGCA-3' 
rat calbindin D-28K YORE 5'-GGGGGA TGT GAGGAG-3' 
rat cytochrome P45014 VDRE 5'·AGGTGA GTG AGGGCG-3' 
avian intcgrin 03 YDRE 5'·GAGGCA GAA GGGAGA-3' 
rat calbindin D-9K S'-GGGTGT eGG AAGCCC-3' 
The table shows nucleotide sequences of the hexameric steroid hormone half elements (underlined) 
in the DC and OP VDREs, as well as VDREs identified ill other genes as indicated (see text for references). 
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for binding to the OC-VDRE (29-40). However, many of the structural parameters of 
receptor interactions with the OC- and OP-VDREs have been investigated by in vitro 
binding studies using VDR and selected RXR proteins, which were obtained by bacterial 
expression, in vitro transcription/translation with crude celllysates, or by vir ally mediated 
expression in insect cells; several studies also employed Iysates derived from non-osseous 
cells in which candidate receptor proteins were over-expressed, or used synthetic 
oligonucleotides that do not resemble native VDREs. Also, functional aspects of 
VDR/RXR interactions have been analyzed by transient transfection experiments in non-
osseous cells using over-expression plasmids encoding VDR or RXR, and artificial 
chimeric reporter gene constructs. These excellent reductionist approaches have provided 
key insights into the potential mechanisms by which VDR mediates transcriptional 
enhancement of responsive genes. However, these approaches do not provide 
physiologically relevant information on the VDR containing complexes present in osseous 
cells, which is required to gain insight into the regulation and regulatory roles of the 
VDR in bone tissue. Therefore, the precise compositions of endogenous VD3 containing 
complexes that interact with the OC- and OP-VDREs and are physiologically responsive 
to VD3 in osteoblasts, remain to be established. 
In this study, using a panel of antibodies against the VDR and RXRs and a 
systematic series of point mutations within the DC VDRE, we performed a molecular 
dissection of the interactions of endogenous VDR/RXR heterodimers from osseous cells 
with VDREs. The results show that the endogenous VDR complexes interacting with OC 
and OP VDREs represent VDR/RXRCI' heterodimers. We present a novel innnuno-
logical line of evidence for the concept that VDREs specify receptor polarity. The VDR 
recognizes exclusively the proximal steroid half element in both the OC and OP VDREs. 
Furthermore, we find that immunologically distinct VDR/RXR complexes bind to the 
OC and OP VDREs, with the conformation of the VDR moiety in each complex 
depending on specific dinucleotides within the proximal steroid half element. Our 
findings are consistent with the concept that VDREs dictate receptor dimer specificity 
and are capable of conferring distinct conformations to DNA bound VDR/RXRCI' 
complexes. 
MATERIALS AND METHODS 
Cell culture 
ROS 17/2.8 osteosarcoma cells, kindly provided by Dr. G. Rodan and Dr. S. Rodan (Merck Sharp 
& Dohme Research Laboratories, West Point, PA) were maintained in Hams F12 medium supplemented 
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with 2 ruM L-glutaminc, 100 IU Iml penicillin and 100 Itg/ml streptomycin and 5% fctal calf serum (FCS) 
at 3t>C under 95% air/5% CO2_ For the experiments, cells were seeded in 100 x 20 mm plastic dishes at 
0.7 x 106 cells/plate in Hams F12 medium containing 5% Fes and cultured for 24 hr. Subsequently, medium 
was replaced by Hams F12 with 2% charcoal-treated FCS and cells were cultured overnight and then 
incubated for 24 hr with VD3, TGF,81 and/or TGF{j2 as indicated in the figure legend. l,25-(OHhD3 was 
kindly provided by Dr. M, Uskokovic Hoffman-La Roche Inc. TGF01 was purchased from R&D Systems, 
Minneapolis, MN. TGP.o2 was kindly provided by Dr. J. Peyen, Sandoz Pharma LtD, Basel, Switzerland. 
Immunological reagents 
The following VDR antibodies were used in our study: IVG8Cll, VD2F12 and 9a7,. The mouse 
monoclonal antibodies IVG8Cll and VD2F12 were directed against the porcine VDR, and recognize both 
human and rat VDR. The epitopes of these antibodies are distinct, and have been mapped to amino acids 
57 to 164 spanning the highly conserved DNA binding domain (41). The 9a7"( antibody represents a 
monoclonal antibody recognizing amino acids 89 to 105. 
Several different mouse monoclonal RXR antibodies (42) were used in our experiments. Antibody 
4RX·ID12 (in this study referred to as antibody RXRa,.a,"() recognizes the D/E regionj this antibody cross-
reacts with all three RXR members, RXRa, RXR.6 and RXR"(. Antibodies 4RX-3A2 and 83-106·PC13 arc 
specific for RXRa and RXR.6, respectively. 
Gel mobility shift assays 
The following VDRE-containing oligonucleotides were used in gel mobility shift assays: rat 
osteocalcin VDREoligo(19),5'.C"'TGCACTGGGTGAATGAGGACATTAC"'TGA-3',andmouseostcopontin 
VDRE oligo (21), 5'-ACAAGGTICACGAGGTICACGTCT-3'j the underlined nucleotides represent the 
steroid hormone half-sites that mediate binding of nuclear receptor complexes and arc shared among distinct 
VDREs (Table 1). A series of mutant OC-VDRE oligonucleotides (Table 2) was used to investigate which 
Ilucleotides in the OC- and OP-VDRE half sites are responsible for differences in immunoreactivity with the 
IVG8Cll antibody. 
Gel-purified oligonucleotides were labeled with e2pJ ATP. Nuclear extracts were prepared as 
described previously (43-45). In brief, cells were scraped in PBS and after centrifugation the cell pellet was 
reconstituted in a hypotonic lysis buffer (10 mM HEPES, pH7.5, lOmM KCI and 0.2 mM EDTA) 
supplemented with 0.75 mM spermidine, 0.15 mM spermine, 1 mM EOTA, 1 mM DTI and a broad 
spectrum of protease inhibitors: 0.2 mM PMSF, 70 Ilg/ml TPCK, 10 pg/ml trypsin inhibitor, 0.5 Ilg/ml 
leupeptin and 1.0 pg/ml pepstatin. 0.5% Nonidet P40 was added and cells were lysed using a dounce 
homogenizer. After centrifugation nuclear extracts were obtained by incubating nuclei in a hypertonic nuclear 
extraction buffer (20mM HEPES, pH 7.5, 420 mM KCI, 25% glycerol and 0.2mM EDTA) supplemented with 
the same reagents previously mentioned for the hypotonic lysis buffer. Desalting was performed by dilution 
,vith KNO buffer (20% glycerol, 0.2 mM EDTA, 0.01% Nonidel-P40, Hepes, pH 7.5). 
Protein/DNA binding reactions were performed in a final concentration of 50 mM KCI and 0.5 
fmoljJll DNA, 0.1 Ilg/pi poly(dI-dC)*(dI-dC) and 4 mM DTT. The results of gel shift immuno-assays 
presented in the figures throughout this study were performed by incubating nuclear protein preparations 
from VD3 treated cells ,vith VDR antibodies 15 minutes prior to addition of radiolabelled VDRE 
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Table 2 
rOC VDRE 5'-CfGCACfGGGTGAATGAGGACATTACfGA-3' 
mOPVDRE 5'-ACAAGGTTCACGAGGTTCACGTCf-3' 
OP/OP 5'-CfGCACfGGTTCAATGGGTTCATTACfGA-3' 
OC/OP 5'-CfGCACfGGGTGAATGGGTTCATTACfGA-3' 
OP/OC 5'-CfGCACfGGTTCAATGAGGACATTACfGA-3' 
pm IG3T 5'-CfGCACfGGGTGAATGGGTACATTACfGA-3' 
pm IG4T 5'-C'TGCACfGGGTGAATGGGGTCATTACfGA-3' 
pm 3T4T 5'-CfGCACfGGGTGAATGGGTTCATTACfGA-3' 
pm 3T 5'-CfGCACTGGGTGAATGAGTACATIACfGA-3' 
pm4T 5'-CfGCACfGGGTGAATGAGGTCATTACTGA-3' 
The table shows nucleotide sequences (upper strand shown) of the wildtype DC- and QP-VDREs 
(the hexameric steroid hormone half clements are underlined), as well as mutant oligonucleotides which were 
used for determining which nuclcotidcs are responsible for differential immunoreactivity of the DC- and QP-
YORE complexes with the IVG8Cll VDR antibody. Substitution mutations were designed within the context 
of DC-VDRE oligonucleotide and the corresponding mutants represent hybrids between the DC- and QP-
VDREs, In mutant QP lOP, both the distal and proximal hcxamers of the OC VDRE have been substituted 
for the analogous elements of the op-VDRE, whereas mutants OC/OP and OP /OC contain substitutions 
of the proximal or distal hexamer, respectively. The remaining oligonucleotides represent point mutations 
within the proximal hexamer of the OC-VDRE. 
oligonucleotides. We did not observe any differences in the outcome of the experiments when we performed 
pre- and post-incubation experiments in which the VDR antibody IVG8Cll was incubated with protein either 
prior to or after addition of radio-labelled DC- and op· VDREs (data not shown). Protein/DNA complexes 
were separated in a 4% polyacrylamide gel (acrylamide: bisacrylamide = 80: 1) run in O.5x TBE. Gels were 
dried and exposed to x-ray film. 
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RESULTS 
Immunologically distinct VDR/RXR complexes illteract with OC- and OP-VDREs 
The OC and OP vitamin D responsive elements each mediate formation of one 
main endogenous complex using nuclear proteins from vitamin D treated ROS 17/2.8 
rat osteosarcoma cells in gel shift assays (Fig. 1). Competition analysis demonstrates that 
the OC-VDRE complex is competed by a IOO-fold molar excess of both the unlabelled 
OC-VDRE and OP-VDRE oligonucleotides. Similarly, cross-competition is also observed 
for the OP-VDRE complex. Thus, the OC- and OP-YDRE complexes detected with 
32p DC VDRE 32p OP VDRE 
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Figure 1 
Characterization of VD3 inducible complexes at the DC-and op-VDREs. The oc- or op-VDRE probes 
(as indicated above the lanes) each mediate formation of one main VD3 inducible complex (designated V) 
when incubated with nuclear protein (approximately 5 Itg) from VD3 treated (10-8 M, 24 hr) ROS 17/2.8 
cells. The left panel represents an oligonucleotide competition assay which was performed using a lOO-fold 
molar excess of unlabelled DC- or OP-VDRE or a nOll-specific competitor (SP-t). Cross-competition is 
observed between the DC- and OP-VDRE complexes, indicaling similar recognition specificities for DNA 
binding. The right panel represents a gel shift intlllUllo-assay with nuclear proteins from VD3 treated ROS 
17/2.8 cells in the presence of a monoclonal antibody to the VDR (IVG8Cll, aVDR) and a polyclonal 
antibody to RXR (recognizing the ex, (J, 'Y subtypes of RXR, ex-RXR). Nuclear proteins and antibodies were 
co-incubated for 15 minutes and subsequently either labelled OC- or OP-VDRE was added to the reaction 
mixtures. Immunoreactivity of the OC-VDRE complex is indicated by loss of binding with the VDR antibody 
(IVG8Cll), and a supershift (S) with the RXR antibody. 
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endogenous receptor proteins and accessory factors in osteoblastic cells are mediated by 
DNA binding activities with similar recognition specificities. 
Immunoreactivity of the OC- or OP-VDRE complexes was tested using a specific 
monoclonal VDR antibody (IVG8Cll) and a monoclonal RXR antibody (4RX-IDI2), 
which cross-reacts with the three RXR subtypes RXR", RXR{3 and RXR'Y. The VDR 
32p DC VDRE 32p OP VDRE 
ADS RDS ADS RDS 
1712.8 24.1 17/2.8 24.1 
CDC 0 CDC 0 
v~ 
Figure 2 
The VD3-responsive complexes of both the DC-
and OP· VOREs require the presence of the 
VDR. As indicated above the lanes, binding 
reactions were performed with either labelled 
DC- or op· VDRE using nuclear extracts that 
were prepared from either ROS 17/2.8 or ROS 
24/1 cells cells after 24 be incubation with (D) or 
without (C) 10.8 M vitamin D. The YD3-
responsive protein/DNA complex observed with 
nuclear proteins from ROS 17/2.g cells 
(designated V) is absent in nuclear extracts from 
VD3-1reated ROS 24.1 cells which lack a 
functional VDR. 
150 
antibody inhibits formation of the OC-
VDRE complex, whereas the RXR 
antibody causes a supershift (Fig. 1). In 
contrast, the OP-VDRE complex is 
supershifted by the RXR antibody, but 
formation of this complex is not reduced 
by the VDR antibody. We 
also analyzed binding to other functional 
VDREs (e.g., human OC and rat 1,25-
dihydroxyvitamin D3 24-hydroxylase; see 
Table 1); the results confirmed the 
selective recognition of the VDR 
antibody for complexes bound at distinct 
VDREs (data not shown). Taken 
together, these gel shift immuno-assays 
reveal molecular distinctions between 
the OC- and OP-VDRE complexes. 
To analyze whether the OP-
VDRE complex depends on the 
presence of VDR, we compared VDRE 
binding of nuclear proteins from ROS 
17/2.8 cells with those from ROS 24/1 
cells, which do not contain functional 
VDR. Nuclear proteins isolated from 
VD3 treated ROS 24/1 cells do not 
mediate inducible complexes with the 
OC- and OP-VDREs (Fig. 2). This result 
indicates that presence of the VDR is 
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OC VDRE OP VDRE 
~ ~ 
'" 
~ 
" 
'" 
.,; 
u: 0 0 ~ u: 0 0 ~ ~ 
'" '" '" '" 
m ~ 
'" '" '" '" 
~ 
" 
~ 
• " 
x x x 
" 
• " 
x x x 
"' 
m >
'" '" '" "' 
m > 
'" '" '" 
Figure 3 
DC· and op· VDRE complexes display selective 
immunoreactivity for several VDR antibodies 
(IVG8Cll, 9a7r and VD2F12) and RXR antibodies 
recognizing all three RXR subtypes (RXRa, (1, 'Y) or 
directed against specific RXR subtypes (RXRa or 
RXR(1). Gel shift assays were performed by pre· 
incubating nuclear proteins from VD3 treated ROS 
17/2,8 cells ,vith tbe antibodies indicated above the 
lanes, The VD3-responsive protein/DNA complexes 
for tbe DC- and DP-VDREs (V) and tbe 
corresponding supershift complexes (S) arc indicatcd 
by arrowheads, Differential immunoreactivity is 
evidenced by complete inhibition of the OC-VDRE 
complex, but not the op· VDRE complex, with the 
IVG8Cll antibody. The other two VDR antibodies 
display more subtle differences in immunoreactivity 
(Le., complete versus partial inhibition of binding), 
whereas the RXR antibodies react with both the DC 
and OP-VDRE complexes in an indistinguishable 
manner (i,e., show quantitative similarities in the 
formation of supershift complexes). 
required for the induction of VD3 
responsive protein/DNA complexes at 
the OP-VDRE (Fig. 2). Therefore, to 
establish directly presence of the VDR 
in the OP-VDRE complex, we analyzed 
VDRE complexes detected with ROS 
17/2.8 nuclear proteins, with additional 
VDR antibodies. Figure 3 shows that 
both OC- and OP-VDRE complexes are 
immunoreactive with the VD2F12 and 
9a77 antibodies. However, only the DC 
VDRE complex, but not the OP VDRE 
complex, reacts with the IVG8Cll 
antibody_ We conclude that the OC- and 
OP-VDREs both interact with 
VDR/RXR heterodimers, but the 
observed differences in immunoreactivi ty 
with this panel of VDR antibodies 
unequivocally establish that these 
dimeric proteins are immunologically 
distinct. 
To address if the order of 
addition of the reagents influences 
recognition of VDR/RXR heterodimers 
interacting with the OC- and OP-
VDREs, we performed pre- and post-
incubation experiments with the VDR 
antibody IVG8Cll added either prior to 
or after addition of radio-labelled 
VOREs. The results obtained in all 
instances were indistinguishable: we 
observed inhibition of VDR/RXR 
binding to the OC-VDRE and absence 
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of inhibition for the OP·VDRE (data not shown; see Figs. 1 and 3). Consistent with the 
observed inhibition of the VDR/RXR complex interacting with the OC· VDRE, the VDR 
antibody IVG8Cll recognizes an epitope near the DNA binding domain of the VDR. 
As inhibition of the VDR/RXR complex at the OC· VDRE also occurs after addition of 
DNA, it appears that the VDR epitope recognized by IVG8Cll is not masked by the 
mere presence of DNA. We also note that the IVG8CII antibody recognizes the VDR 
independently of DNA in western blot and immunoprecipitation experiments (41,43). 
Thus, accessibility of the IVG8Cll antibody for the VDR epitope does not require 
contact between the VDR and the OC· VDRE. The striking observation that the VDR 
antibody IVG8Cll does not inhibit binding of VDR/RXR heterodimers to the OP· 
VDRE, appears to be related to specific DNA sequences in the OP·VDRE. The loss of 
epitope accessibility for the IVG8Cll apparently is mediated by the molecular 
restmcturing of the VDR protein upon binding to the OP· VDRE. 
We addressed the possibility that differential immunoreactivity of VDR/RXR 
heterodimers to the OC· and OP· VDREs is related to the presence of distinct members 
of the RXR family. Heterodimerization of different RXR members with the VDR could 
influence epitope accessibility of the VDR by steric hindrance or by inducing 
conformational modifications of the VDR. To address these possibilities we used 
monoclonal antibodies specific for RXR" and RXRB in gel shift immuno·assays, as ROS 
17/2.8 cells express mRNAs for RXR" and RXRIl but not RXR'Y (39). The results show 
(Fig. 3) that only a monoclonal antibody against RXR", but not RXRIl, quantitatively 
reacts with the Vitamin D inducible complexes of both the OC· and op· VDREs. 
llJerefore, VDR/RXR" heterodimers are the predominant VDRE binding proteins for 
both the OC and OP genes in ROS 17/2.8 cells. This implies that differential 
immunoreactivity of the OC and OP VDRE complexes involves the same pair of 
hormone receptor proteins. 
To verify these conclusions, we analyzed VDRE binding and immunoreactivity of 
VDR and RXR<x proteins that were synthesized ill vitro by coupled transcription/ 
translation using reticulocyte lysates (Fig. 4). The data indicate that VDR and RXR<x 
together mediate complex formation at both the OC· and OP·VDREs. Also, when gel 
shift binding reactions and electrophoresis are performed in parallel, these OC· and OP· 
VDRE complexes formed from ill vitro synthesized components have very similar 
electrophoretic mobilities when compared to VDRE complexes formed with native 
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Differences in immunoreactivity are observed for 
in vitro transcribed/translated VOR and RXRa 
proteins which interact with the DC- and op-
VDREs. Gel shift incubations were performed 
with ill ~'itro transcribed/translated VDR and 
RXRa in the presence of VD3 (10-8 M) using 
either OC- (left portion) or op-VDRE (right 
portion) as probe. rmmunoreactivity of the 
VDRjRXRa complexes (V) with the VDR 
antibody 9a7"(, the RXR antibody RXRa (S) and 
the VDR antibody IVG8Cll was investigated, 
VDR/RXROIheterodimersfrom Vitamin 
D treated ROS 17/2.8 cells (data not 
shown). 
COlltributioll 0/ specific Illlcleotides to the 
cOIl/onnational propelties 0/ VDR/RXROI 
heterodimers 
The OC VDRE is composed of 
an imperfect direct repeat of two distinct 
steroid hormone half elements with a 
three nucleotide spacing (5'-GGGTGA 
fmmullologically distillct VDR/RXROI complexes 
NNN AGGACA), whereas the OP 
VDRE represents a perfect direct repeat 
of a different sequence motif 
(5'GGTICA NNN GGTICA). We 
tested the hypothesis that variations in 
the sequences of the steroid half-sites in 
the OC- and OP-VDREs directly 
influence inllllunoreactivity of the 
corresponding VD3 inducible complexes. 
To evaluate the contribution of 
the OC and OP VDRE steroid half 
elements to recognition by the cognate 
proteins, we introduced a series of 
substitution mutations in the half-sites of 
the OC VDRE. The first mutant OP lOP 
contains several substitutions recreating 
the OP steroid half elements within the 
context of the OC VDRE (Table 2), 
whereas two other mutants contain 
unique mutations in either the distal 
(mutant OP /OC) or proximal (mutant 
OC/OP) steroid half element of the OC-
VDRE. Figure 5 shows that each of 
these mutants compete with equal 
efficiency for the protein/DNA 
complexes interacting with the OC- and 
OP-VDREs. Thus, the mutations 
introduced into the OC-VDRE do not 
have significant rate-limiting effects on 
the interactions of VDRE binding 
proteins. 
ImmunoreactivityofVDR/RXROI 
heterodimers binding to this panel of 
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Figure 5 
Competition analyses of nlutant oligonucleotides containing base pair substitutions in VDRE sequences, 
Competition assays were performed with a ftxed amount of nuclear protein from VD3 treated ROS 17/2,8 
cells and the radio· labelled DC· (panel A) or op-VDRE (panel B) oligonucleotides (0.5 11M). The titration 
experiments for each wildtype or mutant competitor oligonucleotide (as indicated above the lanes) was 
carried out by adding the unlabelled DNA fragments at the following concentrations: 0, 12, 25, 50 nM, 
respectively (from left to right), The oligonucleotides designated mull OP JOP, mut 2 OCjOP, mut 3 
OP JDC represent hybrid YDREs in which one or both of the hexamerie steroid half elements of the DC-
VDRE is replaced by the analogous sequences of the DP-VDRE, whereas pm 3T represent a point-mutant 
with a G to T substution at position 3 within the the proximal DC-YDRE hexamcr (see Table 2 for further 
details). 
substitution-mutants, using the VDR antibody IVOSCII and RXR antibody RXRa,/l,y, 
is presented in Fig 6. The OP lOP mutant shows that replacement of the OC VDRE half 
sites by the steroid hormone half elements of the OP VDRE results in loss of 
immunoreactivity with the VDR antibody (Fig. 6). This finding establishes that the 
sequences determining differences in antibody reactivity between the OC and OP 
VDREs reside exclusively in the steroid hormone half sites, rather than in the flanking 
sequences (5', 3' or internal to the half-sites) of the OC and OP VDREs. 
Strikingly, mutation of the proximal half site in the OC VDRE (mutant OC/OP) 
results in abrogation of VDR antibody (IVOSCII) recognition (Fig. 6). In contrast, 
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Oligonucleotidescontainingsubstitution-mutaliollS 
within the DC-VDRE (see Table 2) were 
analyzed for immunoreactivity with the IV8Cll 
VDR antibody, Complexes were formed with 
nuclear extracts prepared from VD3 treated (10.8 
M, 24 he) ROS 17/2.8 cells and analyzed \vilh the 
VOR antibody. Each oligonucleotide forms a 
VD3 inducible complex (V) and each of these 
complexes was tested in the absence (lane C) or 
presence of the IVG8Cll VOR antibody (0'-
VnR) and the RXRa,/1{y antibody (a-RXR). 
mutation of the distal steroid half 
element (mutant OP JOC) in the OC 
VDRE does not alter VDR antibody 
reactivity. We conclude that integrity of 
the proximal half site of the OC VDRE 
is required for VDR antibody 
recognition. Furthermore, our results 
immunologically distinct VDR/RXROI complexes 
OC pm lG3T pm lG4T pm 3TH OP/O? 
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Figure 7 
Point-mutational analysis of the OC-YORE 
sequences shows that the central dinucleotide of 
the proximal hexameric steroid half clement (5'-
AGGACA, respectively, positions 1 to 6) mediates 
immunoreactivity. Several double-mutants were 
introduced in the proximal half site of the DC-
VORE (see Table 2) and the resulting mutant 
VORE probes were incubated with nuclear 
extracts prepared from VD3-trealed RDS 17/2.8 
cells. The VD3-responsive complexes (V) for each 
probe arc indicated by the arrowhead. The lanes 
designated "e' represent binding reactions in the 
absence of antibodies; the remaining lanes contain 
VDR and RXR antibodies as shown above the 
corresponding lanes_ Similar to the wild type DC-
VDRE probe, the double-mutant probes pm 
IG3T and pm IG4T mediate complexes that 
iml11unorcact \vith the VDR antibody, but the 
double-mutant pm 3T4T does not immunoreact 
with the VDR antibody. All protein/DNA 
complexes show immunoreactivity ("supershifl") 
(S) with the RXR antibody. 
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provide immunological evidence that the proximal half-site in the OC-VDRE interacts 
with the VDR. 
The proximal half-sites of the OC- and OP-VDREs differ by exactly three 
nucleotides which are located at positions 1,3 and 4 of the hexamer element (OC: 5'-
AGGACA and OP: 5'-QGTTCA; nucleotide differences underlined). We designed a 
systematic series of double and single point-mutations of the proximal OC-VDRE 
hexamer. Analysis of this panel of hexamer mutants as probes in gel shift immuno-assays 
shows (Fig. 7) that double-mutations at positions I and 3 (pm IG3T), as well as positions 
1 and 4 (pm IG4T) display the same VDR immunoreactivity as the native OC-VDRE. 
oc 
a: a: 
o X 
> a: 
o b b 
Figure 8 
pm 3T 
a: a: 
o X 
> 0: 
o b b 
pm 4T 
a: !l: 
OX 
> 0: 
o b b 
1\\'0 mutants with a single point-mutation in the 
proximal half site of the DC-VDRE (Table 2) 
were incubated with Iluclear extracts prepared 
from VD3 treated ROS 17/2.8 cells and analYLcd 
for immunoreactivity with both the VDR and 
RXR antibodies. Each oligonucleotide forms a 
VD3.responsive complex (V)(lane C), and 
immunoreactivity of each complex was analyzed 
using the antibodies indicated above the lanes, In 
contrast to the double-mutant probe pm 3T4T 
(Fig. 7), the immunoreactivity of the V complex 
observed with the single-mutant probes pm 3T 
and pm 4T (middle two pancl<;) is more 
pronounced and resembles that of the wildtype 
DC VDRE probe (left panel). 
156 
However, mutation of positions 3 and 4 
(pm 3T4T) abrogates recognition of the 
IVG8Cll antibody for the VDR/RXR" 
complex. Thus, exchanging the internal 
purine-dinucleotide to a pyrimidine-
dinucleotide at positions 3 and 4 
prevents antibody accessibility to the 
epitope within the DNA binding domaln 
of the VDR. 
To dissect the nucleotide-
requirements of VDR antibody 
recognition further, we also performed 
gel shift immuno-assays with probes 
containing single point-mutations at 
either position 3 or 4 (pm 3T and pm 
4T; Fig. 8). Notably, the third position 
within the VDRE half sites is thought to 
represent a key determinant for selective 
interactions with distinct VDRE binding 
proteins (14,15). However, single 
substitution of basepairs with the purine 
dinucleotide of the proximal VDRE 
hexamer at either position 3 (pm 3T) or 
4 (pm 4T) does not cause this 
Immlll1ologically distinct VDR/RXROi complexes 
abrogation ofVDR immunoreactivity. Thus, although both nucleotides at positions 3 and 
4 contribute together to immunoreactivity, neither alone is sufficient to mediate this 
effect. 
DISCUSSION 
In this study we characterized the Vitamin D inducible trans·activating complexes 
interacting with the OC- or OP-VDREs using gel shift immuno·assays with nuclear 
proteins from osseous cells. VD3 inducibility of VDRE complexes can be influenced by 
steroid and/or polypeptide hormones, as well as agents impinging on phosphorylation-
dependent cell signalling mechanisms. In a series of related studies using osseous cells, 
we have analyzed the interactions of the VDR containing complexes with both the OC-
and OP-VDREs using nuclear proteins from VD3 treated cells co-incubated with 
modulators of VDR function (43·45). For example, TGF/ll and TGF/l2, each reduce the 
VD3 induced occupancy of both the OC and OP-VDREs (44). Similarly, co-incubation 
with okadaic acid, but not staurosporinc, dexamethasone or 1{3,25-dihydroxyvitamin D3, 
resuits in a coordinate reduction of complex formation at both VDREs (45; unpublished 
observations). Thus, it appears that agents influencing VD3 mediated cell signalling 
pathways have parallel effects on the regulation of VD3 inducible complexes interacting 
with the OC-and op· VDREs. Results obtained with a panel of monoclonal VDR and 
RXR antibodies establish that endogenous complexes interacting with the OC- and OP-
VDREs quantitatively represent VDR/RXROi heterodimers. These findings provide a key 
addition to previous studies in which functional significance of homo- or 
heterodimerization of protein/DNA complexes at VDREs was pursued using different 
experimental strategies and biological systems (29·40). There appear to be discrepancies 
in the literature that relate to the potential for interactions of VDR homo- and 
heterodimers with the OC and OP VDREs. However, these apparent discrepancies may 
be attributable at least in part to the observation that VDR homo-dimers interact with 
lower affinity to VDREs than VDR/RXR heterodimers (14), as well as differences in 
experimental approaches. 
Using endogenous nuclear proteins from ROS cells in which the VDR and RXR 
proteins are present at normal and physiologically regulated levels, our studies suggest 
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that the VDR containing complexes at both the OC and OP-VDREs have 
indistinguishable VDRE recognition specificity, are regulated in parallel by VD3 and 
VD3 antagonists, as well as are quantitatively composed of VDR/RXRa heterodimers. 
However, we find that VDR/RXRa heterodimers interacting with the OP- and OC-
VDRE complexes are immunologically distinct, when analyzed with the monoclonal 
VDR antibody IVG8Cl1. The IVG8Cll antibody reacts with and inhibits formation of 
the VDR/RXRa complex at the OC-VDRE, but does not inhibit binding of 
VDR/RXRa heterodimers to the OP-VDRE. 
By analyzing VDR immunoreactivity using a systematic series of point-mutations 
in the OC-VDRE, we show that the proximal half-site of OC-VDRE confers positive 
immunoreactivity with the VDR antibody. TIlUs, using the native OC-VDRE sequences 
and endogenously produced VDR/RXRa, this result provides a novel immunological line 
of evidence for the concept that the proximal VDRE half-site of the OC-VDRE interacts 
directly with the VDR, whereas the distal half-site interacts with RXRa (17,46-48). 
Furthermore, our results show that precisely two nucleotides at positions 3 and 4 of the 
proximal OC hexamer-element (OC: 5'-AGGACA versus OP: 5'-GGTTCA) detennine 
the immunoreactivity of the VDR. Iuterestingly, the nucleotide at position 3 is thought 
to confer specificity for distinct VDR homo- and heterodimers (14,15). Here, we extend 
this observation by noting that positions 3 and 4 together influence the conformational 
properties of the same receptor heterodimer pair at two distinct VDREs, and distinguish 
between two apparent classes of VDR/RXR" heterodimers. 
To understand the differences in dinucleotide-dependent immunoreactivity of the 
VDR/RXR" complexes, it is necessary to compare the location of the epitopes for VDR 
antibodies with known structural determinants in the DNA binding domains of steroid 
hormone receptors that specify recognition for the hexamer half-sites. Crystallographic 
data have revealed that the DNA binding domain of steroid hormone receptors 
represents a globular fold which contains two distinct Zn-nucleated substructures ("Zn-
c1usters")(4,49). The Zn-c1usters are capable of adopting different conformations 
depending on the target DNA sequence. Read-out of DNA motifs occurs by the precise 
alignment of an amphiphatic a-helix with the major groove of DNA. Consistent with the 
importance of Zn cluster regions in VDR binding to DNA, this domain is extremely well 
conserved among mammalian species. 
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Studies by Freedman et al. (14) have provided compelling data for the concept 
that glu 42 of the VDR, which is located in the first Zn cluster (amino acids 24 to 44) 
of the VDR, contacts the nucleotide at position 3 in the VDRE hexamer. Our results 
show that position 3 is one of two basepairs required for differences in immunoreactivity 
of the OC- and OP-VDR/RXR" using the VDR antibody IVG8Cl1. Interestingly, the 
IVG8Cll antibody recognizes an epitope located between amino acids 57 and 164, which 
comprises the second Zn-cluster (amino acids 60 to 80) and portions of the flexible 
hinge-region towards the C-terminal ligand binding domain. In contrast, the VDR 
antibody 9a7"( which recognizes an epitope immediately adjacent to the second Zn 
cluster (between amino acids 89 and 105), reacts with VDR/RXROi heterodimers 
irrespective of the VDRE hexamer sequence. Taken together, these observations suggest 
that recognition of the central dinucleotide of the VDRE hexamer by the first Zn cluster 
may dictate the conformation of the second Zn cluster and/or the hinge-region. This 
central dinucleotide may influence the conformation of VDR/RXROi heterodimers 
because basepair differences in the VDRE hexamer translate into different sterie and/or 
biochemical constraints on the molecular interactions between the recognition ex-helix 
of the VDR and the VDRE hexamer. We also note that replacement of the OC hexamer 
dinucleotide (5'-GA) by the OP hexamer dinucleotide (5'-TT) may possibly affect the 
potential for ONA bending and/or kinking, or perhaps switch the orientation of the 
proximal hexamer relative to the distal hexamer of the YORE. 
Conformational modifications that are ligand dependent have been obselved for 
many receptors, including the VOR (1-4). The results presented here provide the first 
evidence for conformational changes in VOR/RXROi complexes upon binding to distinct 
VOREs of the OC and OP genes. As the promoters of the OC and OP genes each 
interact with different trans-activating and repressor proteins, the conformational 
differences between OC- and OP-VOR/RXR" heterodimers may expose different 
protein/protein interaction surfaces. The trans-activating function of the VDR in the 
osteocalcin promoter involves potential contributions of TFIIB (50), MSX-related 
homeodomain proteins (51-54) and AP-l activity (56). These transcription factors are 
capable of interacting with steroid hormone receptors (3) and may directly influence 
VOR/RXR" interactions with and/or trans-activation events at the OC-VORE. Taken 
together, the conformationally distinct VOR/RXROi complexes binding to the OC- and 
OP-VDREs may reflect functional differences in V03 mediated gene regulatory 
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mechanisms that control OC and OP gene transcription in response to physiological 
signals relevant to skeletal homeostasis. 
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GENERAL DISCUSSION 
Chapter 8 
The aim of the study described in this thesis was to assess the significance of 
the locally produced growth factors transforming growth factor B (TGFB), bone 
morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) for the 
action of the systemic factor 1,25-dihydroxyvitamin DJ (1,25-(OHhD3) on bone. We 
show that locally produced factors affect several aspects of 1,25-(OHhD3-regnlated 
bone metabolism. First, we studied the effect of TGFJ3 on vitamin D receptor (VDR) 
level and the relevance of modulation of VDR level for the action of 1,25-(OHhD3 
on osteocalcin and osteopontin expression and on 24-hydroxylase activity in the bone 
forming cell, the osteoblast. Secondly, we studied the effects of locally produced 
factors on stimulation of bone resorption by systemic factors and studied their 
presence and distribution in bone matrix. Finally, we studied the osteocalcin and 
osteopontin promoter regions more closely by investigating the significance of 
sequence variation in the vitamin D response elements (VDREs) for the composition 
of hormone receptor complexes recognizing the VDREs. 
Regulatioll of vitamin D receptor level alld 1,25-(OH);/J3 respollses hy TGFfJ 
Transforming growth factor B (TGFB), which is the most extensively 
investigated factor in this study induced an increase in vitamin D receptor (VDR) 
level in osteoblast-like cells of various origin. Based on this resuit and the general 
concept concerning the relationship between receptor level and hormone action we 
hypothesized that TGFJ3 increases the biological responses to 1,25-(OHhD3 in these 
cells. However, the 1,25-(OHhDJ-stimulated expression of two bone matrix proteins, 
osteocalcin and osteopontin, appeared to be inhibited after TGFJ3 preincubation-
induced up-regnlation of the VDR. These observations clearly demonstrated a 
dissociation between the effect of TGFJ3 on VDR level and its effect on two 
biological responses to 1,25-(OH}zDJ in osteoblast-like cells. Similarly, for 
glucocorticoids, a dissociation has been shown between regulation of receptor level 
and biological response (1). In contrast, previously a relationship between VDR level 
and several biological responses, including osteocalcin synthesis, inhibition of collagen 
synthesis and, especially, 24-hydroxylase activity, has been shown (2-5). To investigate 
the significance of regulation of VDR level more thoroughly, the effect of TGFJ3-
induced increase in VDR level on the induction of 24-hydroxylase activity by 1,25-
(OHhDJ was examined. A direct relationship appeared to exist between regulation of 
VDR level and induction of 24-hydroxylase activity by 1,25-(OH}zD3' not only after 
regnlation of VDR level by TGFJ3, but also after modulation of VDR level by other 
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means, including medium change, PTH and EGF incubation (Chapter 4). In contrast 
to induction of 24-hydroxylase activity, for other biological responses, VDR level 
modulation may not be the primary mechanism through which these effects (e.g. 
osteocalcin and osteopontin expression) are regulated. Additional effects may 
compensate the effect of changes in VDR level or even overrule this effect. 
Therefore, the inhibitory effect of TGFlJ on the l,25-(OHlzD3 enhancement of 
osteocalcin and osteopontin was examined in more detail. In Figure 1 we show that 
TGFlJ causes its inhibitory effect on osteocalcin and osteopontin expression (Chapters 
2 and 3) by the reduction of binding of nuclear protein complexes, containing VDR 
and RXR" (Chapter 7), to the vitamin D response elements (VDREs) in the 
osteocalcin and osteopontin promoter regions (Chapter 3). Because both the 
osteocalcin and osteopontin promoter regions contain binding sites for activator 
protein-l (AP-l), which is a dimer of Fos and Jun, and both TGFlJ and 1,25-(OHlzD3 
have been shown to modulate the expression of the fos and jun family of proto-
oncogenes in osteoblasts (6-9), we also examined the effects of 
RXR VDR 
• Y RXR-VDR~ 
~ 
VDREMd 
PROMOTER 
Figure 1 
OSTEOCALCIN 
OSTEOPONTIN 
TGFB 
/ 
Model for the inhibitory effect of TGFll on the 1,25-(OHhD3-induced binding of VDR/RXRa 
complexes to the vitamin D response clements of the osteocalcin and osteoponlin genes, which leads to a 
reduction of 1,25-(OHhD3-stimulated osteocalcin and osteopontin expression. 
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these agents on binding of nuclear protein complexes to an AP-l consensus 
oligonucleotide. Our results (Chapter 3) indicate that increased levels of AP-l binding 
may contribute to TGFll inhibition of osteocalcin gene transcription. 
Data obtained by Pirskanen et al. (10) argue against a similar mechanism in 
the human MG 63 cells. They did not observe a direct inhibitory effect of TGFll on 
the 1,25-(OHhD3-induced binding of nuclear protein complexes to the YORE of the 
human osteocalcin gene. Jiiiiskeliiinen et al. (11) have recently shown that the MG 63 
endogenous nuclear protein complex recognizing the human osteocalcin YORE 
contains the YOR, but not RXRtx. At this moment, the exact composition of the 1,25-
(OHhD3-induced complex recognizing the human osteocalcin YORE remains 
unknown. The difference in the composition of the rat and human nuclear protein 
complexes binding their cognate YOREs may account for the differences in the 
mechanisms by which TGFB exerts its inhibitory effects on 1,25-(OHlz03-stimulated 
osteocalcin expression. We (Chapter 7) and others (12-15) have provided evidence 
that the YDR binds the proximal half site and RXR the distal half site of the YORE. 
Therefore, and because Jiiaskeliiinen et al. (11) indicated that the complex 
recognizing the human osteocalcin YORE differs in the accessory factor component 
(not RXRtx), it is remarkable that the rat osteocalcin YORE and human osteocalcin 
YORE (Table 1) are identical in the distal half site, and differ at two nucleotides (the 
1st and 4th) in the proximal half site. From the present study it remains unclear, 
whether there indeed exist species differences in the nuclear protein complexes 
binding the human and the rat osteocalcin YORE and in the mechanisms of 
inhibition of 1,25-(OHlzD3-stimulated osteocalcin production by TGFB in human and 
rat osteoblast-like cells. However, the present study demonstrated a discrepancy 
between TGFI3-induced YOR up-regulation and inhibition of 1,25-(OHlzD3-induced 
Table I 
Species differences in the VDREs of the osteocalcin gene promoter. The nucleotides within the half sites 
that differ from the rat OC VDRE are underlined. 
osteocalcin VDREs 
rat 000 TO A nnnA 0 0 A CA 
human OOOTOAnnnQOOQCA 
mouse G G G CAA nnnAG G A CA 
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osteocalcin expression irrespective of species. 
Besides this direct effect of TGFB on VDR/RXR interaction with the VDRE 
in the promoter region of the osteocalcin and osteopontin genes, the observed 
increase in 1,25-(OHlzD3 -induced 24-hydroxylase activity as a result of up-regulation 
of VDR by TGFB may play an indirect inhibitory role. 24-Hydroxylation is the initial 
step in a more extensive C24-oxidation pathway that leads to the degradation and 
elimination of 1,25-(OHlzD3. The relationship between VDR level and this response 
may reflect a negative regulatory feedback loop at target tissue/cell level in the action 
of 1,25-(OH)2D3' As is shown in Figure 2, TGFB may both directly (Chapter 3) and 
indirectly (hypothesis) inhibit the stimulation of expression of the osteocalcin and 
osteopontin genes by 1,25-(OH)zD3' Directly (arrow 1), TGFB inhibits the 1,25-
(OHlzD3-stimulated osteocalcill and osteopontin expression by reducing the binding 
of VDR/RXR" heterodimeric complexes to the VDREs in the promoter regions of 
0 2 
ITGFI3I VDR 
0
3 24-hydroxylase activity 
510 1 
1,25-(OH),D3 0 degradation 
40 61° osteocalcin 
1,25-(OH),D3 
0 osteopontin 
Figure 2 
Model for a direct and indirect mechanism of TGFB inhibition of 1,25-(OHhDrstimulated osteocalcin 
and osteopontin expression. 1) Directly, TGFil has been shown to reduce the 1,25-(OHhD3-induced 
binding of nuclear protein complcxes to the ostcocalcin and osteopontin vitamin D responsive elements. 
Indirectly, 2) TGFB causes an up-regulation of VDR level, which leads to 3 and 4) enhancemcnt' of 1,25-
(OHhD3-stimulated 24-hydroxylase activity. 5) Enhanced 24-hydroxylase activity leads to the degradation 
of 1,25-(OHhD3' 6) A reduced antOunt of 1,25-(OHhD3 causes a reduced response of osteoealcin and 
osteopontin to 1,25-(OHhD3' 
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osteocalcin and osteopontin (Chapter 3). Indirectly, the increase in YDR level 
induced by TOFIl (arrow 2) results in an enbanced induction of the 24-hydroxylase 
activity by 1,2S-(OHlzDJ (arrows 3 and 4). Subsequently, the amount of biologically 
active 1,2S-(OH}zDJ is diminished (arrow 5), thereby reducing the 1,2S-(OH}zDJ 
stimulation of osteocalcin and osteopontin expression (arrow 6). This indirect effect 
may only playa prominent role in MO 63 cells. In this cell line, we have shown the 
effects of TOFIl both on 1,2S-(OH}zDJ-stimulated osteocalcin and l,2S-(OHlzDJ 
induction of 24-hydroxylase activity. In ROS 17/2.8 cells we showed the effects of 
TOFIl on l,2S-(OH}zDJ enhancement of osteocalcin and osteopontin expression, but 
not its effects on the induction of 24-hydroxylase activity, because l,2S-(OHlzDJ-
induced 24-hydroxylase activity appeared hardly detectable in ROS 17/2.8 cells (data 
not shown). This indicates that regulation of 24-hydroxylase activity does not playa 
major role in the inllibitory effect of TOFll on 1,2S-(OHlzDJ-stimulated osteocalcin 
and osteopontin expression in ROS 17/2.8 cells. 
Growth factor specificity ill fhe regulation of l,25-(OH)fJ3 action on osteocalcill and 
osteopontin expression 
The other two growth factors studied for their effect on 1,2S-(OHlzDJ action 
were IOF-I and BMP-2. The results obtained with these growth factors clearly 
indicate that the responses are growth factor specific. The inhibitory effect observed 
with TOFll on 1,2S-(OHlzDJ-enbancement of osteocalcin and osteopontin expression 
appeared to be specific for TOFll. In contrast to TOFll l and TOFll2, BMP-2 did not 
affect 1,2S-(OHlzDJ enbanced osteocalcin synthesis as well as osteocalcin mRNA 
expression, whereas it stimulated the 1,2S-(OH}zDJ enhancement of osteopontin 
mRNA expression (Chapter 5). IOF-I did not affect basal and l,2S-(OHlzDJ-
stimulated osteocalcin synthesis. The 1,2S-(OHlzDJ-induced increase in osteocalcin 
and osteopontin mRNA expression was not significantly affected by IOF-I (Chapter 
5). However, gel shift mobility assays revealed similarities between TOFIl and BMP-2 
in the regulation of 1,2S-(OHlzDJ inducible binding of nuclear protein complexes to 
the osteocalcin and osteopontin YDREs. Like TOFll, BMP-2 reduced the binding of 
YDR/RXRa complexes to these YDREs. IOF-I slightly reduced binding of 
YDR/RXRa complexes to the osteopontin YDRE, but did not affect binding to the 
osteocalcin YDRE. These observations demonstrate a dissociation between regulation 
of osteocalcin and osteopontin expression and regulation of the binding of 
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VDR/RXR" complexes to the osteocalcin and osteopontin VOREs by BMP-Z and 
IGF-I. This indicates that additional mechanisms, that compensate and overrule the 
effect of reduced binding of VDR/RXR" complexes to the VOREs, e.g. binding of 
nuclear proteins to other regulatory sites in the promoter region or effects mRNA on 
stabilization, playa role in the biological response to these factors. 
Regulation of bone resorption by locally produced growth factors 
In Chapter 6 the effect of TGFB on bone resorption was studied. Osteocalcin 
and osteopontin have been suggested to playa role in bone resorption, osteocalcin by 
its involvement in the recruitment and/or differentiation of osteoclasts (16,17) and 
osteopontin by the attachment of os teo clasts to bone (18,19). In view of the observed 
effects of TGFR on 1,25-(OHh03-induced osteocalcin and osteopontin expression in 
rat and human osteoblasts (Chapters 2 and 3) we were interested in the effect of 
TGFB on 1,Z5-(OHh03 enhancement of bone resorption. The effects of TGFB were 
examined in a fetal mouse bone resorption system. Similar to its effect on I,Z5-
(OHhD3-enhanced osteocalcin and osteopontin expression in MG 63 and ROS 17/Z.8 
cells, TGFB appeared to inhibit 1,Z5-(OHhD3 stimulation of bone resorption 
(Chapter 6), thereby supporting the hypothesis that osteocalcin and osteopontin playa 
role in bone resorption. However, in fetal mouse long bone cultures 1,Z5-(OHhD3 
itself appeared to reduce osteocalcin levels, this in contrast to observations in non-
fetal rat and human osteoblast-like cells. Also, in the non-fetal mouse osteoblast-like 
cell line MC3D, I,Z5-(OHhD3 reduced osteocalcin levels in medium and cell 
extracts (Chapter 6), indicating that the reduction we observed in osteocalcin levels in 
medium of fetal mouse long bones after incubation with 1,Z5-(OHhD3 is due to 
species difference. In relation with our data presented in Chapter 7, a possibility can 
be that these species differences are due to a dinucleotide difference in the distal half 
site the vitamin D response element in the promoter of rat/human and the mouse 
osteocalcin gene (Tahle 1). However, additional elements in the mouse osteocalcin 
promoter may play an important role in the inhibitory effect of 1,25-(OHhD3' 
Despite the difference in regulation of the osteocalcin gene between mouse 
and rat/human in vitro, Gundberg et al. (ZO) showed in in vivo experiments that 
osteocalcin level is increased in the serum of mice after 1,25-(OH}zD3 administration, 
thereby demonstrating a discrepancy between osteocalcin regulation in vitro and ill 
vivo. The fact that in vivo mouse osteocalcin levels are increased by I,ZS-(OHhD3' 
does not exclude the possibility that osteocalcin may indeed play a role in bone 
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resorption. In addition, data of Desbois et al. (21), who showed that osteocalcin 
deficiency in mice leads to increased bone formation, may also be suggestive for a 
role of this bone matrix protein in bone resorption in mice. Figure 3 represents a 
model for the role of TGFIl in bone remodelling in relation to its effects on bone 
formation, 1,25·(OH)zD3·stimulated bone resorption, osteocalcin and osteopontin 
expression. The primary effect of TGFIl is stimulation of bone formation, both by 
directly stimulating bone formation (22-25), but also by reducing bone resorption 
(Chapter 6). The proposed intermediary role of osteocalcin and osteopontin in the 
TGFIl-inhibition of 1,25-(OH)zD3-stimulated bone resorption is based on the 
postulated roles of these proteins in bone resorption (16-19), together with the TGFIl 
inhibition of 1,25-(OH)zD3-stimulated osteocalcin and osteopontin expression, and the 
data of Gundberg et ai, and Desbois et al mentioned above. This despite the fact that 
the data obtained with the ill vitro mouse bone resorption model do not directly 
provide evidence for a role of osteocalcin in bone resorption (Chapter 6). This, 
however, can be due to the fact that osteocalcin is involved in aspects of the bone 
resorption process (e.g. recruitment, differentiation of osteoclasts) which do not playa 
prominent role is this bone resorption model. As shown in Figure 3, during bone 
resorption bone matrix is degraded and latent TOFIl that is present in the bone 
matrix can be released and activated during bone resorption (26,27), which in turn 
leads to inhibition of 1,25-(OH)zD3-stimulated bone resorption and to stimulation of 
bone formation. This model provides a target tissue feedback mechanism by which via 
close interaction between a bone cell-derived and bone matrix-stored growth factor 
and a calciotropic hormone bone metabolism is controled. 
The other two growth factors studied were IOF-I and BMP-2. IOF-I had, 
similar to TOFB, an inhibitory effect on 1,25·(OH)zD3-stimulated bone resorption. In 
contrast, BMP-2 caused an enhancement of 1,25-(OH)zD3-stimulated bone resorption. 
The results obtained with these growth factors clearly indicate that the regulation of 
1,25-(OHlzD3 -enhanced bone resorption is growth factor specific (Chapter 5). These 
data are thereby in line with the data obtained with 1,25-(OH)zD3-induced 
osteocalcin and osteopontin expression, which also demonstrated growth factor 
specific interactions. In addition, data presented in Chapter 6 not only demonstrate 
that 1,25-(OH)zD3-stimulated bone resorption is regulated in a growth factor specific 
mallller, but also that the growth factor interactions are hormone specific. For 
example, TOFB and BMP-2 only affected 1,25-(OH)zD3-, but not PTH-stimulated 
bone resorption, whereas IGF-I affected both 1,25-(OH)zD3 and PTH-stimulated 
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Figure 3 
Model for the role of TGPfi in bone metabolism. TGF6 bas been reported to enhance bone formation 
by a stimulatory effect on the osteoblast. Furthermore, TGFfi inhibits l,25-(OHhD3,slimulated bone 
resorption. The bone matrix proteins osteocalcin and osteopontin have been proposed to playa role in 
bone resorption by affecting the recruitment, differentiation and attachment of osteoclasts (dotted lines). 
TGFB inhibits the l,25-(OH)2D3,slimulated expression of osteocalcin and osteopontin in the osteoblast 
and may thereby exert its effect on 1,25-(OHhD3-stimulated bone resorption. During bone resorption, 
bone matrix is degraded and factors stored in the bone matrix, including TGFB, are released. 
bone resorption. 
Taken together, these data implicate that growth factors are involved in the 
control of the extent of bone resorption in response to l,25-(OHhD3 and/or PTH. 
To gain insight into the localization of these growth factors in the bone matrix, the 
presence and distribution of TGFll type 2, TGFll type 3, BMp-2 and IGF-I in adult 
human bone were examined. Immunohistochemical analysis revealed that the 
presence of these growth factors is restricted to specific sites and that they are not 
diffusely distributed. Thus, the amount and type of growth factor present in the bone 
matrix may eventually cause less or more profound resorption in response to 1,25-
(OHhD3 and/or PTH at particular sites. For example, 1,25-(OHhD3-induced bone 
resorption at a TGFI3-positive site may be limited whereas at a TGFI3-negative site 
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resorption can go on. The proposed model requires that growth factors should be 
released from the bone matrix during resorption and must still be biologically active 
or in a configuration to be activated. This seems not unlikely because TGFJJ is stored 
in a latent form in the bone matrix (26,28) and IGF-I binds to IGF-BPs which are 
capable of binding to the extracellular matrix (29,30). These features can have 
protective effects for the growth factors which may result in the eventual release of 
active growth factors. This is supported by the in vitro observation that several factors 
that stimulate bone resorption at the same time enbance TGFJJ activity in the culture 
medium (26,27). 111is indeed suggests that TGFJJ, but possibly also the other growth 
factors, may serve as a local feedback regulatory mechanism for bone resorption. 
The significance of a dinucleotide difference between vitamin D response elements for the 
confonnation of nue/ear protein complexes binding to these elements 
In Chapter 7, we have shown that a dinucleotide difference in the proximal 
half site of the rat osteocalcin VDRE and mouse osteopontin VDRE results in a 
different immunoreactivity of the nuclear protein complexes binding to these VDREs, 
which is probably due to a difference in the conformation of the VDR. 
Conformational modifications that are ligand dependent have been observed for many 
receptors, including the VDR. The results presented here provide the first evidence 
for conformational changes in VDR/RXR" complexes upon binding to distinct 
VDREs of the osteocalcin and osteopontin genes. A, the promoters of the osteocalcin 
and osteopontin genes each interact with different trans-activating and repressor 
proteins, the conformational differences between osteocalcin- and osteopontin-
VDR/RXR" heterodimers may expose different protein/protein interaction surfaces. 
The trans-activating function of the VDR in the osteocalcin promoter involves 
potential contributions of transcription factor lIB (TFIlB), MSX-related 
homeodomain proteins and AP-l activity. These transcription factors are capable of 
interacting with steroid hormone receptors and may directly influence VDR/RXR" 
interactions with and/or trans-activation events at the osteocalcin VDRE. Taken 
together, the conformationally distinct VDR/RXR" complexes binding to the 
osteocalcin and osteopontin VDREs may reflect functional differences in 1,25-
(OHlzD3 mediated gene regulatory mechanisms. Thereby, this may have physiological 
implications for the differential regulation of these two genes in the control of 
skeletal homeostasis. 
In view of our data on 1,25-(OHhD3 regulation of osteocalcin in mice and rat 
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(Chapter 6), one has to consider that the observed conformation differences can be 
due to species differences. The VDREs that were compared were from rat 
(osteocalcin) and mouse (osteopontin) origin. Very recently, in the rat osteopontin 
promoter region two functional VDREs have been identified (31). Comparison of the 
transcriptionally most potent (8-fold induction) rat osteopontin VDRE, 
AGGTCAnnnGGTICA, and the mouse osteopontin VDRE, GGTICAnnnGGTICA, 
demonstrates that the proximal, VDR-binding, half-sites are identical. Therefore, it is 
unlikely that the observed conformational differences in the VDR/RXR complex are 
due to species differences but more likely are due to intrinsic differences in the 
osteocalcin and osteopontin VDREs. 
Conclusions 
Taken together, this study shows that the locally produced factors TGFI.l, BMP-
2 and IGF-I have important effects on the regulation of bone metabolism by the 
systemic factor 1,25-(OHhD3 and do not just serve as mediators through which 1,25-
(OH)2D3 exerts its action. This is demonstrated by the effects of TGFI.l, BMP-2 and 
IGF-I on 1,25-(OH}zD3-stimulated osteocalcin and osteopontin expression and bone 
resorption. More general, this may imply that hormone action depends on the locally 
produced factors present in target tissues. TIle modulation of hormone action by 
locally produced factors may occur at several levels in the target cell, e.g. from the 
regulation of hormone receptor level to the regulation of the binding of nuclear 
proteins to regulatory sites in the promoter region of genes. 
Suggestiolls for further research 
To gain more insight into the specific roles of locally produced factors in the 
modulation of vitamin D action and the mechanism of action of locally produced 
factors further research is necessary. A major concern in our study is the observation 
that species differences exist in the biological responses to locally produced factors 
and 1,25-(OH}zD3' Our studies revealed that in ill vitro experimeuts an opposite effect 
is observed in the regulation of osteocalcin syuthesis by 1,25-(OH)2D3 between 
rat/human and mouse. Therefore, it would be interesting to compare the 
compositions of nuclear protein complexes that bind the rat, human and mouse 
osteocalcin VDREs. Despite the similarity in the effects of TGFI.l and 1,25-(OH}zD3 
in rat osteoblast-like (ROS 17/2.8) and human osteoblast-like (MG 63) cells on 
osteocalcin synthesis, there are indications that the mechanisms whereby the 
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inhibitory effect of TGFG on 1,25-(OHhD3 enhancement of osteocalcin synthesis is 
exerted, differ (cf. page 168). Therefore it is important that the experiments on the 
effects of locally produced factors on 1,25·(OHhD3 are performed in a human model 
and that the mechanisms whereby local factors regulate 1,25-(OHhD3 action are 
studied in the human system. 
In this Chapter (cf. page 169) we proposed a model for the possible role for 
24-hydroxylase activity regulation in the inhibitory effect of TGFfl on 1,25-(OH)zD3-
stimulated osteocalcin and osteopontin expression. Further studies are needed to 
determine whether this mechanism indeed plays a role in the inhibitory action of 
TGFfl on 1,25-(OHhD3-stimulated osteocalcin and osteopontin expression. 
The most extensively studied factor in this thesis was TGFJ3. Additionally, also 
the effects of BMP-2 and IGF-I were studied on 1,25-(OHhD3-stimulated osteocalcin 
and osteopontin expression and bone resorption. These factors also appeared to affect 
these parameters of bone metabolism. However, only modest effects were observed in 
the regulation of osteocalcin and osteopontin expression by BMP-2 and IGF-I. To 
gain further insight in their effects on these genes prolonged incubations may be 
necessary to determine biologically relevant effects and the function of these factors 
in bone metabolism. 
Furthermore, the exact function of osteocalcin and osteopontin in the 
regulation of bone remodelling is still unknown. To gain more insight into their role 
in the regulation of the bone remodelling process, it would be interesting to study 
their function more thoroughly. 
Finally, eventually ill vivo studies will be necessary to reveal whether the 
effects we have observed in ill vitro studies play indeed an important role in the 
regulation of bone remodeling ill vivo. 
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SUMMARY 
The steroid hormone 1,25-dihydroxyvitamin D3 (1,2S-(OHlzD3) plays a 
principal role in calcium homeostasis and skeletal metabolism, and influences 
expression of genes related to establishment and maintenance of the bone cell 
phenotype. 1,2S(OHlzD3 exerts its primary effect by binding to its receptor, the 
vitamin D receptor (VDR), which belongs to the steroid/retinoid/thyroid hormone 
receptor superfamily and acts via binding to distinct vitamin D response elements 
(VDREs) in the promoter region of several genes. 
Besides systemic calciotrophic factors, like 1,25-(OHlzD3, a wide variety of 
locally produced factors has been shown to affect bone metabolism. Systemic factors 
have been demonstrated to modulate the production of local factors thereby 
regulating bone formation and resorption. However, the presence of locally produced 
factors may also have implications for the biological response to systemic factors. 
TIlerefore, it is conceivable that local factors may interfere in the action of 
calciotrophic hormones in bone. The factors transforming growth factor 3 (TGF3), 
bone morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) are 
produced by bone cells and are stored in the bone matrix. The aim of the study 
described in this thesis was to assess the significance of the locally produced growth 
factors TGFfi, BMP-2 and IGF-I for the action of the systemic factor 1,2S-(OHhD3 
on bone. 
First, the effect of TGFfi, which is the most extensively investigated factor in 
this study, on the VDR level in bone forming, osteoblast-like cells was determined. In 
osteoblasts of various origin TGF3 caused a comparable increase in VDR level 
(Chapter 2). To assess the significance of the TGF3-induced increase in VDR level 
for the action of 1,25-(OHlzD3 on osteocalcin and osteopontin expression in these 
cells, cells were preincubated with TGFfi (causing an increase in VDR level) and 
subsequently incubated with 1,25-(OHhD3' Osteocalcin and osteopontin are non-
collagenous bone matrix proteins secreted by osteoblasts and have been suggested to 
play a role in bone resorption, osteocaldn by its involvement in the recruitment 
and/or differentiation of the bone resorbing osteoclasts and osteopontin by the 
attachment of osteoclasts to bone. TGF3 preincubation potently inhibited subsequent 
1,25-(OHlzD3 stimulation of osteocalcin and osteopontin expression in osteoblast-like 
cells (Chapters 2 and 3). This observation demonstrates a dissociation between regu-
lation of VDR level and modulation of two 1,25-(OHlzD3 biological responses by 
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TGFIl in osteoblast-like cell lines. 
In Chapter 3, we investigated the mechanism by which TGFIl inhibits 1,25-
(OH}zD3 enhanced expression of the osteocalcin and osteopontin genes. ROS 17/2.8 
osteoblast-like cells, in which both genes are expressed, were transfected with reporter 
constructs driven by native (i.e. wild-type) rat osteocalcin and mouse osteopontin 
promoters. TGF{3 abrogated the 1,25(OHhD3 enhanced transcription of both the 
osteocalcin and osteopontin genes. TIle inhibitory TGF{3 response for each requires 
VDRE sequences, although there are additional contributions from proximal basal 
regulatory elements. TI1ese transcriptional effects were further investigated for 
contribution of the trails-activating factors, which interact with osteocalcin and 
osteopontin VDREs, involving the VDR and retinoic X receptor (RXR). Gel 
mobility shift assays showed that TGFIl significantly reduces induction of the hetero-
dimeric VDR/RXR complexes in 1,25(OHhD3 treated ROS 17/2.8 cells, which was 
not accounted for by changes in VDR protein levels. We also showed that activator 
protein-I activity, which is up-regulated by TGF{3, may potentially contribute to 
inhibitory effects of TGF{3 on basal osteocalcin transcription. 
A response that has formerly been shown to be coupled to VDR level is 24-
hydroxylase activity. This enzyme initiates the C24-oxidation pathway for side-chain 
oxidation, followed by deavage and ultimate metabolic dearance of 1,25-(OHhD3 
and its precursor 25-(OH)D3. To investigate the significance of regulation of VDR 
level more thoroughly, in Chapter 4 the effect of TGFIl-induced increase in VDR 
level on the induction of 24-hydroxylase activity by 1,25-(OH}zD3 was examined. We 
showed that after preincubation with TGFIl, which causes an increase in VDR level, 
the 1,25-(OHhD3 induction of 24-hydroxylase activity is further stimulated by TGFIl 
in two osteoblast-like cell lines. Using several other means to regulate VDR level, we 
provided evidence that a tight coupling exists between VDR level and induction of 
the C24-oxidation pathway by 1,25-(OH}zD3. As C24-oxidation is involved in the cata-
bolic pathway of 1,25-(OHhD3' the coupling of VDR level to the degradation of 1,25-
(OH}zD3 may provide an important regulatory feedback mechanism in the action of 
1,25-(OH}zD3 at target tissue/cell level. 
In Chapter 5, the effects of two other locally produced growth factors, bone 
morphogenetic protein-2 (BMP-2) and insulin-like growth factor-I (IGF-I) on the 
action of 1,25-(OH}zD3 on osteocalcin and osteopontin expression were compared 
with the effects of TGFIl. Differential effects of these three growth factors were found 
on the 1,25-(OH}zD3-stimulated osteocalcin and osteopontin expression and on the 
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binding of nuclear protein complexes to the osteocalcin and osteopontin VOREs. 
Thus, the results obtained with these growth factors clearly indicate that the interacti-
on with 1,25-(OHhD3 is growth factor specific. 
In Chapter 6, we investigated the effects of TGFB, BMP-2 and IGF-I on the 
bone resorptive action of the systemic factors 1,25-(OHhD3 and parathyroid hormone 
(PTH). Our results show that TGFB inhibits 1,25-(OHhD3-enbanced bone resorption, 
but not PTH-enhanced bone resorption, whereas IGF-I inhibits both PTH- and 1,25-
(OHhD3-enhanced bone resorption. BMP-2 had, depending on its concentration, a 
stimulatory effect on 1,25-(OHhD3-enhanced bone resorption (10-100 ng/ml), or had 
at 1000 ng/ml a strong stimulatory effect on basal bone resorption and no further 
effect on 1,25-(OHhD3 and PTH action. These data confirm the growth factor 
specificity of the effects of TGFI3, BMP-2 and IGF-I on 1,25-(OHhD3 action 
described in the previous Chapter. Furthemore, these data show that the growth 
factor effects are also hormone specific. In addition, the effects of local and systemic 
factors on osteocalcin and collagenase were studied as possible mediators involved in 
the regulation of bone resorption. Remarkably, 1,25-(OHh03 had, in contrast to its 
stimulatory effect on bone resorption, an inbibitory effect on the osteocalcin protein 
levels in fetal mouse long bones. In addition, this inbibitory effect of 1,25-(OHhD3 
was also observed in the mouse osteoblast-like cell line MC3T3. These observations 
point to species specific regulation of osteocalcin by 1,25-(OHh03' 1,25-(OHhD3 did 
not affect collagenase activity. 
Analysis of the distribution of the locally produced growth factors in the bone matrix 
demonstrated that in adult human bone the presence of TGFB type 2, TGFI3 type 3, 
BMP-2 and IGF-I appears to be restricted to specific areas in bone, and are not 
diffusely distributed. This observation may implicate that locally produced factors 
control the response to systemic factors at particular sites in bone. Thus, the amount 
and type of growth factor present in the bone matrix may eventually cause less or 
more profound resorption in response to 1,25-(OHhD3 and/or PTH at particular 
sites. 
Sequence variation between the osteocalcin and osteopontin VDRE steroid 
hormone half-elements provides the potential for recognition by distinct hormone 
receptor homo- and heterodimers. In Chapter 7, we showed that 1,25-(OHhD3 
inducible complexes interacting with the osteocalcin and osteopontin VDREs repre-
sent two distinct heterodimeric complexes, each composed of the VDR and RXRa. 
We found that two internal nucleotides of the proximal osteocalcin VDRE half-site 
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(5'-AGGACA) determine differences in VDR immunoreactivity. The results in 
Chapter 7 provide evidence for polarity of VDR/RXR" binding to osteocalcin and 
osteopontin VDREs, with the proximal half-elements being recognized by the VDR, 
and further suggest that the DNA binding domain of the VDR adopts different 
protein conformations when contacting distinct VDREs. 111is may have physiological 
implications for the differential regulation of these two genes in the control of 
skeletal homeostasis. 
Taken together, this study shows that the locally produced factors TGFfi, BMP-
2 and IGF-I have important effects on the action of the systemic factor 1,25-(OHhD3 
and do not just serve as mediators through which 1,25-(OHhD3 exerts its action. 
More general, this type of interactions may also play an important role in the action 
of other hormones. 
183 
Chapter 9 
SAMENVATTING 
Het steroid hormoon 1,25-dihydroxyvitamine DJ (1,25-(OHlzDJ) speeJt niet 
aileen een belangrijke rol in de calciumhuishouding en het botmetabolisme, maar 
belnvloedt tevens de expressie van genen, die betrokken zijn bij de ontwikkeling en 
het handhaven van het botcel fenotype. 1,25-(OHlzDJ bereikt z'n voomaamste 
effecten door binding aan z'n receptor, de vitamine D receptor (VDR), die behoort 
tot de superfamilie van steraid/retinoid/schildklier hormoon receptoren en werkt via 
de binding aan verschillende vitamine D respons elementen (VDREs) die zich 
bevinden in de promoter van een aantal genen. 
Naast systemische calciotrafe factoren, zoals 1,25-(OHlzDJ, hebben ook 
verschillende lokaal geproduceerde factoren een effect op het botmetabolisme. 
Systemische factoren kunnen de produktie van lokale factoren belnvloeden en 
daardoor de botvonning en afhraak (resorptie) reguleren. Daamaast zou de 
aanwezigheid van lokaal geproduceerde factoren echter ook gevolgen kunnen hebben 
voor de biologische effecten van systemische factoren. Lokale factoren zouden de 
werking van systemische factoren kunnen belnvloeden. De factoren transforming 
growth factor B (TGFB), bone morphogenetic protein-2 (BMP-2) en insulin-like 
growth factor (IGF-I) worden geproduceerd door botcellen en worden opgeslagen in 
de botmatrix. Het doel van de in dit proefschrift beschreven stu die was het vas!stellen 
van de rol van de lokaal geproduceerde factoren TGFB, BMP-2 en IGF-I bij de 
werking van de systemische factor 1,25-(OHlzDJ op bot. 
Allereerst werd het effect van TGFB op het VDR nivo in botvormende, 
osteoblast-achtige cellen bepaald. In osteoblasten van verschillende oorsprong 
verhoogde TGFB op een vergelijkbare marrier het VDR rrivo (Hoofdstuk 2). Om te 
bepalen wat het belang is van dit door TGFB verhoogde VDR nivo voor de werking 
van 1,25-(OHlzDJ op de expressie van osteocalcine en osteopontine in deze cellen, 
werden de cellen eerst gelncubeerd met TGFB (prelncubatie leidt tot een verhoogd 
VDR nivo), en vervolgens werd 1,25-(OHlzDJ toegevoegd. Osteocalcine en 
osteopontine zijn niet-collagene botmatrix eiwitten die worden geproduceerd door 
osteoblasten en waarvan wordt gedacht dat ze een rol spelen bij de botresorptie. 
Osteocalcine zou betrokken zijn bij het aantrekken en de differentiatie van 
osteoclasten, de botresorberende cell en. Osteopontine zou betrakken zijn bij de 
aanbechting van osteoclasten aan het bot. TGFB prelncubatie leidde echter tot een 
sterke remming van de door 1,25-(OHhDJ gestimuleerde osteocalcine en 
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osteopontine expressie in osteoblast-achtige cellijnen. 
In Hoodstuk 3 bestudeerden we het mechanisme waarmee TGPll de door 1,25-
(OHhD3 verhoogde expressie van osteocalcine en osteopontine remt. ROS 17/2.8 
cellen, een osteoblast-achtige cellijn waarin beide genen tot expressie komen, werden 
getransfecteerd met reporter constructen aangestuurd door de wild-type ratle 
osteocalcine en muize osteopontine promoters. TGPil verminderde de door 1,25-
(OHhD3 gestimuleerde transcriptie van zowel het osteocalcine als osteopontine gen. 
De aanwezigheid van de vitamin 0 respons elementen (VDREs) bleek noodzakelijk 
voor de remmende werking van TGFil. Additionele, meer proximaal gelegen basale 
regulatore elementen bleken echter oak een bijdrage te leveren. Verder werd de 
bijdrage van tl'alls-activerende factoren, die binden aan de osteocalcine en 
osteopontine VDREs en bestaan uit o.a. de VDR en retinoic X receptor (RXR), aan 
transcriptionele effecten bestudeerd. Gel mobility shift assays lie ten zien dat TGFll de 
inductie van de binding van heterodimere VDR/RXR complexen aan de VOREs 
significant remt in met 1,25-(OH}z03 behandelde ROS 17/2.8 cellen, en dat dit effect 
niet tot stand kwam door veranderingen in VDR eiwit niVD. Tevens Heten we zien dat 
activator protein-1 (AP-1) activiteit, die verhoogd wordt door TGPil, mogelijk een 
bijdrage levert aan de remmende effecten van TGPil op de basale osteocalcine 
transcriptie. 
Een respons waarvan eerder een koppeling is aangetoond met het VDR nivo is 
24-hydroxylase activiteit. Oit enzym is betrokken bij de eerste stap in de C24-oxidatie 
route van zijketen oxidatie, die wordt gevolgd door afbraak en volledige verwijdering 
van 1,25-(OH}zD3 en z'n precursor 25-(OH)D3. Om de betekenis van de regnlatie van 
VDR nivo verdeI' te bestuderen, werd in Hoofdstuk 4 het effect van door TGPil-
geYnduceerde verhoging van het VDR nivo op de indue tie van 24-hydroxylase 
activiteit door 1,25-(OH}zD3 bekeken. Na prelncubatie met TGPil, die het vitamine 0 
receptor nivo verhoogt, bleek ook de door 1,25-(OH}zD3 geYnduceerde 24-hydroxylase 
activiteit verhoogd te zijn in twee osteoblast-achtige ceWjnen. Door op verschillende 
manieren het VDR nivo te regnleren, laten we zien dat er een sterke koppeling 
bestaat tussen VDR nivo en de inductie van 24-hydroxylase door 1,25-(OH}z03' 
Omdat C24-oxidatie onderdeel vormt van de afbraak van 1,25-(OH}zD3, zou de 
koppeling van VDR nivo aan de afbraak van 1,2S-(OH}z03 een belangrijk regnlatoor 
terugkoppelings mechanisme kunnen vormen bij de werking van 1,25-(OH}z03 op 
doelwit weefsel/cel nivo. 
In Hoofdstuk 5 werden de effecten van twee andere lokaal geproduceerde 
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factoren, BMP-2 en IGF-I vergeleken met TGFfi. Deze drie groeifactoren bleken 
verschillende effecten te hebben op de door 1,25-(OHlzD3 gestimuleerde expressie 
van osteocalcine en osteopontine en op de binding van VDR/RXR complexen aan de 
osteocalcine en osteopontine VDREs. Deze resultaten vormen een aanwijzing dat de 
interactie vau groeifactoren met 1,25-(OHlzD3 groeifactor specifiek is. 
In Hoofdstuk 6 werden de effecten van TGFfi, BMP-2 en IGF-I op de door 
1,25-(OH)2D3 en bijschildklier hormoon (parathyroid hormoon, PTH) gestimuleerde 
botresorptie bestudeerd. TGFfi bleek de door 1,25-(OHlzD3 gestimuleerde 
botresorptie te remmen, maar niet de door PTH gestimuleerde botresorptie. IGF-I 
remde echter zowel de door PTI-I als de door 1,25-(OHlzD3 gestimuleerde 
botresorptie. BMP-2 had, afbankelijk van de con centra tie, een stimulerend effect op 
de door 1,25-(OH)zD3 verhoogde botresorptie (10-100 ng/ml), of had (1000 ng/ml) 
een sterk stimulerend effect op de basale botresorptie, maar geen effect op 1,25-
(OHlzD3 en PTH gestimuleerde botresorptie. Deze gegevens bevestigen de 
groeifactor specifieke effecten van TGFfi, BMP-2 en IGF-I op de werking van 1,25-
(OH}zD3 beschreven in het voorgaande Hoofdstuk. Tevens wordt aangetoond dat de 
effecten ook hormoon specifiek zijn. Daarnaast hebben we de effecten van lokale en 
systemlsche factoren op osteocalcine produktie en collagenase activiteit bestudeerd. 
Deze factoren zouden betrokken kunnen zijn als mediatoren in de regulatie van de 
botresorptie. Het was opmerkelijk dat 1,25-(OH}zD3, in tegenstelling tot het 
stimulerende effect op botresorptie, een remmend effect had op de osteocalcine eiwit 
produktie in foetale muize botjes. Dit remmend effect van 1,25-(OHlzD3 werd ook 
gezien in de muize osteoblast-achtige cellijn MC3T3. Deze gegevens wijzen op een 
species specifieke regulatie van os teo calcine door 1,25-(OH}zD3. 1,25-(OHhD3 had 
geen effect op de collagenase activiteit. 
Analyse van de verdeling van lokaal geproduceerde factoren in de bot matrix 
toonde aan dat in volwassen humaan bot de aanwezigheid van TGFfi type 2, TGFfi 
type 3, BMP-2 en IGF-I beperkt is tot specifieke plaatsen en dat ze niet diffuus 
verspreid aanwezig zijn. Deze observatie kan erop duiden dat lokaal geproduceerde 
factoren de res pons op systemische factoren op specifieke plaatsen in bot bepalen. De 
hoeveelheid en het type groeifactor dat op specifieke plaatsen in de botmatrix 
aanwezig is, zou tot een verlaagde of juist een verhoogde botresorptie in respons op 
1,25-(OHhD3 en/of PTH kunnen leiden. 
Variatie in de sequentie van de osteocalcine en osteopontine VDREs kan leiden 
tot herkenning van deze elementen door verschillende hormoon receptor homo- of 
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heterodimeren. In Hoofdstuk 7 tonen we aan dat de door 1,25-(OHhD3 gelnduceerde 
complexen die aan de osteocalcine en osteopontine YDREs bind en, verschillende 
complexen zijn, \Vaarvan de YDR en RXR type « deel uit maken. De 2 middelste 
nucleotiden in het proximale half element van de osteocalcine YDRE (5'-AGGACA) 
bleken bepalend te zijn voor de verschillen in immunoreactiviteit van een VDR 
antilichaam. De resuItaten in Hoofdstuk 7 wijzen op polarisatie van de binding van 
het VDR/RXR« complex aan de osteocalcine en osteopontine VDREs, waarbij de 
proximaal gelegen balf-elementen van de VDREs worden herkend door de VDR. 
Tevens zijn er aanwijzingen dat het DNA bind end domein van de VDR verschillende 
eiwit conformaties aan neemt bij binding aan de verschillende VDREs. Dit zou 
fysiologische gevolgen kunnen hebben voor de regulatie van deze twee genen 
gedurende de instandhouding van de bothomeostase. 
De in dit proefschrift beschreven studie toont aan dat de lokaal geproduceerde 
factoren TGFIl, BMP-2 en IGF-I belangrijke effecten hebben op de werking van de 
systemische factor 1,25-(OHhD3 en niet aileen dienen als mediatoren waardoor het 
effect van 1,25-(OHlzD3 op bot tot stand komt. Deze interacties tussen lokale en 
systemische factoren zouden in het algemeen een belangrijke rol kunnen spelen in de 
effecten van hormonen op hun doelwit weefse!. 
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